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Foreword 
The present report has been developed within the NANoREG project: "A common 
European approach to the regulatory testing of nanomaterials", funded by the European 
Union's 7th Framework Programme, under grant agreement N° 3105841.  
The objective of this report is to disseminate the "NANoREG framework for the safety 
assessment of nanomaterials" that has been developed within the project via a collective 
effort of several partners and supported by a NANoREG-wide consensus. JRC, as task 
leader, has coordinated the drafting process as well as edited and published the 
document.  
The NANoREG framework represents the project's proposal for a common understanding 
in the field of environmental health and safety (EHS) assessment of nanomaterials (NMs) 
under the current European regulatory framework, with focus on the REACH Regulation 
1907/2006. It is at the same time a contribution to the on-going debate on the need to 
facilitate the implementation of REACH for NMs. The framework elaborates the further 
development, testing and validation of three forward-looking strategies on EHS of NMs, 
such as Safe-by-Design, Life Cycle Assessment, and a Nanospecific approach to 
Prioritisation and Risk Assessment. The NANoREG partners, including JRC, believe that 
the proposed framework will be useful for scientific experts and stakeholders, such as 
regulatory authorities and industry. 
This report contributed to the discussion paper prepared for the ProSafe & OECD Joint 
Conference held in Paris from 30 November to 2 December 2016. This report is 
contributing to the development of the ProSafe Task Force White Paper scheduled for 
release in May 2017.  
The framework consistently uses the NANoREG harmonised terminology for EHS 
assessment of NMs developed by the project and illustrated in a previous JRC report 
released in March 20162. 
This document is interlinked to other NANoREG outputs, including the questions of 
regulatory relevance in the field of EHS of NMs and (elements of) answers to those 
questions, resulting from the research work by numerous project partners (NANoREG 
deliverables D1.013 and D1.094). Moreover, the framework is closely connected to the 
comprehensive NANoREG toolbox that is available in an Excel format (project deliverable 
D1.125). A peer-reviewed publication describing the structure and content of the toolbox 
is currently under preparation. 
                                           
1 http://cordis.europa.eu/project/rcn/107159_en.html; www.nanoreg.eu 
2 In EU Bookshop, DOI: 10.2788/71213. Downloadable from: https://ec.europa.eu/jrc/en/publication/nanoreg-
harmonised-terminology-environmental-health-and-safety-assessment-nanomaterials 
3
uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_01_DR_Report_on_a_Virtual_Workshop_to_identify_formulate_and_prioritize_issues_questions.org  
4
nhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/Work_Package/WP_
1_Scientific_answers_to_regulatory_issues  
5
nhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_12_DR_Toolbox.org 
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Executive summary 
The overall goal of the NANoREG project7 is to support regulatory authorities, and also 
industry, in dealing with environmental health and safety (EHS) issues of manufactured 
nanomaterials (NMs). Data, information and tools generated and/or evaluated in the 
project, as well as relevant publications from scientific literature, on EHS aspects of NMs 
form the knowledge base of the NANoREG framework and related NANoREG toolbox 
(project deliverables D1.11 and D1.12, respectively). Both instruments (framework and 
toolbox) have been developed via a collective effort of project partners under JRC's 
leadership and are supported by a NANoREG-wide consensus. 
Policy context 
The NANoREG framework has been developed in the context of the European 
Commission's Recommendation on the definition of nanomaterial 2011/696/EU (EC 
Definition) and the European Regulation concerning registration, evaluation, 
authorisation and restriction of chemicals 1907/2006 (REACH). The EC Definition is 
currently under review and may undergo adjustments. REACH Annexes are currently 
being revised and may be modified to explicitly address NMs. The update of both EC 
Definition and REACH Annexes is not concluded yet and thus was not taken into account 
when drafting the present report.  
Key conclusions 
The European Commission, the European Chemicals Agency (ECHA), the Organisation for 
Economic Co-operation and Development (OECD) and the scientific community have 
worked closely together in recent years to improve the knowledge on EHS of NMs, 
remove hurdles and concretely help stakeholders in addressing regulatory requirements 
for NMs. Several nanospecific issues are still difficult to address efficiently and may 
hamper the safety assessment of NMs. NANoREG analysed means of overcoming these 
obstacles and partners consider Safe-by-Design (SbD), Life Cycle Assessment (LCA) and 
a Nanospecific approach to Prioritisation and Risk Assessment (NanoRA) valuable paths 
for exploration by scientists, industry and regulators to achieve a more efficient medium 
to long-term implementation of REACH principles for NMs. Clearly, those three forward-
looking strategies need to be further developed, tested and debated before a decision 
can be made on how far they are actually relevant for assessment methodology under 
REACH and, if so, how they can be properly implemented at both industrial and 
regulatory level. 
Main findings 
The scope of the NANoREG framework is two-fold. Firstly, the framework analyses the 
applicability of the current European regulatory framework to NMs, with focus on REACH 
(section 3). To this end, the framework: i) gives concrete, practical, step-by-step 
guidance to industry and regulatory authorities on how to address NMs in that legislative 
context; ii) identifies where issues still reside; and iii) 'shows the path' to solutions based 
on available guidance, e.g. published by ECHA and OECD, and also considering proposals 
in peer-reviewed scientific literature. 
A list of take-home messages was extracted from this work on gathering and 
consolidating existing information (section 7.1). For example: no single technique, but 
rather a range of measurement methods is needed to test whether a material meets the 
EC Definition; there appears to be a need to develop a detailed guidance on the 
implementation of the EC Definition; REACH registrants can address all the nanoforms of 
a substance in the same registration and together with the corresponding non-nanoform, 
provided that the hazard information submitted to demonstrate the safe use of the 
registered substance explicitly cover the different nanoforms; for all properties, non-
testing approaches (e.g. (Quantitative) Structure-Activity Relationships ((Q)SARs), 
                                           
7 http://cordis.europa.eu/project/rcn/107159_en.html; www.nanoreg.eu 
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grouping and read-across) are applicable to NMs on a case-by-case basis only, and 
require detailed scientific justification; thermodynamic equilibrium generally does not 
apply to NMs in the environment and, thus, care must be taken when applying the 
equilibrium partitioning method to NMs and interpreting the results; currently available 
measurement instruments are unable to distinguish between engineered nanoparticles 
and any background nano-sized particles of the same composition. 
Secondly, this framework describes, from a scientist's point of view, the three forward-
looking strategies (SbD, LCA and NanoRA) seeking to facilitate/accelerate the 
implementation of REACH for NMs, while discussing the strategies' benefits and potential 
limitations (sections 4-6). Here, too, a list of take-home messages was produced (section 
7.2). For instance: the most important nanospecific elements to be considered in human 
health risk assessment of NMs are exposure potential, dissolution, transformation, 
accumulation, genotoxicity and immunotoxicity; SbD provides an integrated and iterative 
process where safety information on a certain material is considered within the 
innovation process as early as possible, i.e. from early research and development phases 
onwards; LCA is a well-established procedure, but its application to NMs is presently 
hampered by methodological uncertainties and lack of data, which still need scientific 
work to be solved. 
The NANoREG framework serves as an overarching structure that indicates where and 
how to apply the tools collected in the NANoREG toolbox (project deliverable D1.128). 
The toolbox is organised in worksheets that mirror the structure of the present report. It 
contains a collection of tools – from NANoREG and several other initiatives – that may be 
used to deal with nanospecific aspects at different steps of the safety assessment process 
under REACH. Those available tools also address the needs for tools under the forward-
looking strategies described in sections 4 to 6. The toolbox focuses on 'working tools', i.e. 
tools that are ready-to-use by industry and authorities (e.g. public guidance documents, 
fully developed models that are downloadable from the Internet). It also differentiates 
between tools that are already accepted at regulatory level, such as internationally 
accepted guidelines and standards, and tools that are products of research initiatives, 
which may have only limited use for industry and authorities. 
Finally, in the context of the framework development, an ab initio coordinated effort was 
made to harmonise the use of specific wording within NANoREG. The resulting "NANoREG 
harmonised terminology for safety assessment of nanomaterials" (annex 1)9 is a self-
standing NANoREG output expected to support regulatory-oriented discussions in various 
fora, beyond the remit of this project. 
Related and future JRC work 
The objective of this report is to disseminate the framework for the safety assessment of 
NMs that has been developed within NANoREG via a collective effort of several project 
partners. JRC as task leader has coordinated the drafting process as well as edited and 
published the document.  
Quick guide 
Part I of the framework recalls the existing definitions of NM in the European legislation 
and illustrates step-by-step how REACH applies to NMs (sections 2 and 3). It highlights 
the differences between NMs and conventional or bulk substances, and discusses both 
applicability and regulatory acceptance of approaches that have been developed so far to 
address nanospecific issues. The findings are linked with relevant sections in the second 
part of the framework. 
                                           
8uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_12_DR_Toolbox.org 
9 In EU Bookshop, DOI: 10.2788/71213. Downloadable from: https://ec.europa.eu/jrc/en/publication/nanoreg-
harmonised-terminology-environmental-health-and-safety-assessment-nanomaterials 
 9 
Part II describes three forward-looking strategies: i) the use of NanoRA (section 4); ii) 
the development and implementation of the NANoREG SbD concept (section 5); and iii) 
the integration of LCA and risk assessment in the case of NMs (section 6).  
In the last section, the framework conveys a list of take-home messages for both Part I 
and II, and provides final considerations (section 7). 
Annex 1 makes reference to the self-standing NANoREG harmonised terminology10. 
Annexes 2-5 provide useful complementary information to several sections of this report.  
                                           
10 In EU Bookshop, DOI: 10.2788/71213. Downloadable from: https://ec.europa.eu/jrc/en/publication/nanoreg-
harmonised-terminology-environmental-health-and-safety-assessment-nanomaterials 
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1 Introduction 
 
1.1 Scope  
The overall goal of the NANoREG project11 is to support regulatory authorities, and also 
industry, in dealing with environmental health and safety (EHS) issues of manufactured 
nanomaterials (NMs12). 
Based on questions and requirements of regulatory relevance identified by the NANoREG 
partners in co-operation with those stakeholders (NANoREG deliverable D1.0113), the 
project was set to: i) scientifically evaluate data and test methods that already exist or 
are becoming available and for which the regulatory relevance is still unclear or 
unproven; ii) propose options for solutions to EHS issues of NMs based on existing data 
and information, complemented with new knowledge; iii) for the short to medium-term, 
provide a set of fully developed tools applicable to NMs covering all steps of the risk 
assessment process including physicochemical characterisation, (eco)toxicity testing, and 
exposure monitoring and control; iv) for the long-term, develop new testing strategies 
for NMs adapted to innovation requirements; and v) establish a close collaboration 
among authorities, industry and science to create the basis for common approaches, 
regulatory acceptable datasets and risk management practices. 
Data, information and tools addressing EHS aspects of NMs, which have been generated 
and/or evaluated during the project as well as in relevant publications from scientific 
literature, form the knowledge base for developing the NANoREG framework (task 1.4, 
project deliverable D1.11) and related NANoREG toolbox (task 1.7, project deliverable 
D1.12). Both framework and toolbox have been developed via a collective effort of 
project partners under JRC's leadership and are supported by a NANoREG-wide 
consensus. 
The scope of the NANoREG framework is two-fold. Firstly, the framework analyses the 
applicability of the current European regulatory framework to NMs and aims at giving 
concrete, practical guidance to industry and regulatory authorities, such as European 
agencies, scientific committees and national competent authorities, on how to address 
NMs in that legislative context, with focus on REACH Regulation 1907/200614 (European 
Parliament and Council 2006). To this end, Part I of the framework (sections 2 and 3) 
presents the existing definitions of NM in the European legislation, illustrates step-by-
step how REACH applies to NMs, highlights the differences between NMs and 
conventional or bulk substances, and discusses both applicability and regulatory 
acceptance of approaches that have been developed so far to address nanospecific 
issues. Part I of the framework thus serves as a frame of reference for the risk and safety 
assessment of NMs from a regulatory point of view in the European REACH context. At 
the same time, Part I automatically highlights critical issues in the current safety 
assessment of NMs, such as physicochemical characterisation, applicability of 
(eco)toxicological tests, grouping and read-across between NMs and/or between NMs and 
bulk form(s) of the same substance. 
These findings are then linked with relevant sections in Part II (sections 4, 5 and 6). The 
framework indeed recognises that a change of paradigm in the safety assessment of NMs 
is advocated by several stakeholders15 to address adequately the critical issues identified 
                                           
11  http://www.nanoreg.eu/ 
12 Both acronyms NMs and MNMs refer to manufactured nanomaterials and are interchangeable in NANoREG. 
13uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_01_DR_Report_on_a_Virtual_Workshop_to_identify_formulate_and_prioritize_issues_questions.org 
14 The ongoing review of REACH Annexes was not taken into account while drafting this report, as the process is 
not concluded yet. Moreover, at the time this report is written, the Appendixes to the ECHA guidance on 
implementation of REACH providing recommendations for nanomaterials are under consultation 
(https://echa.europa.eu/support/guidance/consultation-procedure/ongoing-reach). 
15 Industry, some national authorities, members of European scientific committees and part of the scientific 
community. 
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in Part I. Part II of the framework therefore examines, from a scientist's point of view, 
three forward-looking strategies seeking to facilitate/accelerate the implementation of 
REACH objectives for NMs, while discussing the strategies' benefits and potential 
limitations. As depicted in figure 1.1, the three strategies include: 1) the use of a 
Nanospecific approach to Prioritisation and Risk Assessment (NanoRA); 2) the 
development and implementation of the NANoREG Safe-by-Design (SbD) concept; and 3) 
the integration of Life Cycle Assessment (LCA) and risk assessment in the case of NMs. 
NanoRA is described as a new strategy for prioritisation and risk assessment of NMs, 
where approaches for (Quantitative) Structure-Activity Relationships ((Q)SARs), grouping 
and read-across are integrated and expanded, pointing to where and how a more 
efficient risk assessment of NMs can be performed and what type of information could be 
used to scientifically justify it in a REACH context. The NANoREG SbD concept is built 
upon the basic idea that safety should be considered and incorporated early on into the 
design and development of NMs. The integration of outcomes from LCA and risk 
assessment are considered as necessary for a more comprehensive evaluation of EHS 
aspects of NMs. These three approaches and their possible use within the REACH 
implementation process are currently debated in the scientific arena. They are not yet 
fully recognised or accepted by the relevant authorities. The relationship of each 
approach with REACH indeed still needs to be clearly defined. This is illustrated in figure 
1.1 through four triangles that do not touch each other or interlock yet, since their level 
and ways of interaction are not yet (fully) established. 
In this context, the framework emphasises the need to use the flexibility built into 
REACH, such as the options for adaptation of standard information requirements provided 
in Annex XI, and discusses possible ways to (partially) implement those forward-looking 
strategies under existing conditions. 
Figure 1.1. The four components of the NANoREG framework. The triangles do not touch each 
other or interlock, since the relationship between each forward-looking strategy (grey triangles) 
and REACH (green triangle) is still to be defined. LCA = Life Cycle Assessment; NanoRA = 
Nanospecific Risk Assessment; SbD = Safe-by-Design. 
 
 
The framework addresses the needs of both regulatory authorities and industry. It helps 
the regulatory authorities to formulate those legislative questions that need to be tackled 
by industry and themselves for the practical implementation of the REACH requirements 
and guidance for NMs. At the same time, the framework helps industry to identify what 
information is required, currently and likely in the near future, by regulatory authorities 
for NM safety assessment under REACH. 
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The NANoREG toolbox (project deliverable D1.1216) contains a collection of tools that 
may be used to address nanospecific aspects at different steps of the safety assessment 
process under REACH or in other legislative frameworks. Those available tools also 
address the forward-looking strategies discussed in Part II of the framework. The toolbox 
focuses on 'working tools', i.e. tools that are ready-to-use by industry and authorities, 
such as public guidance documents, e.g. published by ECHA, or fully developed models 
that are downloadable from the Internet. The toolbox also differentiates between tools 
that are already accepted at regulatory level, such as internationally accepted guidelines 
and standards, and tools that are products of research initiatives, which may have only 
limited use for industry and authorities. 
The framework hence serves as an overarching structure that indicates where and how to 
apply the assembled tools. The toolbox is organised in worksheets that mirror the 
structure of the present report. 
A very important achievement was made by reaching a consensus within the NANoREG 
scientific community on the scope and contents of both the framework and toolbox. ECHA 
has been involved from the initial stages of development, thus ensuring a strong link with 
current REACH requirements and a 'reality-check' on the possibilities to fulfil them. 
 
1.2 Terminology  
Consistent use of terminology is important in any field to ensure common understanding 
of concepts and tools among experts and stakeholders, such as regulatory authorities, 
industry, and consumers. 
The definition of the terms 'nanotechnology' and 'nanomaterial' has been the subject of 
many discussions in the last 10 years, resulting in the publication of peer reviewed 
papers, reports, legislative initiatives, and international standards. For instance, ISO/TC 
229 (Nanotechnologies) has published a number of Technical Specifications, i.e. the 
ISO/TS 80004 series17, which define an ISO vocabulary in relation to nanotechnology and 
its applications. A recommended, though not legally binding, definition of 'nanomaterial' 
has also been provided by the European Commission (2011). Several other terms in the 
field of NM safety have been defined or used by various organisations such as OECD, 
ECHA and European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), as 
well as in the scientific community. 
Terminology has hence played an important role in the NANoREG internal process of 
developing both framework and toolbox in a collaborative effort across all relevant 
NANoREG tasks. Moreover, both framework and toolbox are addressed to a large 
audience of scientists, industry and regulatory bodies, that extends beyond Europe. A 
coordinated effort has been made to harmonise the use of specific wording within 
NANoREG and this is reflected in the list of terms referred to in the self-standing report of 
annex 1. Definitions have been developed after reaching a consensus among the project 
partners involved in the drafting of the present document. The sources of information 
with which these definitions are aligned are primarily European legislation (e.g. REACH, 
Regulation N° 1272/2008 on classification, labelling and packaging of substances and 
mixtures (European Parliament and Council 2008)), documents from international 
organisations like OECD, ECHA and ECETOC, publicly available documents dealing with 
terminology produced by other European projects or shared with NANoREG by individual 
project partners, and peer-review publications. The terms referred to in annex 1 
                                           
16
uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_12_DR_Toolbox.org 
17 http://www.iso.org/iso/home/store/catalogue_tc/catalogue_detail.htm?csnumber=68058 
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represent the NANoREG harmonised terminology for the safety assessment of NMs, which 
has been published by JRC as a NANoREG output (Gottardo et al. 2016)18. 
Finally, terminology has to be streamlined and agreed upon also for experimental work. 
Scientists from different fields, and sometimes even from the same field but different 
laboratories, often use the same term with a different understanding, or use different 
terms for the same concept or item. This specific issue has been addressed in the 
scientific community by creating ontologies. 'Ontology' is a formal and explicit 
representation of knowledge belonging to a subject area (Thomas et al. 2011). Ontology 
descriptors have been developed within NANoREG in close collaboration with the FP7 
eNanoMapper project19 (task 1.5) and resulted in a series of templates for data logging20 
(project deliverable D1.0421). An adequate ontology supports the recording of 
experimental data and the generation of an experimental database with which project 
partners can share data and information in a coherent and useful way. However, this 
work is beyond the scope of the present framework document and ontology descriptors 
are not reported in annex 1. 
 
1.3 Sources of information 
The framework builds upon the knowledge generated by project partners. In addition, 
input from: i) other European projects, such as ITS-NANO, MARINA, SUN, GUIDEnano, 
NanoDefine, NanoValid, ProSafe and NanoReg2, ii) European institutions (e.g. ECHA), iii) 
international organisations (e.g. OECD), iv) industry-led organisations (e.g. ECETOC), 
and v) peer-reviewed scientific literature, has been considered to ensure consistency at 
European level and alignment to the state-of-the-art. 
More specifically, input to the analysis of the NMs case under REACH has mainly come 
from: i) ECHA guidance documents and related appendices containing recommendations 
for NMs22, which implement the results of the RIPoN projects23, and ii) JRC NANO-
SUPPORT reports (Task I and II)24, including proposals of amendment of the REACH 
Annexes for NMs (still under discussion at EU level25 at the time the present NANoREG 
framework is edited, i.e. February 2017). Input to the discussion on the European 
Commission's Recommendation on the definition of 'nanomaterial' has mainly come from 
publicly available JRC reports concerning the implementation issues and on-going review 
process (Linsinger et al. 2012; Rauscher et al. 2014; Rauscher et al. 2015; Roebben et 
al. 2015). 
The work on development, adaptation, harmonisation and standardisation of 
physicochemical and (eco)toxicity testing protocols for NMs, which has been performed 
by the OECD Working Party on Manufactured Nanomaterials (WPMN)26, ISO/TC 22927 and 
CEN/TC 35228, has also been considered in the development of the framework. 
 
                                           
18 In EU Bookshop, DOI: 10.2788/71213. Downloadable from: https://ec.europa.eu/jrc/en/publication/nanoreg-
harmonised-terminology-environmental-health-and-safety-assessment-nanomaterials 
19 http://cordis.europa.eu/project/rcn/110961_en.html; http://www.enanomapper.net/ 
20 In EU Bookshop, DOI: 10.2787/505397; http://publications.jrc.ec.europa.eu/repository/handle/JRC103178  
21
uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/Work_Package/WP
_1_Scientific_answers_to_regulatory_issues 
22 http://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-
assessment 
23 http://ec.europa.eu/environment/chemicals/nanotech/reach-clp/ripon_en.htm 
24 http://ec.europa.eu/environment/chemicals/nanotech/reach-clp/nano-support_en.htm 
25 https://ec.europa.eu/growth/sectors/chemicals/reach/nanomaterials_en 
26 http://www.oecd.org/science/nanosafety/ 
27 http://www.iso.org/iso/iso_catalogue/catalogue_tc/catalogue_tc_browse.htm?commid=381983 
28 https://www.cen.eu/work/areas/Nanotech/Pages/default.aspx 
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1.4 Structure of this document 
The present document is structured into two parts. Part I focuses on the current 
regulatory framework and provides guidance on how to best implement the European 
Commission's Recommendation on the definition of 'nanomaterial' (section 2) and the 
REACH chemical safety assessment paradigm to NMs (section 3). Part II discusses the 
forward-looking strategies and the pros and cons of a potential integration into the 
REACH safety assessment paradigm of approaches that are considered more efficient for 
NMs by the scientific community. The three forward-looking strategies include: i) the use 
of NanoRA (section 4); ii) the development and implementation of the NANoREG SbD 
concept (section 5); and iii) the integration of LCA and risk assessment in the case of 
NMs (section 6). Annexes 2-5 provide useful complementary information to several 
sections of this document. The framework conveys a list of take-home messages and 
final considerations for both Part I and II (section 7). 
Each section of the present document is linked to the corresponding Excel worksheet of 
the NANoREG toolbox (project deliverable D1.1229), where many publicly available 
'working tools' for that specific step/component of the NM safety assessment process are 
listed and briefly described. 
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Part I – Current regulatory context for nanomaterials 
Part I of the NANoREG framework illustrates the European Commission's definition of 
'nanomaterial' (2011/696/EU) and, in a stepwise manner, how the REACH Regulation 
1907/2006 applies to nanomaterials (NMs). It highlights the differences between NMs 
and conventional or bulk substances and discusses both applicability and regulatory 
acceptance of existing approaches to address nanospecific issues. 
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2 Definition of a nanomaterial in a regulatory context 
In the European Union, the term 'nanomaterial' has been defined in different documents 
with regulatory relevance, namely in an overarching non-binding Recommendation 
published by the European Commission in 2011 (section 2.1) and in several sector-
specific pieces of legislation (section 2.2). Sector-specific legislation either has 
implemented the overarching definition provided by the European Commission or uses a 
dedicated and, to some extent, different definition of the term. 
Outside the European Union, a regulatory definition of the term 'nanomaterial' does not 
exist yet. In most of the cases, working definitions or descriptions are used and public 
authorities provide industry with guidance on how to address nanomaterials in a 
regulatory context (Amenta et al. 2015). 
The currently available tools (e.g. guidance documents, models, protocols and decision 
trees) for implementing the European Commission's Recommendation on the term 
'nanomaterial', including those developed under NANoREG, are listed in the NANoREG 
toolbox (project deliverable D1.1230, see relevant worksheet in Excel file). 
 
2.1 European Commission's Recommendation on the definition of 
'nanomaterial'  
In October 2011 the European Commission published a Recommendation on the 
definition of the term 'nanomaterial' (2011/696/EU), here subsequently referred to as the 
'EC Definition' (European Commission 2011). The purpose of this definition is to clarify 
when a material should be considered as a NM for regulatory purposes in the European 
Union. The definition covers natural, incidental and manufactured materials and is based 
solely on the size of the constituent particles of a material, without regard to specific 
functional or hazard properties or risks. 
The European Commission (2011) recommends the following definition of the term 
'nanomaterial':  
"'Nanomaterial' means a natural, incidental or manufactured material containing 
particles, in an unbound state or as an aggregate or as an agglomerate and where, for 
50% or more of the particles in the number size distribution, one or more external 
dimensions is in the size range 1 nm-100 nm. 
In specific cases and where warranted by concerns for the environment, health, safety or 
competitiveness the number size distribution threshold of 50% may be replaced by a 
threshold between 1 and 50%." 
The Recommendation further specifies: 
"By derogation […], fullerenes, graphene flakes and single wall carbon nanotubes with 
one or more external dimensions below 1 nm should be considered as nanomaterials. 
[…] ‘particle’, ‘agglomerate’ and ‘aggregate’ are defined as follows: 
(a) ‘particle’ means a minute piece of matter with defined physical boundaries; 
(b) ‘agglomerate’ means a collection of weakly bound particles or aggregates where the 
resulting external surface area is similar to the sum of the surface areas of the individual 
components; 
(c) ‘aggregate’ means a particle comprising of strongly bound or fused particles. 
Where technically feasible and requested in specific legislation, compliance with the 
definition […] may be determined on the basis of the specific surface area by volume. A 
                                           
30uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANo
REG_D1_12_DR_Toolbox.org 
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material should be considered as falling under the definition […] where the specific 
surface area by volume of the material is greater than 60 m2/cm3. However, a material 
which, based on its number size distribution, is a nanomaterial should be considered as 
complying with the definition […] even if the material has a specific surface area lower 
than 60 m2/cm3." 
The salient points of this definition are: 
• Legal status: it is a Recommendation (legally non-binding); 
• Scope: broad, generic, not limited to certain compositions or application fields; 
• Origin of materials: all kinds of origin, i.e. natural, incidental, manufactured; 
• Particulate vs. non-particulate materials: limited to particulate materials, 
nanostructured materials generally are not covered (but see the point below referring 
to constituent particles in agglomerates and aggregates); 
• The definition is based on the size (external dimensions) of the particles as the only 
criterion; 
• Size range: one or more external dimensions in the range 1–100 nm, lower limit to 
exclude large atoms and molecules; 
• Threshold: if at least 50% of the particles in a material have one or more external 
dimensions in the range 1-100 nm, the material is a NM; 
• The definition refers to the number fraction of particles in a material; 
• Constituent particles are counted, either unbound or in agglomerates or aggregates; 
• The Volume Specific Surface Area (VSSA) criterion may be used if requested in specific 
legislation. 
Practical guidance needs to be developed for implementing the definition in a regulatory 
context, as pointed out in several reports by the Joint Research Centre (JRC) of the 
European Commission (Linsinger et al. 2012, Roebben et al. 2014). Furthermore, 
measurement methods must be available for manufacturers, to provide accurate 
information, and for authorities, to verify the accuracy of the information they receive. 
These measurements have to meet certain requirements in order to determine whether a 
material is a NM. Currently, these requirements cannot all be met by a single technique 
(Linsinger et al. 2012) and therefore a range of measurement methods is needed to test 
whether a material meets the EC Definition. 
Starting in 2013, the JRC developed a series of three scientific-technical reports with a 
common header: "Towards a review of the EC Recommendation for a definition of the 
term nanomaterial". The reports are based on a list of tasks addressing specific points of 
the EC Definition, which were agreed initially between the European Commission's policy 
services and the JRC. The first report collects information on scientific-technical issues 
that should be considered when reviewing the current EC Definition (Rauscher et al. 
2014). In the second report, JRC assesses the information collected between August 
2013 and April 2014 from scientists, research institutes, regulatory bodies, non-
governmental organisations, and industry regarding implementation of the EC Definition 
(Roebben et al. 2014). In the third report of the series, JRC describes science and 
technology based options to clarify the wording and facilitate the implementation of the 
EC Definition (Rauscher et al. 2015). The options presented in the report are provided to 
the European Commission's policy services, which are assessing in 2017 whether and 
how the definition should be revised or supported with additional guidance. 
The reports support the idea that the scope of the EC Definition regarding the origin of 
NMs should remain unchanged, addressing natural, incidental as well as manufactured 
NMs. Moreover, there is little evidence to support deviating from size as the sole defining 
property of a nanoparticle or from the range of 1 to 100 nm as definition of the 
nanoscale. 
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Certain scientific-technical issues seem to deserve particular attention in terms of 
clarification of the definition and/or provision of additional implementation guidance: 
• The term 'particle': this term should be defined more rigorously for the purposes 
of the EC Definition to leave less room for interpretation, or detailed guidance for 
the interpretation of the term should be provided. 
• The terms 'particle size' and 'external dimension': 'particle size' and 'external 
dimension' or more precisely 'minimum external dimension' should be better 
defined, or more precise guidance on what is considered as (minimum) external 
dimension should be provided. 
• The term 'constituent particle': this term is important for the understanding of 
the definition but does not appear in the definition itself; the term could be 
explicitly included in the definition and/or guidance could be issued on the 
meaning of the term. 
• There is a conceptual difference between a threshold for the definition of a NM 
(number fraction of particles with external dimensions between 1 nm and 100 
nm in a material, currently 50%) and the content threshold for such materials in 
a product; using the phrase "mainly consisting of particles" in the definition 
(rather than the currently used "containing particles") could prevent the 
misunderstanding that products containing nanoparticles become NMs 
themselves. 
• Consequences of the possibility of varying thresholds for the particle number 
fraction in the definition: variable thresholds may allow regulators to address 
specific concerns in certain application areas but may also confuse customers 
and lead to an inconsistent classification (as NM or not) of the same material 
based on the field of application. 
• Ambiguity on the role of VSSA: the potential use of VSSA should be clarified and 
ambiguities arising from the current wording should be eliminated; VSSA could 
either be retained as a proxy or additional criterion but with clearer wording 
about its use in specific cases, or it could be moved from the text of the EC 
Definition into guidance as one screening method (among several) for practical 
implementation of the definition. 
• The means and methods to prove that a material is not a NM: the definition 
makes it very difficult to prove that a material is not a NM; this implementation 
issue should be resolved, for example, by adding an additional criterion, which 
might be based on mass, VSSA, or additional size-based parameters. 
• The alignment of the EC Definition with other international terminology, if 
relevant. 
• The status of nanostructured materials. 
According to the JRC reports, many of the issues listed above could in principle be 
clarified by developing new or improved guidance. Also, the need for specific guidance 
beyond clarification of the definition itself is identified. JRC provides a number of 
suggestions on scientific-technical guidance documents that could help in facilitating the 
practical implementation of the definition. 
The text of the EC Definition is currently included as such in the Biocidal Products 
Regulation (BPR) (European Parliament and Council 2012), in the European Commission's 
proposal for a Regulation on medical devices (COM(2012) 542 final) (European 
Commission 2012) and referred to in the Appendixes to the ECHA guidance for 
implementation of REACH containing recommendations for NMs (e.g. ECHA 2012). 
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2.2 Other regulatory definitions in the European Union 
Specific attention should be given to the harmonisation of the EC Definition and other NM 
definitions included in European legislation, e.g. in the Regulation N° 1223/2009 on 
cosmetics products, Article 2 (1) (k), in which 'nanomaterial' is described as "an insoluble 
or biopersistent and intentionally manufactured material with one or more external 
dimensions, or an internal structure, on the scale from 1 to 100 nm" (European 
Parliament and Council 2009). Differently to the EC Definition, no specific guidance is 
provided so far for number size distribution thresholds and potential exceptions 
therefrom. Other legislation of relevance includes the new Novel Food Regulation 
2015/2283 (European Parliament and Council 2015), which refers to the NM definition 
reported in Regulation 1169/2011 on provision of Food Information to Consumers (FIC 
Regulation) (European Parliament and Council 2011). 
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3 Safety assessment of nanomaterials under REACH 
In the European Union, manufacturing and importing of industrial substances is ruled by 
REACH, i.e. the Registration, Evaluation, Authorisation and Restriction of Chemicals 
Regulation 1907/2006 (European Parliament and Council 2006). 
REACH requires that a substance is registered before being placed into the market 
(section 3.1). The registration dossier must include, as a minimum, data covering the 
Standard Information Requirements specified in Annexes VII-X of REACH, which vary 
according to the volume of production (tonnage level) of the substance (section 3.2). The 
Standard Information Requirements can also be met via submission of data generated 
through alternative methods to animal testing, including grouping and read-across, in 
vitro methods, weight of evidence (section 3.3). If the substance exceeds 10 tons/year 
or is classified as having hazardous properties (e.g. carcinogenicity, acute toxicity in 
aquatic species), a Chemical Safety Assessment (CSA) needs to be performed. The CSA 
consists of three main steps: hazard assessment (section 3.4), exposure assessment 
(section 3.5), and risk characterisation (section 3.6). 
Each of the subsequent sub-sections illustrates: how REACH works for conventional or 
bulk substances; how its provisions apply to nanomaterials (NMs)31; what the 
nanospecific issues are; and how these issues can be addressed based on the state-of-
the-art on NMs32.  
The currently available tools (e.g. guidance documents, models, protocols, decision 
trees) for addressing the nanospecific considerations discussed in the next sub-sections, 
including those developed under NANoREG33, are listed in the NANoREG toolbox (project 
deliverable D1.1234, see relevant worksheets in Excel file – For convenience, the 
numbering of the Excel worksheets of the toolbox mirrors the numbering of the next sub-
sections). 
 
3.1 Substance identification 
A 'substance' is defined under REACH as "a chemical element and its compounds in the 
natural state or obtained by any manufacturing process, including any additive necessary 
to preserve its stability and any impurity deriving from the process used, but excluding 
any solvent which may be separated without affecting the stability of the substance or 
changing its composition" (European Parliament and Council 2006). The concept of 
substance therefore goes beyond a pure chemical compound defined by a single 
molecular structure and includes different constituents such as impurities and additives. 
Each manufacturer or importer of substances is required under REACH to include in his 
technical dossier sufficient information in line with REACH Article 10 "Information to be 
submitted for general registration purposes", which enables the correct and unambiguous 
identification of the composition(s) of the substance that he intends to register. Annex VI 
Section 2 of REACH lists the set of information that shall be used to identify a substance 
(table 3.1). 
Annex VI Section 2 explicitly states that the information provided for each substance 
shall be sufficient to enable the identification of each substance. Consequently, sufficient 
                                           
31 The ongoing review of REACH Annexes was not taken into account while drafting this report. Such a process 
is not concluded yet. 
32 At the time this report is written, the Appendixes to ECHA guidance on implementation of REACH providing 
recommendations for nanomaterials are under consultation. 
33 For example: NANoREG deliverable D2.5 developed a revised substance identification scheme for 
nanomaterials; NANoREG deliverable D2.4 developed a procedure for identification and quantification of 
nanomaterial surface treatments; NANoREG deliverable D2.9 proposed nanospecific revisions to existing OECD 
Test Guidelines; NANoREG deliverable D2.12 further analysed the ongoing revision of ECHA guidance on 
substance identification and the physicochemical methods that can be used to support the revised procedure for 
nanomaterials. 
34uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANo
REG_D1_12_DR_Toolbox.org 
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information relating to the identity of the substance, its composition(s) and the 
corresponding analytical data that enable the identity and composition verification needs 
to be included. Where additional identifiers/characterizers are needed to identify the 
substance, the information included according to this section needs to address them. 
 
Table 3.1. Standard information requirements concerning 'substance identification' under 
REACH Annex VI Section 2. CAS = Chemical Abstracts Service; EINECS = European INventory of 
Existing Commercial chemical Substances; ELINCS = European LIst of Notified Chemical 
Substances; IUPAC = International Union of Pure and Applied Chemistry; SMILES = Simplified 
Molecular-Input Line-Entry system. 
INFORMATION REQUIREMENTS IN REACH ANNEX VI SECTION 2 FOR EACH SUBSTANCE 
2 IDENTIFICATION OF THE SUBSTANCE 
 
For each substance the information given shall be sufficient to enable each substance to be identified. 
If it is not technically possible or if it does not appear scientifically necessary to give information on 
one or more items below, the reason shall be clearly stated 
2.1 NAME OR OTHER IDENTIFIER OF EACH SUBSTANCE 
2.1.1 Name(s) in the IUPAC nomenclature or other international chemical name(s) 
2.1.2 Other names (usual name, trade name, abbreviation) 
2.1.3 EINECS or ELINCS number (if available and appropriate) 
2.1.4 CAS name and CAS number (if available) 
2.1.5 Other identity code (if available) 
2.2 INFORMATION RELATED TO MOLECULAR AND STRUCTURAL FORMULA OF EACH SUBSTANCE 
2.2.1 Molecular and structural formula (including SMILES notation, if available) 
2.2.2 Information on optical activity and typical ratio of (stereo) isomer (if applicable and appropriate) 
2.2.3 Molecular weight or molecular weight range 
2.3 COMPOSITION OF EACH SUBSTANCE 
2.3.1 Degree of purity (%) 
2.3.2 Nature of impurities, including isomers and by-products 
2.3.3 Percentage of (significant) main impurities 
2.3.4 Nature and order of magnitude (... ppm, ...%) of any additives (e.g. stabilising agents or inhibitors) 
2.3.5 Spectral data (ultra-violet, infra-red, nuclear magnetic resonance or mass spectrum) 
2.3.6 High-performance liquid chromatogram, gas chromatogram 
2.3.7 
Description of the analytical methods or the appropriate bibliographical references for the 
identification of the substance and, where appropriate, for the identification of impurities and 
additives. This information shall be sufficient to allow the methods to be reproduced 
 
REACH does not define the rules for identifying and naming substances; however, the 
"Guidance for identification and naming of substances under REACH and CLP" (ECHA 
2016a), hereinafter referred to as the Guidance on Substance Identification (figure 3.1), 
outlines the principles of substance identification under REACH and provides the elements 
that can be considered relevant for substance identity. Thus, it is fundamental for proper 
implementation of REACH aspects related to substance identification. The methodology to 
be used for identifying and naming a substance must be carefully selected depending on 
the substance type. Substances can be divided into three main groups: well-defined 
substances, well-defined substances that require additional identifiers, and substances 
 24 
that qualify as UVCB (Unknown or Variable composition, Complex reaction products or 
Biological materials) substances. 
Well-defined substances are substances with a defined qualitative and quantitative 
chemical composition that can be satisfactorily identified based on the identification 
parameters of REACH Annex VI Section 2. Rules for identification and naming of well-
defined substances differ according to whether there is one main constituent present at 
concentration greater than 80% (mono-constituent substance) or the main constituent is 
present at concentration ≥ 10% (w/w) and < 80% (w/w) (multi-constituent substance). 
In addition to the substance identification parameters as described in table 3.1, for some 
well-defined substances (either mono-constituent substances or multi-constituent 
substances) other information may need to be considered at the substance identity level 
to get their own, unequivocal substance identification. This could be the case for 
inorganic minerals, where additional information on crystal phase, size, shape, etc. may 
be required. The additional identification parameters are to be chosen on a case-by-case 
basis depending on the substance type. 
On the other hand, UVCB substances cannot be sufficiently identified based on the 
composition, as they have a large number of constituents and/or the composition is to a 
significant part unknown and/or the variability of the composition is relatively large. 
Advice on how to identify and name specific types of UVCB substances (in figure 3.1: 
"Substances with variation in the carbon chain length", and "Substances obtained from 
oil or oil-like sources and enzymes") is provided in the Guidance on Substance 
Identification. While for simple substances the identification can therefore be straight-
forward, for more complex substances identification needs to take factors such as 
variability in composition, unknown constituents or/and other parameters that are 
relevant for identification into account. 
 
Figure 3.1. Key to relevant chapters of the Guidance on Substance Identification for various 
types of substances. UVCB = Unknown or Variable composition, Complex reaction products or 
Biological materials. 
 
Source: ECHA 2016a 
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As an example, in the identification of inorganic substances the crystalline phase is a 
factor that needs to be taken into account and X-ray diffraction (XRD) is the typical 
method that is used to verify the crystal phase. Such observations are clearly made in 
the Guidance on Substance Identification (p. 25): "For minerals, it is important to 
combine the results of the elemental composition with the spectral data to identify the 
mineralogical composition and crystalline structure. This is then confirmed by 
characteristic physicochemical properties like crystalline structure (as revealed by X-ray 
diffraction), shape, hardness, swelling capacity, density and/or surface area" (ECHA 
2016a). This is also in line with the general principle of Annex VI Section 2 that the 
information provided is required to be sufficient to enable the identity of the substance to 
be verified. Diamond and graphite represent a typical example, also mentioned in the 
Guidance on Substance Identification, of two substances with the same chemical 
composition (carbon) but with different crystalline structure. Information on crystalline 
structure is in this case essential for their appropriate identification and characterization. 
Accurate identification of a substance underpins all REACH processes and allows the 
sharing of information among registrants, which prevents unnecessary animal testing and 
costs. REACH foresees that substances are registered jointly by parties that 
manufacture/import the same substance to ensure that costs are kept to a minimum and 
that animal testing is not duplicated. This is the "One Substance-One Registration" 
(OSOR) principle where all manufacturers/importers submit a joint registration for the 
same substance (ECHA 2012). Establishing substance sameness is the responsibility of 
these parties, and the name and other identifiers chosen by them collectively determine 
the scope of the registered substance. The criteria to be followed for checking whether or 
not substances from different manufacturer/importers can be regarded as the same are 
described in the Guidance for Substance Identification. 
In terms of technical reporting in IUCLID dossiers, each registrant is required to include 
the substance identity information specific for its substance in his own dossier. The name 
and other identifiers refer to the registered substance and is the same for all registrants 
of that substance while the composition in a specific dossier refers to a composition of 
this substance as manufactured/imported by that specific legal entity. 
 
3.1.1 Nanospecific considerations 
The identification and naming of a substance under REACH may present challenges when 
it comes to nanomaterials (NMs). Such nanospecific considerations are illustrated in this 
sub-section. The currently available tools (e.g. guidance documents, models, protocols, 
decision trees) for addressing the nanospecific considerations discussed in this sub-
section, including those developed under NANoREG, are listed in the NANoREG toolbox 
(project deliverable D1.1235, see relevant worksheet in Excel file). 
REACH deals with substances in whatever size, shape or physical state they come. 
Substances at the nanoscale, i.e. NMs, are therefore covered by the definition of 
'substance' under REACH and are subject to the same obligations as any substance, 
which means that sufficient information is required to be included in the dossier to enable 
safe use of the substance. REACH currently does not explicitly address NMs in the legal 
text (European Commission 2013), just like it does not explicitly refer to fibres, 
petroleum substances, enzymes, etc. In the second regulatory review on NMs, the 
European Commission concluded that REACH offers the best possible framework for the 
risk management of NMs, but also that within this framework more specific requirements 
for NMs have proven necessary (European Commission 2012). As a consequence, a 
process of revision of the REACH Annexes is currently ongoing and explicit obligations 
both in the reporting and in the information requirements for NMs are foreseen in the 
near future (mid 2017). According to ECHA, the term 'nanoform' refers to a particular 
                                           
35uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANo
REG_D1_12_DR_Toolbox.org 
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form of a substance that meets the criteria of the European Commission's 
Recommendation on the definition of 'nanomaterial' (2011/696/EU) (European 
Commission 2011), here subsequently referred to as the EC Definition (see section 2 for 
more information), as opposed to the 'bulk form(s)' of the same substance, i.e. (the) 
form(s) of the substance not meeting the criteria of the EC Definition. ECHA is preparing 
an appendix on recommendations for NMs applicable to the Guidance on Registration 
under REACH36. The aim is to define the term nanoform, the minimum criteria for 
distinguishing between different nanoforms, and the minimum set of parameters which 
must be reported to characterize a reported nanoform.  
The Guidance on Substance Identification (ECHA 2016a) does not include any specific 
advice for the identification and naming of NMs. However, nanotechnology is mentioned 
in the chapter concerning "Substances of defined chemical composition and other main 
identifiers" (Section 4.2.3 of the Guidance on Substance Identification, p. 24), where it is 
stated that the current developments in nanotechnology may cause the need for 
additional information on size of substances in the future. 
The EC Definition comprises the statement: "Member States, the Union agencies and 
economic operators are invited to use the following definition of the term ‘nanomaterial’ 
in the adoption and implementation of legislation and policy and research programmes 
concerning products of nanotechnologies" (European Commission 2011). ECHA applies 
the EC Definition when implementing REACH and registrants are advised to assess 
whether their substance or form of a substance meets the criteria outlined in the EC 
Definition. The EC Definition is at the moment under review (see section 2 for more 
information); if modified, ECHA guidance may need to be adjusted in the near future.  
A registered substance may have compositions that have multiple shapes and sizes 
(including nanoforms). Some registered substances refer solely to one specific 
morphology (e.g. nanotubes) while others cover multiple shapes and sizes (e.g. bulk 
silver, powder silver, and nano silver; bulk copper, granulated copper, flake copper, 
powder copper, and nanocopper). The question whether substances in nanoform should 
be regarded as new or existing substances was answered in 2008 during the 6th Meeting 
of Competent Authorities for REACH and CLP, where it was agreed that "the decisive 
criterion whether a nanomaterial is a new or existing substances is the same as for other 
substances, i.e. whether or not the substance is on EINECS. Thus, substances in 
nanoform which are in EINECS (e.g. titanium dioxide) shall be regarded as existing 
substances. Substances in nanoform which are not in EINECS (e.g. carbon allotropes 
other than those listed in EINECS) shall be regarded as new substances" (European 
Commission 2008). Under REACH substances at the nanoscale listed on EINECS are 
considered as 'phase-in' substances and can benefit from the extended registration 
deadlines, while substance at the nanoscale which are not listed in EINECS are 
considered as 'non-phase-in' substances and need to be registered before manufacturing 
or importing (European Commission 2008). When an existing chemical substance, 
already placed on the market and registered under REACH as bulk substance, is 
introduced in the market in a NM form, the registration dossier has to be updated to 
include specific properties of the nanoform of the substance (Bleeker et al. 2013). 
Registrants can therefore register all the nanoforms of a substance under a same 
registration and together with the corresponding non-nanoform. This approach is well in 
line with the OSOR concept. A registration may cover compositions of a substance having 
different hazards profiles: UVCB substances may have more than one reported 
composition that is relevant for hazard assessment; the same applies to mono-
constituent substances with different impurities triggering different classification. The 
situation of multiple nanoforms covered by one registration is analogous to the above 
mentioned situations, in the sense that different nanoforms that may also trigger 
different hazard can be reported under the same registration. However, what is crucial 
under REACH is that the different compositions and/or the different nanoforms must be 
                                           
36 https://echa.europa.eu/support/guidance/consultation-procedure/ongoing-reach 
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covered by the hazard information submitted to demonstrate the safe use of the 
registered substance. 
One aspect that should be taken into particular consideration for nanoforms is the 
presence of surface treatment, i.e. the modification of the surface chemistry of the 
particle. The interaction of a particle with its environment is in fact strongly driven by its 
surface chemistry, and the effect becomes more prominent as the size of particles 
decreases and the ratio of the specific surface area to the mass increases. Thus, the 
modification of the surface chemistry of nano-sized particles can have a significant effect 
on their interaction with the environment and living organisms. Without thorough 
knowledge of the particle surface chemistry and all deliberate modifications, it is not 
possible to determine whether the interaction of NMs with their environment is 
underestimated or not and, consequently, if the hazard information provided for the 
different forms is applicable also to the modified counterparts. 
The particular impact that surface treatment may have on the properties of compositions 
that fulfil the EC Definition is also explicitly reflected in the recent "Guidance on sample 
preparation and dosimetry for the safety testing of manufactured nanomaterials" 
published by the OECD (2012) where the relevance of surface treatment for hazard 
assessment of NMs is addressed: "such modifications have been shown to significantly 
affect the chemical reactivity of a nanomaterial and thereby its potential effects on (or 
interactions with) living organisms and the environment […] therefore the surface 
functionality of a nanomaterial is likely to have a strong impact on its (eco)toxicological 
behaviour". In addition, the OECD Working Party on Manufactured Nanomaterials 
(WPMN) listed surface treatment as an endpoint for phase 1 testing of NMs at the level of 
"nanomaterial information/identification" in its sponsorship program for testing a number 
of representative manufactured NMs (OECD 2010). 
In light of these considerations, the information included in registration dossiers needs to 
contain sufficient characterization of surface treated NMs and potential difference in 
hazard between surface treated and non-surface treated nanoforms should not be 
underestimated. 
While no designated location for reporting surface treatment was available in IUCLID 5, 
IUCLID 6, which was released in April 2016, includes new "conditionally active" fields to 
describe composition-related information on NMs (particle number size distribution, 
shape and aspect ratio, specific surface area and surface treatment), therefore providing 
the opportunity for registrants to improve clarity when presenting information on 
nanoforms within their registration dossiers. 
ECHA has developed requirements and new specifications for IUCLID 6 on the basis of 
test cases proposed by industry. A new reporting tool has been developed in this context, 
the Assessment Entity (AE) reporting tool. The AE has been defined as a wrapper for a 
set of substance property data (across endpoints) used for assessment purpose. When 
different compositions with different hazard potential (e.g. bulk vs. nano) are covered by 
the same registration, the AE is meant to enable logical grouping of data to facilitate IT 
processing and a transparent documentation of the safety assessment in IUCLID and the 
Chemical Safety Report (CSR) (for complex assessment cases). These new different 
functionalities that have been included in IUCLID 6 therefore represents an opportunity 
for the assessor to present information on the substance that he intends to register in a 
transparent manner and to make disseminated information more understandable. 
Detailed information on how to use the AE tool in IUCLID 6 and, more in general on all 
new IUCLID 6 features is available in the ECHA manuals on "Functionalities of IUCLID 6" 
(ECHA 2016b) and on "How to prepare registration and PPORD dossiers" (ECHA 2016c). 
Moreover, a new appendix to the Guidance on Registration under REACH including 
recommendations for NMs has been prepared by ECHA in order to provide advice to 
registrants preparing their registration dossiers for NMs. The aim of this document is to 
provide the registrant with a definition of the term nanoform, the minimum criteria for 
distinguishing between different nanoforms within a registration dossier, and the 
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minimum set of parameters which must be reported to characterize a nanoform. Such an 
appendix is currently under consultation. The draft (public) version is downloadable from 
ECHA website37. 
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3.2 Information requirements 
Under REACH, all relevant and available information on the intrinsic properties of a 
substance must be collected. The type and minimum quantity of information on the 
intrinsic properties of a given substance that is required depends on the amount of the 
substance (tonnage level) that is manufactured, imported, or used in the EU. This 
minimum set of "Standard Information Requirements" is specified in Annexes VI-X of 
REACH.  
In this sub-section, a summary is presented for physicochemical properties (table 3.2), 
toxicological properties (table 3.3) (updated according to: European Commission 2016), 
and ecotoxicological properties (table 3.4).  
It is, however, important to recognize that the registrant is required to collect all 
information that is relevant and available regardless of whether information on a given 
endpoint is required or not at the specific tonnage level (REACH Annex VII). 
For each information requirement, specific rules are reported in Annexes VI-X allowing 
the registrant to omit, replace, or adapt the required information under particular 
circumstances (see sub-section 3.3). These rules refer to cases when the study does not 
need to be conducted, e.g. if the substance is highly insoluble in water or the substance 
is inorganic.  
 
Table 3.2. Standard information requirements on physicochemical properties of substances to 
be provided in the REACH registration dossier according to the manufacture/imported substance 
tonnage level. 
REACH Standard Information Requirements 
Physicochemical properties 
Annual tonnage level 
manufactured or imported (t/y)  
≥1 ≥10 ≥100 ≥1000 
7.1. State of the substance at 20 °C and 101.3 kPa + + + + 
7.2. Melting/freezing point + + + + 
7.3. Boiling point + + + + 
7.4. Relative density + + + + 
7.5. Vapour pressure + + + + 
7.6. Surface tension + + + + 
7.7. Water solubility + + + + 
7.8. Partition coefficient n-octanol/water + + + + 
7.9. Flash-point + + + + 
7.10. Flammability + + + + 
7.11. Explosive properties  + + + + 
7.12. Self-ignition temperature + + + + 
7.13. Oxidising properties + + + + 
7.14. Granulometry + + + + 
7.15. Stability in organic solvents, identity of relevant degradation products   + + 
7.16. Dissociation constant   + + 
7.17. Viscosity   + + 
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ECHA has developed detailed guidance on REACH information requirements and 
endpoint-specific guidance (ECHA 2011, 2014, 2015, 2016)38. In the guidance, ECHA has 
specified what parameters need to be reported in the registration dossier for each 
property listed in tables 3.2, 3.3 and 3.4 of this document (e.g. when providing 
information on water solubility (property required in Annex VII and listed in table 3.2) 
the registrant is asked to report the value of the saturation mass concentration of the 
substance in water at a given temperature (parameter describing that property), 
specified in units of mass per volume of solution (kg/m3)). 
 
Table 3.3. Standard information requirements on toxicological properties of substances to be 
provided in the REACH registration dossier according to the manufacture/imported substance 
tonnage level (updated according to: European Commission 2016). 
REACH Standard Information Requirements 
Toxicological properties 
Annual tonnage level 
manufactured or imported (t/y)  
≥1 ≥10 ≥100 ≥1000 
8.1. Skin corrosion/irritation     
8.1.1  In vitro skin corrosion + + + + 
In vivo skin corrosion test to be performed if in vitro test not 
applicable or results not adequate for classification and risk 
assessment 
 + + + 
8.1.2. In vitro skin irritation + + + + 
In vivo skin irritation test to be performed if in vitro test not applicable 
or results not adequate for classification and risk assessment 
 + + + 
8.2. Serious eye damage/eye irritation     
8.2.1. Serious eye damage/eye irritation, in vitro + + + + 
In vivo eye corrosion/eye irritation test to be performed if in vitro test 
not applicable or results not adequate for classification and risk 
assessment 
 + + + 
8.3. Skin sensitization + + + + 
8.4. Mutagenicity     
8.4.1. In vitro gene mutation study in bacteria + + + + 
8.4.2. In vitro cytogenicity study in mammalian cells or micronucleus study  + + + 
8.4.3. In vitro gene mutation study in mammalian cells  + + + 
8.5. Acute toxicity     
8.5.1. By oral route  + + + + 
8.5.2. By inhalation  + + + 
8.5.3. By dermal route  + + + 
8.6. Repeated dose toxicity     
8.6.1. Short-term repeated dose toxicity study (28 days)  + + + 
8.6.2. Sub-chronic toxicity study (90-day)   + + 
8.6.3. Long-term repeated toxicity study (≥ 12 months)    + 
8.6.4. Further repeated dose toxicity studies    + 
8.7. Reproductive toxicity     
8.7.1. Screening for reproductive/developmental toxicity  + + + 
8.7.2. Pre-natal developmental toxicity study   + + 
8.7.3. Extended One-Generation Reproductive Toxicity Study   + + 
8.8. Toxicokinetics     
8.8.1. Assessment of the toxicokinetic behaviour   + + + 
8.9. Carcinogenicity      
8.9.1. Carcinogenicity study    + 
 
  
                                           
38 Please note that at the time this document is drafted ECHA guidance is being updated. More information at: 
https://echa.europa.eu/support/guidance/consultation-procedure/ongoing-reach 
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Table 3.4. Standard information requirements on ecotoxicological properties of substances to be 
provided in the REACH registration dossier according to the manufacture/imported substance 
tonnage level. 
REACH Standard Information Requirements 
Ecotoxicological properties 
Annual tonnage level 
manufactured or imported (t/y) 
≥1 ≥10 ≥100 ≥1000 
9.1. Aquatic toxicity     
9.1.1. Short-term toxicity testing on invertebrates + + + + 
9.1.2. Growth inhibition study aquatic plants + + + + 
9.1.3. Short-term toxicity testing on fish  + + + 
9.1.4. Activated sludge respiration inhibition testing  + + + 
9.1.5. Long-term toxicity testing on invertebrates   + + 
9.1.6. Long-term toxicity testing on fish   + + 
9.1.6.1. Fish early-life stage (FELS) toxicity test    + + 
9.1.6.2. Fish short-term toxicity test on embryo and sac-fry stages    + + 
9.1.6.3. Fish, juvenile growth test   + + 
9.2. Degradation     
9.2.1. Biotic     
9.2.1.1. Ready biodegradability + + + + 
9.2.1.2. Simulation testing on ultimate degradation in surface water   + + 
9.2.1.3. Soil simulation testing   + + 
9.2.1.4. Sediment simulation testing    + + 
9.2.2. Abiotic  + + + 
9.2.2.1. Hydrolysis as a function of pH  + + + 
9.2.3. Identification of degradation products   + + 
9.3. Fate and behaviour in the environment     
9.3.1. Adsorption/desorption screening  + + + 
9.3.2. Bioaccumulation in aquatic species, preferably fish   + + 
9.3.3. Further information on adsorption/desorption   + + 
9.3.4. Further information on the environmental fate and behaviour    + 
9.4. Effects on terrestrial organisms     
9.4.1. Short-term toxicity to invertebrates   + + 
9.4.2. Effects on soil micro-organisms   + + 
9.4.3. Short-term toxicity to plants   + + 
9.4.4. Long-term toxicity testing on invertebrates    + 
9.4.5. Long-term toxicity testing on plants    + 
9.5 effects on sediment organisms     
9.5.1. Long-term toxicity to sediment organisms    + 
9.6 Toxicity to birds     
9.6.1. Long-term or reproductive toxicity to birds    + 
 
3.2.1 Nanospecific considerations 
Fulfilling the Standard Information Requirements under REACH may present challenges 
when it comes to NMs. Such nanospecific considerations are illustrated in this sub-
section. The currently available tools (e.g. guidance documents, models, protocols, 
decision trees) for addressing the nanospecific considerations discussed in this sub-
section, including those developed under NANoREG, are listed in the NANoREG toolbox 
(project deliverable D1.1239, see relevant worksheet in Excel file). 
Standard Information Requirements (Annexes VII-X of REACH) in principle apply equally 
to bulk forms (i.e. non-nanoforms) and nanoform(s) of a substance (see sub-section 3.1 
for a definition of these terms). While preparing a registration dossier, the registrant has 
to make sure that the data provided are representative for all the specified form(s) of 
that substance (sub-section 3.1). 
                                           
39
uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_12_DR_Toolbox.org 
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The technical adequacy of the ECHA guidance for implementation of REACH for 
application to NMs was initially reviewed in the European "REACH Implementation 
Projects on Nanomaterials" (RIP-oNs) launched by the European Commission in 200940. 
It provided specific advice on the key aspects of implementation of REACH with regard to 
NMs concerning Standard Information Requirements and Chemical Safety Assessment 
(CSA) (JRC 2011, Hankin et al. 2011, Aitken et al. 2011). Based on the outcomes of the 
RIP-oNs, in 2012 ECHA published a series of appendices to the guidance for 
implementation of REACH containing recommendations for NMs in relation to the 
Standard Information Requirements (ECHA 2012a, 2012b, 2012c)41. The main points 
addressed in those appendices are summarized in tables 3.5, 3.6 and 3.7 of this 
document. The recommendations published by ECHA partly implement the advice 
generated by the RIP-oNs (Hankin et al. 2011). Specifically, the appendices implemented 
those points that were unanimously agreed and recommended to be changed in the 
review of the RIP-oNs. The appendices are currently under revision. ECHA has recently 
proposed updates that are under evaluation by the established expert groups42. 
3.2.1.1 Sample preparation 
ECHA guidance specifically addresses sample preparation and dosimetry when dealing 
with NMs (ECHA 2012a, 2012b). Various parameters related to sample preparation have 
been recognized as highly important for obtaining reliable and repeatable results. Issues 
that have been raised include, for example, methods to achieve a representative test 
aliquot from the particulate material, the degree of agglomeration, the difference 
between dispersed and dissolved particles, and the influence of contaminants and 
impurities on (eco)toxicological test results. Sample preparation is inherently linked to 
dosimetry, which together with the biokinetics of nanoparticles, determines the internal 
dose. Guidance on sample preparation and dosimetry has also been published by OECD 
(2012a). 
3.2.1.2 Physicochemical properties 
Table 3.5 illustrates the nanospecific considerations regarding the REACH Standard 
information Requirements for physicochemical properties. 
 
Table 3.5. Nanospecific considerations regarding the Standard Information Requirements on 
physicochemical properties in the REACH registration dossier. NM = nanomaterial. 
NANOSPECIFIC CONSIDERATIONS ON REACH STANDARD INFORMATION REQUIREMENTS 
Physicochemical properties 
7.1. State of the substance at 20 °C and 101.3 kPa 
 
No nanospecific recommendations provided in ECHA guidance. 
 
As no differences are detected between bulk forms and nanoforms, in most of the materials this endpoint is not considered as 
nanospecific. Nonetheless, in some cases e.g. colour may differ from bulk to nanosize (e.g. depending on the shape and size, 
gold nanocrystals have different colours ranging from blue-purple to red) (Daniel and Astruk 2004) and this information 
should be reflected in the dossier. 
                                           
40 http://ec.europa.eu/environment/chemicals/nanotech/reach-clp/ripon_en.htm 
41 Please not that at the time this document is drafted ECHA guidance is being updated. More information at: 
https://echa.europa.eu/support/guidance/consultation-procedure/ongoing-reach 
42 http://echa.europa.eu/support/guidance/consultation-procedure/ongoing-reach 
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NANOSPECIFIC CONSIDERATIONS ON REACH STANDARD INFORMATION REQUIREMENTS 
Physicochemical properties 
7.2. Melting/freezing point 
 
No nanospecific recommendations provided in ECHA guidance. 
 
Nanoparticles exhibit lower melting point temperatures as compared to their bulk counterpart (temperature depression 
phenomena) because of the large fraction of (more reactive) surface atoms. The melting temperature in nanoparticles is 
inversely proportional to the radius of the nanoparticles (Goldstein et al. 1992, Burda et al. 2005). For example, the melting 
point of bulk silver is 962 °C but for a 2 nm diameter silver nanocrystal the melting point drops about 800 degrees below that 
of the bulk form, i.e. to 127 °C (experimentally) (Little et al. 2012). This information should be properly addressed when 
characterising the substance in the nanoform and when applying endpoint specific rules. 
 
OECD has concluded that the Test Guideline relevant to characterising melting point/melting range (i.e. OECD TG 102) is 
considered to be applicable to NMs (OECD 2009). 
7.3. Boiling point 
 
No nanospecific recommendations provided in ECHA guidance. 
 
ECHA Guidance (ECHA 2015) advices to use OECD TG 103 for testing boiling point of a substance. OECD (2009) concluded 
that TG 103, though applicable for determining the boiling point of manufactured NMs, is probably not relevant to existing 
solid NMs. 
 
It should be noted that REACH does not require the determination of boiling point for solids which either melt above 300 °C 
or decompose before boiling. This in practice means that determination of boiling point may not be required for certain NMs. 
Yet, the dependency of melting temperature from the radius of a nanoparticle should be properly addressed when 
characterising the substance in the nanoform and when applying endpoint specific rules. 
 
Although the boiling temperature (like the melting temperature) of NMs is expected to decrease when the particle is below a 
critical size, liquid nanoparticles (or, more accurately, nanodrops formed in the melting process) are expected to coalesce 
very rapidly to produce a single melt, thus destroying the structure of the NM, which is not expected to be re-established 
during the cooling process. Consequently, the boiling point determination is extremely unlikely to be a characteristic of the 
manufactured NM, per se, but of the generic material composition (OECD 2009). 
 
In the case of liquid manufactured NMs (nanoemulsions), the act of heating to the boiling point may again destroy the 
structure of the NM, which is also unlikely to re-establish on condensation; hence, the boiling point determination is for a 
material in a different form. Furthermore, the multiphase nature of a nanoemulsion means that it is unlikely to have a 
characteristic boiling point but rather a boiling range (OECD 2009). 
7.4. Relative density 
 
No nanospecific recommendations provided in ECHA guidance. 
 
OECD has concluded that the Test Guideline relevant to characterising relative density (i.e. OECD TG 109) might be 
applicable under some circumstances or to some classes of manufactured NMs, although further work is required to 
determine this and adjust the Test Guideline, if necessary (OECD 2009). 
7.5. Vapour pressure 
 
No nanospecific recommendations provided in ECHA guidance. 
 
It should be noted that determination of vapour pressure is not required under REACH for substances that have a melting 
point above 300 °C. This in practice means that determination of vapour pressure may not be required for certain NMs, 
regardless of any nanospecific changes in the vapour pressure compared to the bulk material. 
 
ECHA Guidance (ECHA 2015) advices to use OECD TG 104 for testing vapour pressure of a substance. The OECD has 
concluded that TG 104 might be applicable under some circumstances or to some classes of manufactured NMs, hence no 
further work was planned on adjusting this Test Guideline (OECD 2009). 
 
Although vapour pressure is not considered to be a nanospecific property, nanoparticles can have a significantly higher 
vapour pressure than that of its bulk counterparts (Cao and Wang 2004) and this information should be addressed when 
registering a nanoform of a substance. 
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NANOSPECIFIC CONSIDERATIONS ON REACH STANDARD INFORMATION REQUIREMENTS 
Physicochemical properties 
7.6. Surface tension 
 
No nanospecific recommendations provided in ECHA guidance. 
 
It should be noted that REACH requires information on surface tension only if the substance’s structure indicates that surface 
activity is expected, or if surface activity is a desired property of the material. This in practice means that information on 
surface treatment may be needed for those nanoforms that meet the aforementioned criteria. 
 
Generally speaking, surface tension is not relevant for NMs, except for the special sub-classes of Janus particles which may 
exhibit domains of different hydrophilicity (Granick et al. 2009). 
 
In its preliminary review of OECD Test Guidelines and their applicability to NMs, OECD concluded that the Test Guideline 
relevant to characterising surface tension (i.e. OECD TG 115) might be applicable under some circumstance or to some 
classes of manufactured NMs. It was stated that this TG is applicable to solutions, but it is not known how the results might 
be impacted by the presence of a colloidal suspension, which might be present if the sample of manufactured NM does not 
completely dissolve. Hence, further work is required to determine this and to adjust the TG, if necessary (OECD 2009). 
7.7. Water solubility 
 
Nanosized materials may be more soluble than the same substance in bulk form. ECHA guidance (ECHA 2012a) further 
defines 'solubility' as: "the degree to which a material (the solute) can be dissolved in another material (the solvent) such 
that a single, homogeneous, temporally stable phase (a suspension down to the molecular level) results, and is relevant to 
solids, liquids and gases". ECHA further specifies that "the three properties, solubility, hydrolytic stability and acid 
dissociation constant are inter-related. It is not possible to measure any of these without some knowledge of the other two”, 
and that, in the case of NMs, the preliminary test assessing solubility might need to be performed by instrumental means 
rather than visual. 
 
Current methods for solubility assessment of a bulk material could in principle be used for NMs; specific nano-tailored 
protocols and guidelines are under development (Hartmann et al. 2015, Tantra 2016). 
 
A review of OECD TG 105 (water solubility), with respect to NM testing, is ongoing (OECD 2016a). OECD (2014a) previously 
concluded that TG 105 is not appropriate for NMs and a new TG should be created to address the dissolution behavior of 
NMs. OECD suggested that the measurand of interest (beginning with a pre-determined unit of particles in a standardised 
solution and temperature) is the mass proportion of NMs held in solution. OECD also advised that, whether this mass 
diminishes after a set period of time or not, the amount of time required for mass to diminish by X% needs to be determined 
(OECD 2009). 
 
It is important to distinguish between water solubility, as defined by ECHA, and other parameters (e.g. dispersibility, 
dissolution rate, aggregation, etc.). While such parameters may be of importance to NMs, they may not fall under the 
definition of water solubility in the ECHA guidance. Both ECHA (2012a) and OECD (OECD 2012a) highlight that it is important 
not to confuse solubility, which occurs at molecular level, with dispersibility, which occurs at particle level. The distinction 
between the two can be difficult in case of a colloidal suspensions of NMs. ECHA (based on OECD 2012a) defines dispersibility 
as the degree to which a particulate material can be uniformly distributed in another material (the dispersing medium or 
continuous phase). 
 
The state of dispersion is typically assessed using comparative particle size measurements (ECHA 2012a), which requires a 
reliable method of measuring the baseline particle size distribution of the material. By comparing changes in particle size 
distribution (including agglomeration/aggregation state), a qualitative assessment or proxy measure of the state of 
dispersion can be made. Zeta potential measurement, combined with Dynamic Light Scattering (DLS) also enables the 
stability of nanoparticles dispersions to be monitored and a qualitative understanding of the agglomeration process (ECHA 
2012a). 
7.8 Partition coefficient n-octanol/water 
 
The current Test Guidelines for n-octanol/water partition coefficient (OECD TG 107, 117, 123) might be applicable under 
some circumstances or to some classes of NMs, although further work is required to determine this and modify the TGs, if 
necessary (ECHA 2012a, OECD 2009). Results might be impacted by the formation of a colloidal suspension if manufactured 
NMs do not dissolve completely (OECD 2009). In case of NMs, it can be difficult to distinguish if a sample is dissolved or 
dispersed due to the small particle size. 
 
Measurement of the water-octanol partition coefficient for NMs turned out not to be meaningful, as the coefficient relates to 
distribution of dissolved material between the two phases. NMs, however, are not dissolved but dispersed as particles (or if 
dissolved, they become bulk forms without the need to apply nanospecific considerations) (OECD 2014a). 
7.9. Flash-point 
 
No nanospecific recommendations provided in ECHA guidance. 
 
It should be noted that measurement of the flash-point is not required for inorganic substances, which may exclude a large 
number of NMs. Furthermore, as the flash-point is a property of liquids, the property may not be relevant for many NMs. 
 
OECD concluded that the Test Guideline relevant to characterising the flashpoint (i.e. OECD TG 113) is considered applicable 
to NMs (OECD 2009). 
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NANOSPECIFIC CONSIDERATIONS ON REACH STANDARD INFORMATION REQUIREMENTS 
Physicochemical properties 
7.10. Flammability 
 
No nanospecific recommendations provided in ECHA guidance. 
 
Flammability and explosive properties may differ between nano and bulk form of a same substance (Bouillard 2008). 
According to Bouillard (2008), most nanopowders display high reactivity characteristics that can lead to fire or explosion 
accidents, providing support to the suggestion that the REACH information requirements on explosive properties are as 
relevant for NMs as for bulk materials. The following properties have been defined as important for estimating the explosive 
risk of NMs: i) particle size, size distribution and shape; ii) surface area and surface charge; and iii) particle and surface 
composition. The author further reports that several commonly applied methods for explosivity studies are unsuitable for 
nanopowders, namely: i) current modified, open-ended Hartmann tubes (used to visualise ignition of powders and measure 
the minimal ignition energy), due to the potential release of nanoparticles during the experiment; ii) current falling hammer 
equipment used to measure mechanical stability with regards to shock/impact. Both methods were adapted for NMs by the 
NANOSAFE2 project. 
 
Bouillard (2008) highlights that there is not enough supporting evidence available in the literature to judge whether there 
may be the potential for read-across of explosivity data from bulk equivalents to NMs. In addition, it is suggested by others 
that read-across of explosivity data from bulk materials to NMs is not possible, since NMs may have explosive properties 
which are solely due to the small particle size (RIVM 2009). 
7.11. Explosive properties 
 
No nanospecific recommendations provided in ECHA guidance. 
 
See 7.10. Flammability. 
7.12. Self-ignition temperature 
 
No nanospecific recommendations provided in ECHA guidance. 
7.13. Oxidising properties 
 
No nanospecific recommendations provided in ECHA guidance. 
7.14 Granulometry 
 
In ECHA guidance (ECHA 2012a), granulometry is defined as the determination of particle size distribution. When a group of 
particles are of differing sizes, they may be described by a particle size distribution. The guidance further specifies that in the 
case of NMs, shape and specific surface area are inseparable parts of granulometry. Thus, additional information on these 
two properties should also be provided. Available techniques specific for the determination of particle size distribution of NMs 
are summarized in ECHA guidance (ECHA 2012a). The OECD Test Guideline 110, Method B (electron microscopy), is 
considered applicable to NMs, but not Method A (sedimentation of centrifugation) (ECHA 2012a). Additional information on 
sizing techniques has been published by OECD (2014a, 2016a, 2016b) and CEN/TC 35243. 
 
The ECHA guidance (ECHA 2012a) further specifies that the data on particle size distribution should contain information on: 
suspending medium, concentration (relevant to particles or fibres), representative image(s) from microscopy, particle size 
distribution histogram from the applied measurement technique, average particle size(s) for resolvable peaks in the 
distribution, as mass number and surface area per unit volume as appropriate, among others. It is also assumed that particle 
size distribution is available as a histogram. 
 
Particle size distribution should not only be measured for the material under investigation but also for the airborne dust 
(dustiness), where appropriate, as it may influence the decision regarding which route of administration is most appropriate 
for the acute toxicity and repeat dose toxicity animal studies. A number of methods are provided for determining the particle 
size fractions, which are then used to assess the possible health effects resulting from inhalation of airborne particles in the 
workplace. Generally, dustiness, which is the propensity of a material to become suspended in air, is of interest when NMs 
are manufactured or handled. As highlighted by the OECD, "the methods that are readily available were generally developed 
with an aim to assess the likelihood of workplace exposures to powders and were not designed with nanomaterials in mind. 
An additional challenge is that many methods require a large mass of material which is often not available for nanomaterials"  
(OECD 2012a). As identified in the RIP-oN 2 report, some methods alter the pristine NMs and can fracture 
aggregated/agglomerated NMs into smaller entities (NanoCare 2009). The methods chosen needs to take these factors into 
account. The Vortex Shaker and the Rotating drum method have been specifically developed for NMs (Nanogenotox 2012, 
Rasmussen et al. 2013). Both methods are currently under standardisation at CEN level. 
7.15. Stability in organic solvents and identity of relevant degradation products 
 
No nanospecific recommendations provided in ECHA guidance. 
                                           
43https://standards.cen.eu/dyn/www/f?p=204:32:0::::FSP_ORG_ID,FSP_LANG_ID:508478,25&cs=18E152154
F73BA190A16C4D279047F5FD 
 36 
NANOSPECIFIC CONSIDERATIONS ON REACH STANDARD INFORMATION REQUIREMENTS 
Physicochemical properties 
7.16. Dissociation constant 
 
No nanospecific recommendations provided in ECHA guidance. 
 
This endpoint should be taken into consideration especially when dealing with surface treated nanoparticles. OECD (OECD 
2012a) highlighted that surface acidity (related to dissociation constants of surface ionisable sites) is an aspect of surface 
chemistry that may be particularly relevant, noting that: ionisable sites may influence the surface charge, which has been 
considered significant in toxicological studies; and surface ionisation may also play a major role in colloidal particle stability 
and even inhibit migration into hydrophobic phases (e.g. octanol/water partition coefficients). 
 
OECD concluded that the Test Guideline relevant for dissociation constant characterization (i.e. OECD TG 112) might be 
applicable under some circumstances or to some classes of manufactured NMs. It stated that this TG is applicable to solutions 
but it is not known how the results might be impacted by the presence of a colloidal suspension, which might be present if 
the sample manufactured NM does not completely dissolve. Hence, further work is required to determine this and to modify 
the TG, if necessary (OECD 2009). This TG is currently referenced in the ECHA guidance (ECHA 2015), and it is the only one 
suggested for testing. 
7.17. Viscosity 
 
No nanospecific recommendations provided in ECHA guidance. 
 
OECD concluded that the Test Guideline on relevant viscosity characterization (i.e. OECD TG 114) is not applicable to 
manufactured NM or, if applicable, provides no useful information. TG 114 is only applicable to liquids and does not refer to 
solutions, suspensions or emulsions (OECD 2009). Although the viscosity of a solution can be measured, standardized 
preparation procedures are needed to be included but are not given in TG 114. Additionally, it is unknown what impact a 
colloidal suspension may have on the results. It is not clear yet what the importance of this property might be for the 
behaviour of NMs, both in the environment and in living organisms. At the same time, there is the need to define the medium 
or media in which such suspensions should be assessed. 
 
Nanospecific considerations on other physicochemical properties and endpoints (e.g. 
shape, surface area, agglomeration/aggregation, adsorption/desorption), which are not 
explicitly mentioned in REACH Annexes VII-X but are considered relevant when fulfilling 
the Standard Information Requirements, can be found in annex 2 of this document. 
3.2.1.3 Toxicological properties 
Table 3.6 illustrates the nanospecific considerations regarding the REACH Standard 
Information Requirements for toxicological properties. 
 
Table 3.6. Nanospecific considerations regarding the Standard Information Requirements on 
toxicological properties in the REACH registration dossier. NM = nanomaterial. 
NANOSPECIFIC CONSIDERATIONS ON REACH STANDARD INFORMATION REQUIREMENTS 
Toxicological properties 
8.1 Skin corrosion/irritation 
 
The standard test methods are applicable also for testing the effects of NMs. However, non-testing approaches (e.g. 
(Q)SAR, grouping and read-across) can be applied on a case-by-case basis only, and require detailed scientific justification 
(ECHA 2012a). 
8.2 Serious eye damage/eye irritation 
 
The standard test methods are applicable also for testing the effects of NMs. However, non-testing approaches (e.g. 
(Q)SAR, grouping and read-across) can be applied on a case-by-case basis only, and require detailed scientific justification 
(ECHA 2012a). 
8.3 Skin sensitization 
 
The standard test methods are applicable also for testing the effects of NMs. However, non-testing approaches (e.g. 
(Q)SAR, grouping and read-across) can be applied on a case-by-case basis only, and require detailed scientific justification 
(ECHA 2012a). 
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Toxicological properties 
8.4. Mutagenicity 
 
The majority of the test methods are applicable also for testing the effects of NMs. However, the bacterial reverse mutation 
test (Ames test) is not considered reliable for the assessment of NMs and should not be used as a single test for 
mutagenicity (ECHA 2012a, 2013a, OECD 2014b). 
Non-testing approaches (e.g. (Q)SAR, grouping and read-across) can be applied on a case-by-case basis only and require 
detailed scientific justification (ECHA 2012a). 
8.5. Acute toxicity 
 
When selecting the exposure route, it is important to remember that the route of exposure should reflect the most likely 
route of human exposure. For NMs, inhalation may be the most likely route of exposure. ECHA may require testing by 
inhalation when the substance is a solid with inhalable particle size (ECHA 2015). When performing acute inhalation toxicity 
studies with NMs, it is important to include aspects on lung overload in the interpretation of the study results (ECHA 
2012a). Non-testing approaches (e.g. (Q)SAR, grouping and read-across) can be applied on a case-by-case basis only and 
require detailed scientific justification (ECHA 2012a). 
8.6. Repeated dose toxicity 
 
Inhalation may be the most likely route of exposure for NMs. When performing repeated dose inhalation toxicity studies 
with NMs, it is important to include aspects on lung overload in the interpretation of the study results. For details, see ECHA 
(2012a). Non-testing approaches (e.g. (Q)SAR, grouping and read-across) can be applied on a case-by-case basis and this 
requires scientific justification (ECHA 2012a). 
The RIPoN-2 report recommended the analysis of the bronchoalveolar lavage fluid (BALF) (cell count and total protein) as 
an additional endpoint or measurand (Hankin et al. 2011). The addition of this endpoint and lung burden measurements 
were also discussed at the OECD inhalation toxicity testing expert meeting (OECD 2012b). Currently, OECD TG 412 and 413 
are under review to address NMs by including evaluation of bronchoalveolar lavage (BAL) when testing gases, vapours, and 
aerosols, and lung burden measurements. 
8.7. Reproductive toxicity 
 
ECHA guidance does not provide nanospecific recommendations on testing reproductive toxicity for NMs. The available 
standard test methods can be considered as applicable to NMs. 
 
Non-testing approaches (e.g. (Q)SAR, grouping and read-across) can be applied on a case-by-case basis and this requires 
scientific justification (ECHA 2012a). 
8.8. Toxicokinetics 
 
Physicochemical characteristics of a substance may be modified in the test systems because of metabolism transformations 
or other physicochemical changes. These potential modifications may change the toxicokinetics behaviour of the substance 
compared to what is expected from the parent substance, before being tested. In the case of NMs, ECHA guidance 
recommends paying special attention to these potential modifications during the toxicokinetics evaluation. 
ECHA guidance also underlines the consideration of translocation of nanoparticles across the gastrointestinal wall in the 
models to predict absorption and bioavailability. Nanoparticles' translocation may also occur for other uptake routes (ECHA 
2012a, 2012c). 
 
In a discussion on best practices for hazard assessment of NMs, the ECHA Group Assessing Already Registered 
Nanomaterials (GAARN) encouraged evaluating toxicokinetic data for grouping and read-across as well as for extrapolation 
of information from in vitro to in vivo. Such data should also be considered when defining the testing strategy for 
ecotoxicological endpoints (ECHA 2013a). In the working document by ECHA/RIVM/JRC (2016), information on toxicokinetic 
behaviour is also considered important in the substantiation of read-across between nanoforms. 
 
Nanospecific considerations on other toxicological properties and endpoints (e.g. 
respiratory tract corrosion and irritation, oxidative stress, short-term inhalation studies), 
which are not explicitly mentioned in REACH Annexes VII-X but are considered relevant 
when fulfilling the Standard Information Requirements, can be found in annex 2 of this 
document. 
3.2.1.4 Ecotoxicological properties 
Table 3.7 illustrates the nanospecific considerations regarding the REACH Standard 
Information Requirements for ecotoxicological properties. 
Nanospecific considerations on ecotoxicological properties and endpoints (e.g. NM aging, 
transformation, detection), which are not explicitly mentioned in REACH Annexes VII-X 
but are considered relevant when fulfilling the Standard Information Requirements, can 
be found in annex 2 of this document. 
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Table 3.7. Nanospecific considerations regarding the Standard Information Requirements on 
ecotoxicological properties in the registration dossier. NM = nanomaterial. 
NANOSPECIFIC CONSIDERATIONS ON REACH STANDARD INFORMATION REQUIREMENTS 
Ecotoxicological properties 
9.1. Aquatic toxicity 
 
OECD (2014c) suggested three tiers of decision trees for establishing: firstly, how the stock/stem solution for a NM should 
be prepared; secondly, how the exposure solution should be prepared; and thirdly, how the actual aquatic toxicity test 
should be conducted. These tiers involve various pilot tests, aiming at stability and realism of the testing conditions. It was 
also suggested that grouping on basis of material properties and characteristics, mode of action etc. is used for identifying 
NMs for which the same testing protocol can be used. 
 
When performing toxicity testing on fish with NMs, it is recommended to collect data on the following parameters as 
supportive evidence: fish ventilation rate, gill pathologies, mucus secretion, brain pathology, animal behaviour and activity 
levels of enzymes (catalase, superoxide dismutase, glutathione peroxidase, glutathione-S-transferase) (ECHA 2012b). 
 
Regarding algal tests, OECD (2014c) recommends that the assay to be used is tested in advance for lack of interference 
due to particle presence, which has been reported to confound the measurement of algal cell counts. NM photoreactivity 
and effect on the availability on solved nutrients should also be considered in algal tests.  
9.2. Degradation 
 
OECD (2014c) identified degradation (abiotic and biotic) of NMs among the important pieces of information to be known 
before further tests in water compartments are conducted, and included it in a planned decision tree, stating that TGs need 
to be developed for appropriate degradation tests. 
 
ECHA (2012b) clarified that a majority of OECD TGs on biodegradability are applicable for those NMs that are of organic 
nature. Moreover, despite the fact that many NMs are inorganic and even carbon-based NMs tend to be of inorganic nature, 
surface coating and functionalization might be organic and consist of biodegradable materials. If several conclusive aerobic 
tests indicate very low or negligible degradation, it may be concluded that the substance is not biodegradable, without 
performing further tests (ECHA 2012b). 
9.3.1. Adsorption/desorption screening 
 
With regard to NMs, the distribution coefficient Kd has to be based on actual testing using one of the methods for the 
measurement of adsorption, since estimations of Kd derived from the organic carbon-water partition coefficient (KOC) and 
the octanol-water partition coefficient (Kow) have no or questionable merit when it comes to NMs (ECHA 2012a). 
 
OECD (2014c) concluded that TG 106 (Adsorption -- Desorption Using a Batch Equilibrium Method) is not appropriate for 
testing the adsorption/desorption of NMs, and that a new adsorption test should be developed, also as a pre-test for TG 
312 (Leaching in soil columns). 
9.3.2. Bioaccumulation in aquatic species, preferably fish 
 
It is not possible to estimate BCF values from log Kow for those NMs that are dispersed as particles and not in solution 
(ECHA 2012c) (see also property 7.8 in table 3.5). For the same reason, OECD concluded that BCF (TG 305) is an 
inappropriate endpoint for NMs that do not dissolve; however, further research is needed to determine which alternative 
endpoint (including internalisation rate, attachment efficiency, bioavailable fraction) may be appropriate for those NMs. 
Dietary exposure route should therefore be used for testing NMs (as a worst-case situation), and the test procedure used 
should be described in detail. OECD guidance on assessing the apparent accumulation potential for NMs (which provides 
information on how to test NMs via dietary exposure and how to quantify the accumulation potential in fish) is under 
development. ECHA guidance (2012c) is also being updated to reflect this. 
 
For BCF measurements of dissolving NMs, information on the form of the substance present in the animal tissue is 
important (ECHA 2012c).  
 
Non-testing approaches (e.g. (Q)SAR, read-across) can be applied on a case-by-case basis and require scientific 
justification (ECHA 2012c). 
 
According to OECD (2014c), nanospecific guidance should also be developed for TG 315 (Bioaccumulation in sediment-
dwelling benthic oligochaetes) and TG 317 (Bioaccumulation in terrestrial oligochaetes). 
9.4. Effects on terrestrial organisms 
 
OECD (2014c) recommended continuing with both wet and dry spiking of soils in order to identify which procedure is the 
most suitable for testing. It was also recommended to use the same stock solution as in aquatic toxicity tests. The amount 
of NM accumulating in organisms is seen as likely the key for regulatory policies. It was stated that guidance on detection 
techniques for NMs in soil is needed, and understanding the state of the NM in soils was considered critical for interpreting 
results. 
Estimates based on partitioning may not be relevant, as substances may be distributed in the environment as particles 
(ECHA 2012c). Non-testing approaches (e.g. (Q)SAR, grouping and read-across) can be applied on a case-by-case basis 
only, and require detailed scientific justification (ECHA 2012c). 
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9.5. Effects on sediment organisms 
 
OECD (2014c) recommended continuing with both wet and dry spiking of sediments in order to identify which procedure is 
the most suitable for testing. It was also recommended to use the same stock solution as in aquatic toxicity tests. The 
amount of NM accumulating in organisms is seen as likely the key for regulatory policies. It was stated that guidance on 
detection techniques for NMs in sediment is needed, and understanding the state of the NM in sediments was considered 
critical for interpreting results. 
Estimates based on equilibrium partitioning methods may not be relevant, as substances may be distributed in the 
environment as particles (ECHA 2012b). 
9.6. Effects on birds 
 
No nanospecific recommendations provided in ECHA guidance. 
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3.3 Rules for adaptation of the standard testing regime 
Annex XI of REACH sets out the "General rules for adaptation of the standard testing 
regime set out in Annexes VII to X". The registrant may adapt the standard testing 
regime under REACH according to three general rules.  
The first rule concerns the cases when (animal) testing does not appear to be 
scientifically necessary and data may be obtained through other approaches. The 
adaptations include: 
 Use of existing data (from experiments not performed according to GLP or 
performed according to test methods not recognised by the European 
Commission or ECHA and from historic human data). 
 Weight of Evidence (WoE) (when there is evidence from several independent 
sources leading to a certain conclusion on a property). 
 Qualitative or Quantitative Structure-Activity Relationship ((Q)SAR) (when the 
substance falls within the applicability domain of the model and the obtained 
results are scientifically valid, adequate for the purpose of use, and adequately 
and reliably documented). 
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 In vitro methods (when the model is considered as 'suitable' i.e. well-developed 
according to internationally agreed ECVAM criteria). 
 Grouping of substances and read-across (when substances have structural 
similarities and results are adequate for the purpose of use, have adequate and 
reliable coverage of the key parameters addressed in the corresponding test 
method, cover an exposure duration comparable to or longer than the 
corresponding test method, and are adequately and reliably documented). 
The second rule applies when (animal) testing to fulfil a specific information requirement 
may be omitted/waived without the need of providing data from other approaches, if it is 
technically not possible to conduct the study because of the properties of the substance. 
The third rule concerns the possibility of omitting/waiving (animal) testing based on the 
exposure scenarios (i.e. substance-tailored exposure-driven testing), for example when 
absence of or no significant exposure is demonstrated for all scenarios or when the 
substance is incorporated in an article and is demonstrated that no release is expected 
during its life cycle. 
 
3.3.1 Nanospecific considerations  
Using the rules for adaptations of Standard Information Requirements under REACH may 
present challenges when it comes to NMs. Such nanospecific considerations are 
illustrated in this sub-section. The currently available tools (e.g. guidance documents, 
models, protocols, decision trees) for addressing the nanospecific considerations 
discussed in this sub-section, including those developed under NANoREG, are listed in the 
NANoREG toolbox (project deliverable D1.1244, see relevant worksheet in Excel file). 
3.3.1.1 Use of existing data 
In many cases, existing data may not be available for the nanoform(s) but for the non-
nanoform(s) of the substance (e.g. bulk form(s)) (see sub-section 3.1 for a definition of 
these terms).  
As for any substance, data on a certain information requirement for a certain NM can be 
available from studies not performed according to GLP or mutually accepted guidelines. 
The use of such data must be carefully considered and relevant conditions must be met 
(e.g. that the method is adequate for the purpose, reliable, of sufficient duration, and 
well-documented).  
The existing data should be considered and used as appropriate to develop a suitable 
testing strategy for NMs. 
3.3.1.2 Weight of evidence 
Where the Weight of Evidence (WoE) approach is particularly important for NMs is for the 
use of information from newly developed test methods that may not yet be fully 
validated. However, the experience on the use of WoE for NMs is limited and based on 
expert judgment.  
Some scientists, e.g. Hristozov et al. (2014) and Cuddy et al. (2016), attempted to apply 
WoE principles to NMs for hazard and exposure screening.  
3.3.1.3 Qualitative or Quantitative structure-activity relationship ((Q)SAR)  
When applying (Q)SAR methods to NMs (sometimes referred to as Qualitative or 
Quantitative Nanostructure-Activity Relationship, (Q)NAR) there are in general no 
nanospecific adaptations as the general requirements are considered applicable to NMs 
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REG_D1_12_DR_Toolbox.org 
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(Tantra et al. 2015). Several (Q)SAR/(Q)NAR approaches are under development but 
their use as alternative methods in a regulatory context still needs to be accepted. Most 
of them are based on very small datasets and this limits their applicability. 
3.3.1.4 In vitro methods 
When performing risk assessment mostly based on in vitro test results, in vitro to in vivo 
extrapolation (IVIVE) shall be performed. One of the essential aspects of IVIVE is kinetic 
information. In vitro tests generally do not consider the kinetics of a body as animal tests 
do: the absorption in the gut, for example, is not considered in an in vitro test with liver 
cells. Thus, in vitro test results must be supplemented with kinetic data using kinetic 
models to enable IVIVE. This approach is valid for non-nano (molecular) substances and 
there is no reason why this general approach should not be valid for NMs as well.  
Some NMs can dissolve into the molecular or ionic form. As a result, such NMs essentially 
lose their nanoparticle properties and can be dealt with using the same approach applied 
to the non-nano (molecular) substances. For the NMs that do not dissolve (and are thus 
durable), there is a high potential for accumulation as no other elimination pathways are 
currently known besides dissolution. In case of accumulation of molecular substances and 
NMs, the accurate determination of the kinetics becomes of greater importance for the 
correct estimation of human health risk as an extrapolation over time needs to be made.  
Even though kinetic information in general is just as important for molecular substances 
as for NMs, the type of kinetic information that is necessary differs (table 3.8). Available 
kinetic studies generally demonstrate a distribution pattern for nanoparticles that differs 
from molecular substances. Particles tend to disappear from the blood very rapidly and 
distribute to liver, spleen, and to a lesser extent to lung and testis (e.g. Geraets et al. 
2014, van Kesteren et al. 2014). It is remarked that comparisons between molecular 
substances and nanoforms are not always possible as some of the most widely used 
nanoparticles are not available in molecular form. A few PBPK-models45 for nanoparticles 
have been published based on the paradigm that the distribution is not a diffusion-driven 
process (as for most organic molecular substances) but a process governed by the active 
uptake of the nanoparticles by macrophages (e.g. Bachler et al. 2015, Carlander et al. 
2016, Lin et al. 2016). This implies that sampling plasma is not suitable to monitor 
nanoparticle exposure and kinetics. 
Kinetic parameters important for IVIVE with NMs are: 
• Dissolution rate in the various surroundings (including in macrophages); 
• Protein corona composition and size in the various surroundings; 
• Absorption (i.e. translocation over the barriers encountered, dependent on the 
exposure route); 
• Some form of uptake rate by macrophages or by monocytes in tissues, which is 
a very new parameter and thus has a very high uncertainty associated with its 
determination. 
Together with physiological information on macrophage content of tissues, knowledge on 
uptake rate by macrophages/monocytes should help determine the uptake rate into 
tissues. 
According to Landsiedel et al. (2012) the distinct factors strongly influencing the specific 
kinetics of NMs (apart from those that also influence the kinetics of molecular 
substances) are: 
• Protein binding to NMs; 
• The size (primary particle and agglomeration) of NMs; 
• The surface charge of NMs. 
                                           
45 Physiologically Based Pharmaco-Kinetic models (PBPK) 
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Table 3.8. Comparison of kinetic aspects that distinguish nanoparticles from conventional 
(molecular) substances. PBPK = Physiologically Based Pharmaco-Kinetic models. 
Kinetic aspect Molecular substances Nanoparticles 
Type of kinetics Dissolved substance kinetics Particle kinetics 
Substance form Uniform Pluriform, also during internal exposure 
Linearity Less/more than or equal to dose-
proportional 
Less than dose-proportional is observed 
at higher doses due to agglomeration 
Barrier transport Gradient driven Against gradient is observed 
0-100% Mainly low (<10%) 
Proteins Protein binding decrease free 
fraction, free fraction determines 
activity 
Protein corona formation (may) affect 
kinetics 
Metabolism (enzymatic 
degradation) 
0-100% Not relevant for metals; maybe for 
organic-metal combinations 
Conjugation Aids excretion Probably not relevant 
Distribution Flow and extraction ratio 
dependent 
Uptake by macrophages, thus 
distribution mainly to tissues with 
phagocytic capacity 
Uptake into tissue Diffusion driven, carrier mediated In principle driven by active processes, 
but passive processes cannot be 
excluded 
Excretion Renal, hepatic, etc. Clearance from tissues in general very 
low 
Renal, hepatic transporters Mechanism of clearance not fully 
understood 
Accumulation Possible, both in plasma and 
tissues 
Possible, merely in tissues, hardly in 
plasma 
Mechanism of 
accumulation 
Hydrophobic or bound to cellular 
structures or proteins 
In vesicles 
Interactions Mechanisms known Unknown 
Route-to-route 
extrapolation 
Basic understanding Unknown, but route-dependent kinetics 
seem plausible related to changes in 
physicochemical properties or protein 
corona 
Interspecies 
differences 
Basic understanding Not clear, some indications 
PBPK models Physiological parameterization is 
understood 
Physiological parameterization is under 
development 
 
In vitro methods are prone to nanospecific issues. The exposure conditions in in vitro 
methods are susceptible to aggregation/agglomeration and subsequent sedimentation, 
flotation, and protein corona formation, which affect the fate of the NM. Also the read-out 
of in vitro methods can be influenced by NMs, e.g. for light scattering. As a consequence, 
the outcome of an in vitro method is often difficult to interpret for NMs. Efforts are 
ongoing to develop suitable dispersion protocols, analysis of cellular dose, and quality 
criteria. 
3.3.1.5 Grouping of substances and read-across  
The general approach for grouping and read-across (e.g. OECD 2014, ECHA 2015) are in 
principle applicable to NMs but several additional aspects shall be considered when 
relevant. 
It is recognised that, when it comes to NMs, similarity cannot be based on structural or 
chemical composition only. The ECHA Group Assessing Already Registered Nanomaterials 
(GAARN) clarified that while read-across commonly involves substances of different 
chemical composition but structural similarity, read-across for NMs largely involves 
different nanoscale materials of the same chemical composition, i.e. different nanoforms 
of a certain substance addressed in the same REACH registration dossier (ECHA 2013). 
In addition to the Standard Information Requirements for a substance under REACH 
(Annexes VII-X, see sub-section 3.2), a full physicochemical characterisation of the NM is 
recommended, including other properties e.g.: solubility, (rate of) dissolution, specific 
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surface area, particle size and particle size distribution, surface characteristics (including 
surface chemistry coating, functionalization, surface charge), hydrophobicity, 
agglomeration and aggregation, crystalline phase, shape/morphology, rigidity, aspect 
ratio, photocatalytic properties, porosity and pour density, dustiness, dispersibility, zeta 
potential, flammability, explosivity, and reactivity (redox potential, radical formation) as 
well as cellular effects, kinetics, and fate parameters like biopersistence, biodegradation 
(of coating), biodurability, and (toxic) ion release.  
Several recent scientific publications can provide additional details on how these different 
parameters can be used for grouping and read-across of NMs (e.g. Oomen et al. 2015).  
Specific recommendations for NMs are provided by ECHA/RIVM/JRC (2016). This 
document intends to help the user to design a testing strategy that fulfils the REACH 
information requirements for the substance and is schematically presented as a stepwise 
approach. The read-across hypothesis can be substantiated by a toxicokinetic argument 
related to parameters under "where they go" and a hazard argument related to 
parameters under "what they do" (ECHA/RIVM/JRC 2016). ECHA is currently updating its 
guidance on (Q)SAR and grouping of chemicals with recommendations for NMs based on, 
among the others, the content of this document46. 
3.3.1.6 Adaptations when testing is technically not possible 
There could be instances where the technical development is not sufficiently advanced to 
allow appropriate measurements to be performed (e.g. instrumentation or detection of 
organic NMs in certain organic matrices can pose such difficulties). Consequently, the 
testing of NMs should be adapted on a case-by-case basis. 
3.3.1.7 Substance-tailored exposure-driven testing 
REACH Annex XI describes the specific conditions in which exposure scenarios developed 
in the Chemical Safety Assessment (CSA) may be used as grounds to omit the testing 
required in Annexes VII-X. All the described conditions are relevant for NMs. For 
instance, absence of exposure or no significant exposure to the NM may be demonstrated 
due to the permanent embedding of the NM in a matrix, resulting in no release in the 
course of its life cycle. 
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3.4 Hazard assessment 
The objective of the hazard assessment under REACH is to identify the hazards of the 
substance with respect to human health and the environment. It encompasses: the 
collection of all relevant and available information on the intrinsic properties of the 
substance; the identification of critical effects; the classification and labelling of the 
substance based on Regulation (EC) N° 1272/2008 on classification, labelling and 
packaging (CLP) of substances and mixtures (European Parliament and Council 2008); 
the calculation of Derived No-Effect Levels (DNEL) for human health and Predicted No-
Effect Concentrations (PNEC) for the environment from available testing results and other 
appropriate information on various endpoints; and the determination of whether the 
substance should be regarded as a persistent, bioaccumulative, and toxic (PBT) 
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substance or as a (very) persistent, (very) bioaccumulative (vPvB) substance (ECHA 
2014). 
The hazard assessment includes the following 4 steps. 
 
 
Step1. Hazard identification 
For the identification of the hazards of a substance, all the relevant available data for 
each information requirement (see sub-section 3.2) must be assessed and integrated in 
order to determine whether the substance may have adverse effects on human health 
and/or the environment. Regarding the identification of physical hazards, information on 
at least flammable, explosive and oxidising properties are necessary. The major part of 
the hazard identification involves evaluating all existing toxicological and ecotoxicological 
data to identify the critical effects and estimate the dose descriptors (the relationship 
between a specific effect of a substance and the dose at which it takes place) for each 
critical adverse health or environmental effect. The outcome includes e.g. the derivation 
of No Observed Effect Level/Concentration (NOAEL/NOAEC), Lowest Observed Effect 
Level/Concentration (LOAEL/LOAEC), or Lethal Dose 50% (LD50) values. 
When a quantitative dose-response relationship cannot be defined, a semi-quantitative or 
qualitative analysis is performed (ECHA 2009). 
Step 2. Classification and labelling 
When the nature and severity of an identified hazard meets the classification criteria, 
hazard classification is the assignment of a standardised description of this hazard to a 
substance or a mixture causing harm to human health or the environment. The 
determination of the appropriate classification and labelling of a substance on its own, in 
a mixture or in an article is a requirement under REACH and has to be documented both 
in the registration technical dossier and in the Chemical Safety Report (CSR). 
Harmonised criteria for classification and labelling have been developed within the United 
Nations (UN) structure and are compiled in the "Globally Harmonised System of 
Classification and Labelling of Chemicals" (GHS), which was adopted in 200247. In the EU, 
the classification and labelling criteria for substances and mixtures, based on GHS, are 
provided in Annex I of the CLP Regulation (European Parliament and Council 2008). 
Guidance on the application of the CLP criteria has been provided by ECHA (2015a, 
2015b). 
For physical hazards, the hazard classes according to CLP Regulation include: Explosives, 
Flammable gases, Aerosols, Oxidising gases, Gases under pressure, Flammable liquids 
and solids, Self-reactive substances and mixtures, Self-heating substances and mixtures, 
Self-reactive substances and mixtures, Pyrophoric liquids and solids, Substances and 
mixtures which in contact with water emit flammable gases, Oxidising liquids and solids, 
Organic peroxides, and Corrosive to metals. 
For health hazards, the hazard classes are: Acute toxicity, Skin corrosion/irritation, 
Serious eye damage/eye irritation, Respiratory or skin sensitisation, Germ cell 
mutagenicity, Carcinogenicity, Reproductive toxicity, Specific target organ toxicity, and 
Aspiration hazard. 
For environmental hazards, the hazard class is Hazardous to the aquatic environment. 
One additional hazard class to be considered is Hazardous to the ozone layer. 
The corresponding labelling is also stated in the CLP Regulation and guidance is provided 
by ECHA (2015a, 2015b). 
Step 3. Derivation of the hazard threshold levels for human health and the environment 
                                           
47 http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html 
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Based on the hazard identification (Step 1), the threshold levels for exposure below 
which risks for human health and for the environment are considered to be controlled 
have to be derived. 
Derived No-Effect Level (DNEL) 
The DNEL is the level of exposure to a substance above which humans should not be 
exposed. For each health effect and each relevant exposure pattern, a DNEL needs to be 
established. 
The DNELs are calculated by dividing the value of the health effect dose descriptor (see 
Step 1) by an assessment factor (AF). Dose descriptors identified in the hazard 
assessment are expressed as NOAEL/NOAEC, LD50, etc. Default AFs have been proposed 
by ECHA (2012a) but it may also be appropriate to use other factors as long as 
justification is provided. Since dose descriptors are often obtained from experimental 
data, an AF is required to allow for extrapolation between test animals and humans. 
Furthermore, the AFs are addressing intraspecies differences among individuals, 
differences in exposure duration between experimental setting and real scenarios, issues 
related to dose-response and the quality of the whole database. 
DNELs need to be derived for the different populations likely to be exposed to the 
substance, i.e. workers, consumers or humans exposed through the environment. In 
some cases, specific vulnerable subpopulations can be considered such as pregnant 
women or children. In addition, DNELs can be set for different durations of exposure, 
normally meaning single/short-term exposure and repeated/long-term exposure (e.g. 
calculated as worker exposure for 8 h/day). Furthermore, DNELs need to be derived for 
the relevant routes of exposure: oral, inhalation and/or dermal. After the values have 
been derived, the lowest DNEL for each exposure pattern is identified and used for risk 
characterisation (see sub-section 3.6). 
In situations, where no safe threshold level can be obtained, it is not possible to derive a 
DNEL. This is the case, for example, for non-threshold carcinogens. In these cases, a 
semi-quantitative value, known as the Derived Minimal Effect Level (DMEL), may be 
developed. The DMEL values represent exposure levels where the likelihood that the 
identified adverse effect occurs in a population is sufficiently low to be of no concern. 
DMELs can be used later on in the risk characterisation process in the same way as 
DNELs. 
Guidance on the derivation of DNELs and DMELs has been published by ECHA (2012a). 
Predicted No-Effect Concentration (PNEC) 
The PNEC quantitatively assesses the effects of a substance in the environment by 
determining the concentration of the substance below which adverse effects in the 
environmental compartment of concern are not expected to occur. Three main 
environmental compartments are considered: aquatic (both freshwaters and marine 
waters), soil and air. In addition, adverse effects need to be assessed for predators 
exposed via the food chain and microorganisms in wastewater treatment plants. In 
aquatic environments, the main compartments are the water column and the sediment. 
In terrestrial ecosystems, the environment is divided into the soil and the 'above soil' 
compartments covering both e.g. earthworms living in soil and terrestrial organisms. 
Inland waters that are generally protected against wind (e.g. ponds) may develop a 
surface layer on top of the water column. This layer forms a special habitat with a special 
exposure pattern to chemicals, i.e. exposure is mainly via atmospheric deposition and 
not via the water column.  
Because the conditions in laboratory tests differ from natural conditions, it is considered 
likely that ecosystems are more sensitive to chemicals than are individual organisms in 
the laboratory. Therefore, test results are not used directly for the assessment but as a 
basis for extrapolating the PNEC. Two different types of extrapolation methods exist: 
Species Sensitivity Distribution (SSD) and AF method. In the AF method the result from a 
laboratory test is divided by an appropriate AF. The sparser the available data, the higher 
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is the AF applied. PNECs are estimated by dividing the environmental effect dose 
descriptor with the lowest value by the relevant AF. Long-term tests are preferred over 
short-term tests, as long-term results give a more realistic picture of effects on the 
organisms in the course of their entire life cycle. When establishing the size of the AFs, a 
number of uncertainties have to be addressed to extrapolate from single-species 
laboratory data to a multi-species ecosystem. These are: intra- and inter-laboratory 
variation of toxicity data, intra- and inter-species variations (biological variance), short-
term to long-term toxicity extrapolation, and laboratory data to field impact 
extrapolation. The SSD is a statistical distribution and usually requires experimentally 
determined NOEC values for a number of species from different taxonomic groups. These 
method aims at calculating a concentration, which is assumed to protect a certain 
percentage (e.g. 95%) of the species of the ecosystem against toxic effects. The method 
assumes that the species-specific NOEC values follow a certain distribution function and 
that this can be applied for other taxonomic groups of species in the environment. When 
the available data do not fulfil these requirements (which is most often the case), the AF 
method is used.  
Guidance on the derivation of PNECs has been published by ECHA (2008). 
Step 4. PBT and vPvB assessment 
Substances that persist for long periods of time in the environment and have a high 
potential to accumulate in biota are of specific concern since their long-term effects are 
rarely predictable. Having once entered the environment, exposure to these substances 
is very difficult to reverse by the cessation of emissions. Protection of pristine remote 
areas from PBT/vPvB substances is particularly difficult, as these substances do not 
degrade close to their emission sources but may be gradually transported to remote 
areas. 
Environmental persistence is expressed as degradation half-life, i.e. the time required for 
a 50% reduction of the initial concentration by degradation. Substances that are 
persistent in the environment, lipophilic, and slowly eliminated by organisms have an 
elevated tendency to bioaccumulate. Bioaccumulation is the process through which there 
is an increase of concentration of a substance in an organism compared to the 
concentration in the surrounding environment. The extent of bioaccumulation is 
quantitatively expressed by the Bioconcentration Factor (BCF), which is the ratio of the 
concentration of a contaminant in the organism and its average concentration in water. 
The transfer process of the contaminant through the food webs is called biomagnification 
and is measured by the Biomagnification Factor (BMF).  
For PBT/vPvB substances, a 'safe' concentration in the environment cannot be 
established by using the currently available procedures. 
The objective of the PBT/vPvB assessment of a substance is to determine if it fulfils the 
numerical criteria set up under REACH Annex XIII (European Parliament and Council 
2011) for persistence, bioaccumulation and toxicity, which are: 
 Persistence (P) 
- half-life in sea water > 60 days, or 
- half-life in freshwater > 40 days, or 
- half-life in marine sediments > 180 days, or 
- half-life in freshwater sediments > 120 days, or 
- half-life in soil > 120 days. 
 Bioaccumulation (B) 
- BCF > 2000 l/kg (aquatic species). 
 Toxicity (T) 
- NOEC < 0.01 mg/l, aquatic species or 
- Carc. (cat. 1 or 2), mut. (cat. 1 or 2), or reprotoxic (cat. 1, 2, or 3). 
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 Very persistent (vP) 
- half-life in water > 60 days, or 
- half-life in sediments > 180 days, or 
- half-life in soil > 180 days. 
 Very bioaccumulative (vB) 
- BCF > 5000 l/kg. 
The criteria for PBT/vPvB assessment apply to all organic substances, including organo-
metals, and generally to any substance containing an organic moiety but are not 
applicable to inorganic substances (ECHA 2014). 
PBT or vPvB substances give rise to 'very high concern' and can be proposed for inclusion 
in REACH Annex XV ("List of substances subject to authorisation"). The authorisation for 
a specific use of the substance can be granted only if risks resulting from the use are 
adequately controlled or if no economically and technically feasible alternative exists. 
 
3.4.1 Nanospecific considerations 
The hazard assessment under REACH may present challenges when it comes to NMs. 
Such nanospecific considerations are illustrated in this sub-section. The currently 
available tools (e.g. guidance documents, models, protocols, decision trees) for 
addressing the nanospecific considerations discussed in this sub-section, including those 
developed under NANoREG, are listed in the NANoREG toolbox (project deliverable 
D1.1248, see relevant worksheet in Excel file). 
Under REACH, NMs are registered in the same dossier as the corresponding bulk 
substance. Only in cases where there are solid scientific grounds for considering the NM 
as a distinct substance, the NM can be registered in a separated dossier (see sub-section 
3.1.1). For each form of a substance, safe use should be ensured. Additional data, 
potentially derived from NM specific testing, may thus be necessary to demonstrate the 
safety of NMs. The provisions that apply to the registration of NMs under REACH are the 
same that must to be fulfilled for any other chemical substance. However, in line with 
scientific developments, there are specific considerations that the registrant should report 
for specific endpoints to facilitate the evaluation of whether the tests performed and the 
data obtained are adequate for the safety assessment of NMs (e.g. sample preparation, 
solubility/dispersion, use of stabilisers) (ECHA 2013a). Nanospecific considerations 
regarding the different steps of the hazard assessment (as previously described) are 
addressed in the following paragraphs. Other nanospecific considerations (i.e. 
nanospecific intracellular pathways and effects, nanospecific protocols, and NM 
carcinogenicity in vitro) are reported in annex 3 of this document. 
Step1. Hazard identification 
Nanospecific considerations for hazard identification regarding human health and the 
environment have been analysed in detail as a part of the REACH consultation process 
under "Specific Advice on Fulfilling Information Requirements for Nanomaterials under 
REACH Implementation Project on Nanomaterials 2 (RIP-oN2)" (Hankin et al. 2011); 
nanospecific recommendations formulated during the 2nd GAARN meeting have been 
published by ECHA (2013a); and the appendixes to ECHA guidance for implementation of 
REACH containing recommendations for NMs are under consultation at the time the 
present document is drafted49.  
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uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
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49 https://echa.europa.eu/support/guidance/consultation-procedure/ongoing-reach 
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Nanospecific issues concerning information requirements and collection of data are 
discussed in sub-section 3.2. Among those, hazard-related nanospecific issues (ECHA 
2012b, 2012c, 2013a) include: 
• Lung overload 
Issues related to particle overload in rat inhalation studies performed with poorly 
soluble low-toxicity (PSLT) particles have been identified. It has been argued 
that observed effects may be a reflection of the experimental conditions and not 
of the intrinsic potential of the NM to cause, for instance, inflammation or 
fibrosis. When evaluating and interpreting inhalation studies with NMs, attention 
should be paid to the doses and any data indicating lung overload. 
• Interference with assays 
It is important to note that studies have indicated that NMs may cause inhibition 
or enhancement in assays related to cytotoxicity. Examples of interference may 
include direct effects on absorbance or fluorescence or binding to assay 
components due to the large surface area of the particles. Such effects need to 
be considered when studies with NMs are evaluated in the hazard identification. 
• Mutagenicity/Bacterial mutation assays 
Bacterial mutation assays are not recommended for studying the mutagenicity of 
NMs as several studies have indicated that NMs are not always capable of 
penetrating the cell wall of bacteria. The identification of the potential 
mutagenicity of a NM should therefore be based on data from other types of 
studies than the Ames test. 
• Non testing data 
Currently there is a lack of comprehensive data that could be used as basis for 
approaches including grouping, read-across or (Q)SAR in the case of NMs. If 
such approaches are used, the hazard identification step should include, for each 
hazard endpoint, a critical evaluation of the scientific justification for using those 
approaches (see sub-section 3.3 for more information). 
Step 2. Classification and labelling 
The CLP Regulation (European Parliament and Council 2008) explicitly states that it 
applies to substances and mixtures in all physical states or forms (Art. 9(5)). In ECHA 
guidance (2015b), it is specified that: "Putative forms comprise properties such as crystal 
structure, particle size, homogeneity (e.g. emulsions) and texture (e.g. viscosity or tablet 
form). Examples of physical state factors are: surface treatment (e.g. coating), state of 
aggregation, moisture content, residual solvent, activation or stabilisation". Accordingly, 
if the physical state or form of a substance is changed it has to be evaluated whether this 
might affect the classification and whether re-testing is necessary. This means the 
nanoform of a substance can have a different classification compared to the 
correspondent bulk form if the available relevant information indicates a variation in the 
hazard properties (European Commission 2009). 
The UN GHS Sub-Committee, in its 24th session (UNSCEGHS 2013), agreed to review the 
applicability of the GHS to manufactured NMs. In this framework, the Informal 
Correspondence Group (ICG) on NMs was established to make clear if nanoforms of a 
substance are within the scope of the GHS and to review whether the classification and 
labelling criteria of GHS are appropriate for nanoforms as well as bulk forms of a 
substance. In its 28th session (UNSCEGHS 2014) the UN GHS Sub-Committee agreed that 
the ICG should focus its work on a classification exercise for some selected NMs. This 
exercise includes review on physical, health and environmental hazard classes. The work 
is still ongoing50 and no definite conclusions have yet been drawn. The progress of the 
                                           
50 At the time this report is written. 
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work can be followed from the working and informal documents of the ECOSOC Sub-
Committee of Experts on the GHS website51. 
One highly important issue in this context is the NM characterization and identification. It 
is very likely that in some cases there may be a need to classify a certain NM in a 
different way than the substance in a bulk form or in a slightly different nanoform. To be 
able to make conclusions on classification, the reports on studies on hazardous properties 
must contain detailed characterisation data on the material tested. In IUCLID 6 there is 
already a possibility to choose "nanoform/nanomaterial" from a pick list under the section 
"Classification and labelling". 
Step 3. Derivation of the hazard threshold levels for human health and the environment 
Derived No-Effect Level (DNEL) 
ECHA published guidance addressing issues to be considered when deriving DNELs for 
NMs (ECHA 2012d). The guidance focuses on the following issues: 
• Metrics 
The choice of metrics, or parameters, is of critical importance since it is not 
possible to establish a single metric that is applicable to all NM cases. There are 
many metrics, all of which include mass or number, which are currently used in 
the risk assessment of NMs (both regulatory and otherwise) across the three 
elements of exposure, toxicology, and risk. The most commonly used metrics 
have been identified and discussed by Hankin et al. (2011) and ECHA (2013b). 
• Mode of action 
For the decision on whether identified hazards are based on threshold or non-
threshold mechanisms, it is important to notice that carcinogenic/mutagenic 
effects may occur also via mechanisms secondary to a threshold effect. In the 
case of NMs, such situations could for example occur if exposure to poorly 
soluble nanoparticles results in particle overload and inflammation, triggering 
oxidative stress and as a final outcome tumour formation. In such cases it may 
be correct to derive a DNEL and not a DMEL. 
• Route to route extrapolation 
If data originating from studies performed using the relevant route of exposure 
is lacking, REACH allows route-to-route extrapolation from studies using another 
exposure route. In the case of NMs, there is, however, not much experience 
from such extrapolations and therefore it is not advised to extrapolate from 
other exposure routes. 
• AFs for interspecies differences 
If the default AFs are not used it is relevant to consider differences in ventilation 
rates, deposition and clearance between humans and experimental animals when 
deciding on specific factors to be derived.  
• Differences in the duration of exposure 
It should be noticed that in the case of exposure to poorly soluble low toxicity 
particles by inhalation, exposure at high concentrations may result in local 
accumulation, further increasing the toxicity following long-term exposure. 
• DNEL derivation when an occupational exposure limit value is available 
In some situations it may be justified to use an occupational exposure limit value 
(e.g. Indicative Occupational Exposure Limit and Binding Exposure Limit 
established at European level or a national occupational exposure limit) instead 
of deriving a DNEL. In the case of NMs, it is highly important to consider whether 
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the route and duration of exposure as well as the physicochemical attributes 
(including size, shape, crystallinity and surface characteristics), which may affect 
the toxicity, are the same as for the substance for which the occupational 
exposure limit has been set. If not, the limit value cannot be used in place of a 
DNEL and a specific DNEL should be derived. 
Predicted No Effect Concentration (PNEC) 
The outputs concerning PNEC derivation for NMs agreed by Aitken et al. (2011) are 
implemented in ECHA guidance for implementation of REACH. The current version of the 
guidance (ECHA 2012e) addresses the following issues: 
• Extrapolation methods 
The default AFs can sometimes be changed if properly justified. One of the 
plausible justifications is when evidence established by read-across from closely 
related substances can demonstrate the use of a higher or lower AF. In relation 
to NMs, where there is uncertainty due to the absence of available data, the use 
of read-across from available data on bulk or other forms of the material to the 
NM being assessed must be scientifically justified and may be associated with 
additional uncertainty. 
• Equilibrium partitioning methods 
Estimates based on results from equilibrium partitioning methods are limited to 
the distribution of a substance in molecular form. As NMs may also be distributed 
in the environment as particles, extrapolation based on partitioning may not be 
relevant. In such a case, the equilibrium partitioning method may underestimate 
exposure of soil and sediment environments and overestimate the exposure in 
water. If the particle size is small, air distribution may also occur (ECHA 2012f). 
The equilibrium partitioning method uses the PNEC for the water compartment 
and the partitioning coefficient between soil or suspended matter and water as 
inputs to estimate the PNEC for freshwater sediment, marine sediment and soil. 
Several factors have to be taken into account when using this method for NMs, 
including the fact that the method considers only exposure via water phase and 
not, for example, ingestion of soil or sediment particles to which NMs have been 
adsorbed (ECHA 2008). To increase the reliability of PNEC for sediment or PNEC 
for soil estimates derived by using the equilibrium partitioning method, it is 
important to choose a realistic partitioning coefficient (Kd, Kow, or Koc). Normally, 
equilibrium partitioning can mainly be applied to neutral organic chemicals; as 
the method is based on a thermodynamic equilibrium of the concentrations of 
the substance in the solid and the aqueous phase and in the organism, and such 
a thermodynamic equilibrium generally does not apply to NMs in the 
environment, care should be taken when applying the method to NMs and 
interpreting the results (Praetorius et al. 2014).  
When deriving PNEC values for NMs, it is important to consider the relevance of 
potential indirect effects that may contribute to the adverse effects observed at 
environmentally-relevant concentrations or at concentrations that are considered 
to be safe for the environment (ECHA 2013b). 
• Danish study (Lützhøft et al. 2015) on PNEC estimation of engineered NMs. The 
key findings include the following: 
- Investigations have shown that currently accepted PNEC estimation 
approaches within the present European legislation (e.g. REACH) in principle 
can be used for NMs as well. This concerns the AF and SSD methods. These 
methods do, however, not take nanospecific processes (such as aggregation) 
during the testing of NMs into account and the tests may therefore not always 
be representative of natural conditions. Based on a literature review 
performed by Lützhøft et al. (2015), three other methods were suggested: 
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the Probabilistic SSD (PSSD), the dissolved metal ion, and the Indicative No 
Effect Concentration (INEC). 
- The current approach to select data for PNEC estimation favors effect studies 
conducted according to Good Laboratory Practice (GLP) and accepted 
guidelines. A consequence is that effect studies conducted according to 
guidelines for soluble chemicals may be unreliable as they do not take into 
account the specific nature of engineered NMs. 
Step 4. PBT and vPvB assessment 
REACH and the associated guidance do not specifically address the PBT or vPvB 
assessment of NMs. However, considering the scope of the PBT and vPvB assessment, it 
is expected to be relevant for NMs that have an entirely or predominantly organic 
chemical nature as well as for NMs that contain (an) organic moiety/ies even if the main 
chemical structure of the NM is not organic.  
The PBT/vPvB criteria are based on persistence, bioaccumulation and toxicity of 
chemicals, which are strictly related to their behaviour. The behaviour of NMs in the 
environment is related both to their physicochemical properties and to the environmental 
compartments where they are released. For this reason the applicability of existing 
environmental exposure or distribution models is limited. High surface area to volume 
ratio results in highly reactive and physicochemically dynamic materials in the 
environmental media. Mobility, stability and transformation are important aspects of NM 
behaviour in the environment.  
NMs dispersed in water behave according to the mechanisms of colloid science. NMs may 
undergo a number of processes in water, including partitioning to sediment and 
suspended particulate matter and transformation through abiotic and/or biological 
degradation. The possibility of bioaccumulation depends on stability/reactivity, 
elimination and degradation rates of NMs and their degradation/transformation products. 
The stability of NMs in the aquatic environment depends on their chemical structure, 
other particle properties (e.g. size and surface coating), as well as environmental 
conditions. Surface properties of NMs, including hydrophobicity, are identified as critical 
in determining their transformation and aggregation behaviour, and thus for their 
mobility in aquatic environment and their ultimate interaction with and general 
bioavailability to organisms. Surface modifications, both intentional functionalization and 
modifications due to natural processes, complicate interactions and ultimate fate and 
behaviour. In particular, polymeric surface coatings are identified as stabilizers reducing 
autoaggregation.  
While evidence suggests that NMs released into the environment most likely end up in 
association with sediments and soils, very little is known about how NMs behave in these 
compartments. Environmental factors such as pH and ionic strength, together with the 
NM physicochemical properties and interactions with particles, determine whether they 
are bound within or transported out of soils and sediments. The lack of data is so 
pronounced, that no general conclusions can be drawn at the moment.  
Preliminary information regarding the fate and behaviour of NMs in air can be provided 
by aerosol science. However, some major issues still require validation, including the 
effect of differing particle morphologies. There is a need for systematic studies on 
different types of airborne NMs using a range of physicochemical parameters to generate 
data and support the development of reliable models.  
In conclusion, not much can be said about long-term forecasts related to persistent and 
bioaccumulative properties of NMs due to the lack of data. Anyway, it can be argued that 
a PBT substance in bulk form has to be considered as PBT also when it is in nanoform. 
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3.5 Exposure assessment 
The text below illustrates how an exposure scenario is defined (sub-section 3.5.1) and 
exposure is estimated (sub-section 3.5.2) in the Chemical Safety Assessment (CSA) 
process under REACH. Nanospecific considerations are reported in sub-section 3.5.3. 
 
3.5.1 REACH exposure scenarios 
An Exposure Scenario (ES) is defined under REACH as a set of information describing the 
conditions under which the risks associated with the identified use(s) of a substance can 
be controlled. An ES includes Operational Conditions (OCs) and, if needed, Risk 
Management Measures (RMMs) (ECHA 2012): 
• OCs include any action, use of tool or parameter state that prevails during the 
manufacture or use of a substance that may have an impact on exposure of 
humans and/or the environment (e.g. the duration and frequency of use, the 
amount used, the process temperature or pH).  
• RMMs include any action, use of tool or technique, or change of parameter state 
that is introduced during the manufacture or use of a substance in order to 
prevent, control, or reduce exposure of humans and/or the environment (e.g. 
local exhaust ventilation or a certain type of glove, wastewater and gas 
treatment). 
An ES is the cornerstone of the CSA and the related communication in the supply chains 
under REACH. As illustrated in figure 3.2, ESs must be identified along the entire life 
cycle of the substance. Firstly, the different stages of the life cycle are defined 
considering the use of the substance on its own, in mixtures or in articles (i.e. 
manufacturing, functionalization, manufacturing of intermediates, manufacturing of end-
products, use, and end-of-life). Secondly, a series of Identified Uses (IUs) is associated 
to each life cycle stage. Thirdly, Use Mapping is applied to each IU. The aim of the Use 
Mapping is the identification of those activities and processes (i.e. OCs) that could pose a 
risk for the upstream or downstream users of the substance or for the environment. 
Fourthly, appropriate RMMs are assigned to each IU to ensure that any risk due to 
exposure is sufficiently controlled. 
 
Figure 3.2. Step by step approach for the development of Exposure Scenarios under REACH. 
OCs = Operational Conditions. RMMs = Risk Management Measures. 
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In occupational ESs, OCs and RMMs for workers are described for each handling activity. 
ESs for consumers should include information on the population exposed (e.g. children, 
adults), particular conditions of use (e.g. in spray, in cream), body parts exposed, and 
any behavioural advice to reduce exposure. For environmental ESs, OCs (e.g. river flow 
rate, STP size, and annual number of working days) and RMMs (e.g. oil skimmer, carbon 
filter) are described as part of "Specific Environmental Release Categories" (spERCs) 
(ECHA 2015a).  
Finally, Exposure is estimated for each Identified Use. The Exposure Estimation 
(described in detail in sub-section 3.5.2) is the input to the Risk Characterisation (see 
section 3.6). 
 
3.5.2 REACH exposure estimation 
Conceptually, exposure assessment is the process of measuring or estimating the dose or 
concentration of the substance to which the human population or the environment is or 
may be exposed, depending on the uses and consequent releases of the substance.  
Figure 3.3 depicts the exposure assessment approach as required under REACH, 
including the scope of the exposure assessment in terms of human and environmental 
exposure. A comprehensive assessment of the potential exposure to chemicals should 
include all life cycle stages and take into account all exposure routes for human exposure 
and all environmental compartments for environmental exposure. Human exposure 
include occupational exposure, which occurs at workplaces during the performance of the 
job duties, and consumer exposure, which refers to exposure of the general public to 
products that can be purchased in retail outlets. Consumer exposure includes exposure 
from the direct use of the product or as a bystander, due to being in the vicinity of the 
product being used indoors or in public areas (e.g. air fresheners). However, it does not 
include indirect exposure via the environment, i.e. through contaminated air, water, food 
or soil (ECHA 2016a). 
The exposure assessment needs to be performed for each ES. The exposure assessment 
should preferably be based on quantitative measurements for each relevant target 
exposure route or environmental compartment. 
The availability of reliable exposure data is generally very limited and mostly focused on 
the workplace. This dearth of data implies that in the vast majority of cases, exposure 
levels must be estimated by making use of exposure estimation models. There is a wide 
range of exposure estimation models that can be used under REACH to obtain an initial 
estimation of exposure based on conservative or worst-case exposure conditions. This 
estimation is usually defined as the Tier 1 estimation. A higher Tier estimation can be 
made using more sophisticated and detailed models or by carrying out exposure 
measurements or experiments. 
ECHA guidance is available for occupational (ECHA 2015b), consumer (ECHA 2016a) and 
environmental (ECHA 2016b) exposure assessment, providing further details on the 
methods and models available to carry out the exposure assessments. It may be 
necessary to address aggregated exposure, either across different routes of exposure 
(e.g. inhalation, dermal and ingestion) or across different ESs. The ECHA guidance 
specifies that for systemic health effects the Risk Characterisation Ratios (RCRs) for 
different routes of exposure needs to be summed up to obtain a total systemic RCR 
(ECHA 2016c) (see sub-section 3.6 for more details on RCRs). Assessment of risks due to 
combined exposure from different sources usually requires experimental data sets or 
more sophisticated (probabilistic) modelling approaches, e.g. using detailed information 
on distribution of use patterns of different products containing the same chemical agent. 
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Figure 3.3. Exposure assessment approach as required under REACH. PBT/vPvB = Persistent, 
Bioaccumulative, Toxic/very Persistent, very Bioaccumulative. 
 
 
3.5.3 Nanospecific considerations 
The exposure assessment under REACH may present challenges when it comes to NMs. 
Such nanospecific considerations are illustrated in this sub-section. The currently 
available tools (e.g. guidance documents, models, protocols, decision trees) for 
addressing the nanospecific considerations discussed in this sub-section, including those 
developed under NANoREG, are listed in the NANoREG toolbox (project deliverable 
D1.1252, see relevant worksheet in Excel file). 
The life cycles of many NMs are determined by their application within products. While 
the manufacturing stage of the life cycles are likely be in a controlled industrial setting, 
the use of nano-enabled products by consumers are decidedly less predictable and 
involve more variables. In particular, it is clear that the released fraction of NMs from 
nano-enabled products no longer represents the primary particles initially dispersed in 
the matrix, but rather, a variety of different fragments, agglomerates, and transformed 
products that may have significantly different physical and chemical properties than the 
original, as manufactured NMs (Mitrano et al. 2015). NM aging and transformation 
processes therefore need to be accounted for. 
In the course of NANoREG, a selection was made of available Standard Operating 
Procedures (SOPs) that could be used to simulate, in controlled conditions, the release of 
nanoparticles from products and their subsequent transformation in the main 
compartments where exposure is likely to occur (i.e. indoor air, outdoor air, and water) 
(NANoREG deliverable D3.0353): 
• Nanoparticle release from textiles to the water compartment during washing 
cycles; 
• Nanoparticle release from polymers to the water compartment during 
accelerated aging; 
                                           
52uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANo
REG_D1_12_DR_Toolbox.org 
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• Nanoparticle release to the indoor air and/or outdoor air during sanding 
processes; 
• Nanoparticle release to the indoor air and/or outdoor air as well as to the water 
compartment during environmental weathering/aging. 
One of the most important added values of the SOPs described within NANoREG 
deliverable D3.03 was to implement previously developed normalized ISO tests. It means 
that the described tests were accepted as tests that reproduce at best the aging or 
weathering of materials.  
Qualitative and quantitative estimation of NM exposure is very complex, as these 
materials have very low mass, can be highly dynamic in terms of particle 
aggregation/agglomeration or reactivity and co-exist with ambient particles of the same 
size range. There are currently no agreed, standardized and validated methods for 
measuring personal exposure (i.e. measurements in the breathing zone) to NMs. 
Furthermore, there are currently no validated models providing quantitative estimates of 
human (worker or consumer) or environmental exposure. The existing Tier 1 and higher 
Tier exposure models described in ECHA guidance are designed and evaluated for use 
with chemicals and should not be applied to obtain quantitative estimates of exposure to 
NMs, unless there is evidence that the models perform appropriately (i.e. that the NMs 
agglomerate into larger stable micron-sized particles).  
Occupational Exposure 
A number of control banding tools and semi-quantitative exposure assessment tools have 
been developed that can be used to determine if exposure needs to be controlled. For 
occupational exposure, the following tools are currently available: 
- The Swiss Precautionary Matrix (Höck et al. 2013); 
- The CB NanoTool54 (Paik et al. 2008, Zalk et al. 2009); 
- Stoffenmanager-Nano; 
- NanoSafer55. 
While these tools are useful for screening purposes, there is still a lack of information on 
the validity of the exposure models the tools use. 
Exposure to airborne particles is generally assessed by measuring the individual exposure 
in the personal breathing zone, defined as a 30 cm hemisphere around mouth and nose. 
Measurements in the personal breathing zone require instruments that are small and 
lightweight. In recent years, novel samplers and monitors have been introduced that 
allow for an assessment of the more nanospecific personal exposure to airborne NMs. In 
particular, projects such as nanoIndEx56 evaluated the performance of personal devices 
in laboratories but also in real case studies (NM production pilot lines and SMEs).  
In 2015, the OECD published a "Harmonized tiered approach to measure and assess the 
potential exposure to airborne emissions of engineered nano-objects and their 
agglomerates and aggregates at workplaces" (OECD 2015). This three-tiered approach is 
based on a systematic evaluation of previously proposed and used strategies, which 
mainly address the fact that many of the instruments used for nanoparticle 
measurements are non-specific, i.e. they cannot distinguish the engineered nanoparticles 
from ambient nano-sized particles. In Tier 1, information is gathered from the workplace, 
while in Tier 2 some basic measurements are carried out to determine the potential for 
nanoparticle release in the workplace. Tier 3 consists of a detailed and comprehensive 
survey to determine:  
i) Whether or not exposure to nano-objects has the potential to occur; 
                                           
54 http://www.controlbanding.net/Home.html 
55 http://NanoSafer.i-bar.dk/ 
56 http://www.nanoindex.eu/ 
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ii) The level of exposure; and 
iii) The need for additional risk management steps. 
Figure 3.4 illustrates the OECD approach. It should be noted, however, that this 
approach was developed with the intention to be used as part of a risk 
management/mitigation rather than a risk assessment approach. CEN is also developing 
a standard named "Assessment of Inhalation Exposure to Nano Objects and their 
Agglomerates and Aggregates (NOAAs)" (CEN TR 137)57.  
Figure 3.4. OECD tiered approach for exposure assessment. CPC = Condensation Particle 
Counter; NOAA = Nano Objects and their Agglomerates and Aggregates; SMPS = Scanning Mobility 
Particle Sizer. 
 
Source: OECD 2015 
 
There is a wide range of measurement and sampling devices for airborne NMs that have 
been used for measuring airborne concentrations. Table 3.9 summarizes the direct 
reading instruments most frequently cited in the literature for detecting nano-sized 
                                           
57 http://www.cencenelec.eu/research/tools/Horizon2020/IndustrialLeadership/nanotech/Pages/default.aspx 
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airborne particles. These direct reading instruments are able to generate real-time 
measurement data on particle size, number and/or surface area; however, as mentioned 
earlier, these instruments generally lack specificity, i.e. they do not distinguish between 
engineered nanoparticles and any background/ambient nano-sized particles. Therefore, 
the choice of instruments is affected by the measurement strategy. If, for example, task-
based exposure with short-lived spikes in the concentrations is to be assessed, the use of 
personal monitors with high time resolution is inevitable. To the contrary, for the 
determination of shift-based averages samplers may also be used. If personal exposure 
to a certain chemical species need to be assessed, then with the currently available 
technology this can only be achieved by particle sampling and subsequent offline 
chemical analysis. Placement of the instruments for monitoring of the background or far-
field concentrations is also an important component of the measurement strategy. 
 
Table 3.9. Overview of direct reading instruments used for monitoring nanoparticles. CPC = 
Condensation Particle Counter; EEPS = Engine exhaust particle sizer; ELPI = Electrical Low 
Pressure Impactor; FMPS = Fast mobility particle sizer; LAS = Laser aerosol spectrometer; NSAM = 
Nanoparticle Surface Area Monitor; OPS = Optical Particle Sizer; SMPS = Scanning mobility particle 
sizer 
Instrument Method  Type Remarks 
Particle counters 
 
Heated saturator Size 
integrated  
CPC 
Particle counter intended for measuring ultrafine 
particles (10-100 nm) 
Concentration range of 0 to 100,000 particles/cm3 
Metrics: particles number concentration (PNC) 
Diffusion charging Size 
resolved 
Nanotracer, 
DiSCmini 
Detects ultra-fine airborne particles (10 to 300 nm) 
Concentration range of 0 to 1.106  particles/cm3 
Measures both particle concentration (PC) and 
average particle diameter (APD) 
Optical particle 
sizer/Laser aerosol 
spectrometer  
Laser light 
scattering 
Size 
resolved 
OPS 
LAS 
Provides fast and accurate measurement of particle 
concentration and particle size distribution (300 
nm-10 µm) 
Metrics: number size distribution  
Surface area 
monitor 
Diffusion charging  Size 
integrated  
NSAM, 
Partector 
Provides fast and accurate measurement of active 
particle surface area / Size range: 10 nm-1 µm) 
Concentration range: 0 to 10,000 µm2/cm3 
Metrics: surface are reported as µm2/cm3 
Scanning mobility 
particle sizer  
Electrical mobility 
diameter  
Size 
resolved 
SMPS 
 
Provides fast and accurate measurement of particle 
concentration and particle size distribution 2.5 nm-
1000 nm 
Concentration range from 1 to 107 particles/cm3  
Metrics: number size distribution  
Fast mobility 
particle sizer/Engine 
exhaust particle 
sizer  
Electrical mobility 
diameter/Unipolar 
diffusion charger 
Size 
resolved 
FMPS, EEPS 
Provides fast and accurate measurement of particle 
concentration and particle size distribution: 5.6 
nm-560 nm 
Metrics: number size distribution 
Electrical low 
pressure impactor  
Unipolar diffusion 
charger 
Size 
resolved 
ELPI 
Real-time particle size distribution and 
concentration in the size range of 6nm-10μm 
Metrics: size distribution 
Inertial 
spectrometer 
Aerosol Time-of-
Flight Mass 
Spectrometry 
Size 
resolved 
 
Provides accurate measurement of particle size 
distribution and chemical composition of individual 
particles  
Metrics: particle size distribution 
Sampler Filter sampling Personal 
sampler 
NanoBadge 
Light-weight, battery-operated and portable 
device, which can collect airborne particles directly 
in the breathing zone of a worker 
The sampler is connected to a cassette, the filter of 
which is analysed offline by X-ray fluorescence 
spectroscopy providing a cumulative mass-based 
quantification of the chemical elements on the 
filters 
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In many cases, however, the study may be focused on workplace exposure to specific 
NMs and in those cases, the omnipresent, non-workplace related background of ultrafine 
particles must be properly addressed. How well this is done largely determines the 
quality of the whole study. The following possibilities exist:  
• Specific measurement of only the NM in question with direct discrimination of the 
background (e.g. chemical or morphological speciation); 
• Spatial compensation of the background by measurements close to and during 
the relevant activity (near field) as well as at some distance from the activity (far 
field); 
• Temporal compensation by measuring with and without the specific activities of 
the workplace; 
• A combination of the latter two. 
In addition, special consideration should be given to the 'outdoor' (i.e. outside the 
respective building) background, which may mostly be influenced by combustion engine 
exhaust.  
In addition to direct reading instruments, it is also possible to collect air samples in 
adequate filter media for off-line chemical and microscopic analyses (e.g. using SEM or 
TEM with Energy Dispersive X-ray Spectroscopy). 
In the course of NANoREG, a selection has been made of available instruments, tools and 
methods that can be used to assess occupational, consumer or environmental exposure 
(NANoREG deliverable D3.0658). A total of 14 different instruments, tools and methods 
were selected, and the corresponding SOPs were prepared in order to cover the three 
main compartments (soil, air, and water) and two exposure routes (inhalation and 
dermal exposure). The instruments tested apply different principles and aim at providing 
portable monitoring solutions and/or techniques for specific cases. Moreover, state-of-
the-art direct reading instruments for occupational exposure assessment were directly 
used without further development in field measurements. The corresponding SOPs, when 
available, were collated from other projects (e.g. NanoGEM, nanoIndEx). In addition to 
air measurements for aerosol exposure assessment, biomonitoring tools were selected 
since they are essential for determining whether there is real individual exposure. The 
following instruments, tools and methods were covered: 
• MiniParticleSampler (MPS); 
• Light Induced Breakdown Spectroscopy (LIBS); 
• NanoBadge Sampler; 
• Electrical Low Pressure Impactor (ELPI); 
• Nasal paper flag; 
• Exhaled breath condensate; 
• Field-Flow Fractionation coupled to Inductively Coupled Plasma Mass 
Spectrometry (FFF-ICPMS); 
• Transmission Electron Microscopy (TEM), Cryogenic mode; 
• X-Ray Tomography; 
• Small-angle X-ray scattering (SAXS); 
• Surface swab and Tape stripping techniques. 
Consumer exposure 
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Modelling of consumer exposure to NMs is less advanced than that of worker exposure. A 
modification of the ConsExpo tool is available for estimating exposure to NMs from 
applying spray products59. There is also a control banding tool, NanoRiskcat (Hansen et 
al. 2014), which provides a ranking of the exposure risk for consumers and professional 
users (i.e. none, possible, expected, unknown). The assessment is based on the location 
of the NM in the product (e.g. embedded in a matrix, on the surface) and the description 
of the activity but not on the amount of the NM used in the product.  
Environmental exposure 
For environmental exposure, terrestrial and aquatic mesocosms are currently being 
developed (Auffan et al. 2014, Tella et al. 2014). Mesocosms are one of the rare 
biophysicochemical exposure characterization tools but their application extends to 
ecotoxicity testing in a realistic setting. Depending on the NM and the contamination 
scenarios, the mesocosms can operate with different physical and physicochemical 
features (e.g. soil properties, water quality and depth, sediment mineralogy and depth, 
current velocity, tidal reservoirs) and biota thanks to their high flexibility. The currently 
available data from mesocosms testing demonstrate the capability of this exposure 
testing strategy to characterize and distinguish acute and chronic exposure and account 
for varying surface chemistries (coated vs. uncoated) by quantifying the distribution of 
NMs and their alteration residues within the different compartments of an ecosystem. 
The main obstacles to the characterization and quantification of NMs in the different 
environmental compartments are the very low environmental concentrations of NMs and 
the similar chemical composition of NMs in respect to other matter and particles 
commonly present in the environment. Moreover, the isolation of NMs from their 
environmental matrices by filtration, extraction and separation processes may alter their 
physicochemical properties compared to their original state in the system. 
Another challenge is to understand if a NM, present at a certain time and in a certain 
space in the environment, originates directly from a point source (a production process 
or a NM-embedded product) or was transported there and underwent transformation in 
the environment. In fact, the environment is a dynamic system in which NMs, as any 
chemical, can migrate from one environmental compartment to another and react with 
other entities present in the system with the possibility of disappearing from one 
compartment due to aggregation, sedimentation or dissolution phenomena or changing 
their identity due to chemical reactions, thus producing different NMs.  
As the detection, characterization and quantification of NMs in the environment is usually 
challenging and often not feasible, modelling approaches have been developed for 
estimating the occurrence and concentration of NMs in the environment. One way to 
obtain estimates of existing environmental levels of NMs is to employ refined and 
updated models to predict their concentrations in the environment (Sun et al. 2016). 
The first modelling attempts were proposed in 2008 employing NM flow analysis instead 
of hypothetical calculation (Mueller and Nowack 2008). These studies were based on 
deterministic models in which the NM flow was calculated considering as input the NM 
production quantity and as output the NM release rate. Certain natural and technical 
compartments were selected mainly for the availability of measurement data to be used 
in the validation of the predicted environmental concentrations (PECs). Most of these 
studies took into account only one application of the NM, were restricted to a single NM 
production event, and considered only a few NM transfers from one compartment to 
another (Blaser et al. 2008). Later on, the fate and behaviour of NMs in environmental 
compartments were introduced in the mass balance of the models and dynamic 
processes such as aggregation, sedimentation, and degradation were taken into account. 
A further improvement was achieved when probabilistic models were implemented to 
describe each NM transfer event from one compartment to another (Gottschalk et al. 
2010). Further refinement was obtained by employing updated NM production values and 
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correlating them with the NM release in the course of all the NM life stages from 
production, use (e.g. ageing, abrasion, washing) and end-of-life (e.g. waste water 
treatment, incineration) (Mueller and Nowack 2008). With the growing production of NMs 
and nano-enabled products more data became available and different ESs were 
investigated within the models. This allowed for the introduction of a further level of 
complexity that was represented by the temporal and spatial resolution of the NM 
releases (Ort et al. 2009), which also made it possible to consider multiple NM sources. 
More recent models include the per capita consumption of nanoproducts and the product 
lifetime (Sun et al. 2016) and implement physical theory in order to model process NM 
heterocoagulation with natural particles and reactions of NMs with organic matter 
(Arvidsson et al. 2012).  
Even if current modelling approaches are able to predict environmental NM 
concentrations, more sophisticated environmental fate models, including mechanistic 
descriptions of fate processes and considering chemical reactions and physical changes of 
NMs (i.e. NM particle size), are needed in order to refine these models. On the other 
hand, more measured environmental exposure data are required to assess, validate and 
improve the accuracy of the models and to further hone and improve them in order to 
obtain tools useful for NM environmental risk assessment. 
Risk Management Measures 
Risks should be reduced to the lowest reasonably practicable level by taking preventative 
measures in the order of priority. Therefore, wherever reasonably practicable, exposure 
to hazardous particles and liquids, including NMs, by all routes (inhalation, dermal and 
ingestion) should be eliminated or controlled to the lowest reasonably practicable level, 
following the principles of the hierarchy of controls. The hierarchy of controls involves the 
following steps: 
• Elimination  
• Substitution  
• Technical measures - Engineering controls 
• Organizational measures (use of administrative controls) 
• Personal Protective Equipment (PPE) 
Often a combination of RMMs is used to obtain the required level of protection. Although 
the hierarch of control dictates that elimination and substitution of hazardous materials 
should be considered first in controlling exposure, in practice occupational exposures are 
generally controlled with ventilation systems and PPE. 
The data published so far and evaluated within NANoREG suggest a good level of 
performance for respiratory protective equipment. Most of the data retrieved from peer-
reviewed publications showed efficiencies above the threshold levels defined in reference 
harmonized standards. In the case of protective clothing and chemical protective gloves, 
there are still a lot of unknowns as to whether or not traditional protective measures 
provide a proper level of protection against NM exposure. The information retrieved from 
the literature highlight two main challenges linked with protective suits and gloves. The 
first is to understand the external parameters that can influence the penetration of 
nanoparticles through commonly issued fabrics. The second is to consider the variations 
of the surface properties of the materials used in protective gloves and clothing, which 
results in a high variation of performance results. 
All guidelines specific to NMs emphasize the need for technical exposure mitigation 
including physical and technical solutions in the work process in order to isolate, 
encapsulate and shield the process as well as using mechanical ventilation and filters 
(locally and/or centrally). Technical measures are likely the most effective and applicable 
control strategy for most processes involving NMs. Ventilation is the most common 
technical measure used for controlling occupational exposures to air contaminants 
including NMs. The use of general ventilation is limited to low toxicity sources in 
 66 
circumstances where the sources are usually diffused throughout the workplace and the 
workers are at a sufficient distance from them. The use of Local Exhaust Ventilation 
(LEV) systems is preferred to general ventilation and should be considered when working 
with NMs60. Table 3.10 summarizes the degree of recommendation of different technical 
measures when dealing with NMs in the workplace according to NANoREG deliverable 
D3.0961. 
 
Table 3.10. Recommended technical measures when working with nanomaterials (content from 
NANoREG deliverable D3.09). HEPA = High-efficiency particulate arrestance; LEV = Local Exhaust 
Ventilation. 
Protection level Technical measures 
Highly recommended  
(High protection)   
Local exhaust enclosure (Glove Box)  
HEPA filtered down flow booth 
Custom-fabricated enclosures 
HEPA filtered down flow room   
Ventilated Laboratory Hood + built-in water wash down systems (sprays) 
Negative pressure rooms  
Acceptable level of 
protection (non-hazardous 
nanomaterials) 
Ventilated Laboratory Hood (partial enclosure)  
Biological safety cabinet (small amounts of nanomaterials) 
Walk-in hoods 
Ventilated collar-type exhaust hoods 
Movable LEV systems (extendable arms) 
Receiving hood (hot process) 
Work processes in furnaces (High cost)  
Not recommended  Biological safety cabinet (amounts above 100 g) 
Ventilation by dilution  
 
According to the hierarchy of controls, the use of PPE is the least desired option for 
controlling worker exposure, to be used when engineering and administrative controls 
are not feasible or effective in reducing exposures to acceptable levels. The respiratory 
protective equipment, chemical protective gloves and protective clothing used must offer 
a good barrier against hazardous particles in the nanometer scale (i.e. airborne 
nanoparticles), liquid splashes, nanoaerosols and liquids (i.e. jets). Table 3.11 
summarizes the degree of recommendation of different PPE when dealing with NMs in the 
workplace according to the outcomes of NANoREG deliverable D3.09. 
Finally, regarding emission control technologies, several of them intended to capture and 
remove NMs from air and water streams generated in occupational settings are starting 
to appear. These technologies are key to controlling unintended releases of NMs into the 
environment, especially the freshwater, soil and air compartments.  
Current studies suggest that the use of current adsorption and filtration technologies can 
be effective in removing from wastewater a wide range of NMs, which may have different 
properties such as different zeta potentials, different surface charge and unpredictable 
behaviour under the operating conditions of the wastewater treatment system. 
Ultrafiltration, nanofiltration and reverse osmosis can be used to remove NMs from 
wastewater considering the specific properties of the NMs release, including particle size 
distribution, speciation, and surface chemistry (Yang and Tsai 2006, Lingxiangyu et al. 
2013, Park et al. 2013, Tzu-Ming et al. 2014). 
Concerning unintended emissions of NMs into air, common technologies aimed to collect 
and remove particulate matter are being re-designed. The electrostatic precipitator is 
used for removing particles and it has been satisfactorily used to trap and remove dust 
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particles from the exhaust gas stream of industrial processes. However, conventional 
electrostatic precipitators cannot remove submicron particles, and the collection 
efficiency drops to less than 40% when the particle size is less than 1 μm. Scrubbers can 
also be used to remove some particulates and/or gases from industrial exhaust streams.  
Finally, removal of NMs from soils is still a challenge. Several techniques are applied, 
including common techniques such as landfilling. Promising efficiencies of novel 
techniques, such as phytoremediation and fast crystal growth, have been retrieved from 
peer-reviewed publications (Mahmood et al. 2012, Jacob et al. 2013). 
 
Table 3.11. Recommended Personal Protective Equipment when working with nanomaterials 
(content from NANoREG deliverable D3.09). PVC = Polyvinyl chloride. 
Protection level Personal Protective Equipment  
Highly recommended  
(High protection)  
Full Face particulate respirators (P3) 
Half Face particulate respirators (P3) 
Nitrile gloves – Double glove for large exposure periods  
Full body protective coverall (EN type 4-6) made of PE laminated with 
built-in hood 
Tight-fitting dustproof (i.e. non-vented) safety goggles 
Acceptable level of protection 
(non-hazardous nanomaterials) 
Half-Face particulate respirators (P2) 
Neoprene gloves/Butyl gloves  
Full body protective coverall (EN type 4-6) made of polypropylene with 
or without built-in hood 
Laboratory coats (Non-woven) 
Dustproof safety goggles 
Not recommended  Filtering Facepiece (FFP3) 
Latex/Cotton/PVC gloves  
Laboratory coats (cotton/spunbonded polypropylene) 
Safety glasses 
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3.6 Risk characterization 
The text below illustrates how risk is estimated (sub-section 3.6.1) and uncertainty is 
analysed (sub-section 3.6.2) in the last step of the Chemical Safety Assessment (CSA) 
under REACH. Nanospecific considerations are reported in sub-section 3.6.3. 
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3.6.1 Risk estimation 
Under REACH, risk characterization is defined as the comparison of exposure levels of a 
certain substance and quantitative or qualitative hazard information to evaluate if risks 
are adequately controlled in each identified Exposure Scenario (ES) for different human 
populations and environmental compartments (see sub-sections 3.4 on hazard 
assessment and 3.5 on exposure assessment). ECHA published guidance on how to 
perform risk characterisation under REACH (ECHA 2016a). The reader is referred to that 
document for more detail. 
The comparison of quantitative estimations of exposure and hazard levels lead to the 
calculation of the Risk Characterization Ratio (RCR). The RCR needs to be calculated for 
each identified ES and for each relevant combination of human populations, 
environmental compartments, exposure routes, time scales, and (eco)toxicological 
endpoints. The RCR is calculated by comparing the measured or estimated exposure 
levels (i.e. Predicted Environmental Concentrations (PECs), sub-section 3.5) and the 
Predicted No Effect Concentrations (PNECs) for the environment or Derived No Effect 
Levels (DNELs) for human health (sub-section 3.4). If it is not possible to derive a DNEL 
(e.g. for non-threshold endpoints such as mutagenesis and carcinogenicity), a Derived 
Minimal Effect Level (DMEL) can be obtained. If no quantitative information is available to 
calculate the RCR, then the risk characterisation can be performed in a qualitative way to 
estimate the likelihood that effects are avoided in that specific ES. When both 
quantitative and qualitative information for different endpoints (not for the same 
endpoint) for the same substance are available, both a (semi-)quantitative and 
qualitative assessment of the risks has to be made, for the respective endpoints.  
To demonstrate that the risk associated with a certain ES is adequately controlled and 
therefore the use is safe, the RCR for that ES has to be below 1, or, for semi-quantitative 
or qualitative RC, the high likelihood that effects are avoided in that specific ES has to be 
demonstrated. 
According to ECHA guidance on adaptation of information requirements (ECHA 2011), it 
is possible to waive the derivation of PNEC/DNEL/DMEL and the risk characterization only 
when no exposure is expected with a high level of certainty for a certain life cycle stage 
of the substance and the related targets (sub-section 3.3). When exposure is low, or 
considered to be unlikely to happen (but not excluded), the risk characterisation has to 
be performed anyway and the consequent negligible or absent risk has to be 
demonstrated. 
It is important to highlight that the risk characterisation heavily relies on expert 
judgement; therefore, all assessments need to be transparent and traceable. 
If a substance is assessed to have hazardous properties, the risk characterization has to 
be performed taking into account the physicochemical properties of the substance, the 
exposure factors (e.g. storage, on site transfer), and the likelihood and severity of the 
exposure. The scope is to estimate the magnitude of risks in different conditions, verify if 
risks are controlled, and identify where Risk Management Measures (RMMs) are needed. 
RMMs for occupational exposure are addressed in sub-section 3.5. 
The outcome of the risk characterization, being it a quantitative or semi-quantitative one, 
needs to be qualitatively discussed by identifying the uncertainties and any other aspect 
that was not addressed in the assessment. 
Qualitative risk characterisation is defined as "the likelihood that effects are avoided 
when implementing the exposure scenario" (ECHA 2016a). It aims at reducing or 
avoiding the contact of the targets (i.e. human beings or environmental species) with the 
substance; therefore, the implementation of RMMs is highly important in this context, 
and the strictness of the required RMMs is linked to the hazard classification of the 
substance according to the CLP Regulation (sub-section 3.4). According to ECHA (2016a), 
the human health-related information requirements for which a qualitative risk 
characterisation may be necessary are: irritation/corrosion, sensitisation, acute toxicity, 
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carcinogenicity and mutagenicity (sub-section 3.2). For the environment, a qualitative 
risk characterisation is recommended when a PNEC cannot be calculated but also in 
another case, i.e. when the calculated short-term PNECs show no risks but a long-term 
effect is suspected or possible according to inherent properties of the substance, such as 
Kow and Kd partitioning coefficients (ECHA 2016a). 
'Combined exposure' is defined in ECHA guidance for consumers’ exposure assessment 
(ECHA 2016b) as exposure to the same substance through multiple exposure routes (e.g. 
inhalation and ingestion), while 'aggregated exposure' is intended as exposure to the 
same substance through one exposure route but from multiple sources. Both combined 
and aggregated exposures are sometimes relevant for chemicals, when the human 
population and the environmental targets are exposed to the same substance through a 
variety of exposure routes and products. In case of combined exposure, the overall risk is 
obtained by adding up the RCRs of the substance per contributing ES. In case of 
aggregated exposure, risks resulting from exposure to the substance via simultaneous 
use of different products may be derived by summing up the RCRs for systemic effects 
across ESs. 
 
3.6.2 Uncertainty analysis 
Uncertainty analysis under REACH is well described in ECHA guidance (ECHA 2012). Key 
elements of uncertainty analysis, which are relevant to NMs as well, include: 
• A tiered approach should be applied, with the level of detail proportionate to the 
level of uncertainty and impact of the risk characterization 
• It is necessary to distinguish between 'uncertainty', which can be reduced, and 
'variability', which is inherent to the system, and address both 
• There are three categories of uncertainty, i.e. scenario, model and parameter 
uncertainty: 'scenario uncertainty' is linked to the uses of the substance; 'model 
uncertainty' is linked to use of extrapolation, parametrisation, and correlation 
between parameters; and, finally, 'parameter uncertainty' is linked to the 
measurement of the parameter, sampling error, choice of dose descriptors, and 
extrapolation factors. 
When is uncertainty analysis necessary and to which degree 
Uncertainty analysis is not always necessary. ECHA suggests that uncertainty analysis is 
used in CSA when: i) the RCR is close to 1; ii) more insight about the robustness of the 
risk characterisation is needed; iii) non-standard regulatory methods are used to derive 
exposure and/or hazard; or iv) the registrant sees a specific need. 
Uncertainty analysis is organized into three levels: 
• Level 1: qualitative uncertainty analysis to refine the exposure estimate and 
provide an indicative range of unquantifiable uncertainties; 
• Level 2: derivation of a range of point estimates by means of a deterministic 
approach to describe the extent of uncertainty; 
• Level 3: use of probability distributions to provide statistical information about 
the likelihood that the RCR is exceeded under specific circumstances and 
according to the parameterisation used. 
Qualitative uncertainty analysis (Level 1) is basically a process where as many sources of 
uncertainty are identified and described through a stepwise process. This process 
involves a great deal of expert judgement. Uncertainties regarding exposure and hazard 
are firstly identified and secondly categorized, e.g. as model uncertainty or data 
variability. As a third step, the direction (i.e. underestimation or overestimation of risk) 
of each uncertainty item is identified and, as a fourth step, the magnitude of each 
uncertainty item is qualitatively estimated. No numerical integration of qualitative 
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uncertainties is performed. The final outcome describes the main sources of uncertainty, 
the ways to reduce it, and the overall effect of uncertainty on risk estimation. 
This kind of uncertainty analysis always needs to be performed. A checklist of uncertainty 
sources for each category (i.e. model, parameter, and scenario uncertainty) is provided 
by ECHA (2012). 
If Level 1 (qualitative uncertainty analysis) shows that uncertainty can affect the risk 
estimation, it is necessary to proceed to the deterministic analysis (Level 2) based on the 
creation of alternative scenarios – by varying selected parameters – such as reasonable 
worst case and average case. A tiered process to carry out the Level 2 analysis is also 
described by ECHA (2012). The last step (Level 3), the probabilistic analysis, is 
undertaken only for substances of high risk and when a large amount of data is available. 
What must be considered in uncertainty analysis 
The ECHA guidance provides the registrant checklists to be followed to ensure that as 
many sources of uncertainty as possible in both effect and exposure assessment are 
considered. A short list of sources is reported below (for a full dissertation consult the 
ECHA guidance (ECHA 2012)). The sources of uncertainty are generic and therefore 
relevant for all chemicals including NMs. Of course, given the specific physicochemical 
properties and the state-of-the-art of the scientific knowledge on exposure and effects of 
NMs, different sources of uncertainty may have higher or lower weight than for other 
chemicals. Nanospecific considerations are reported in the next sub-section 3.6.3. 
Effects 
• Model uncertainty: oversimplification, use of out-of-domain models, dependency 
errors. 
• Parameter uncertainty: measurement errors, sample size, dose descriptor, AF 
adequacy, extrapolation uncertainty. 
Exposure 
• Scenario uncertainty: disregarding sources and pathways/routes, target 
population/community, environment of exposure, spatial and temporal settings, 
use scenario. 
• Model uncertainty: oversimplification, use of out-of-domain models, dependency 
errors. 
• Parameter and data uncertainty: see effects, conservativeness in emission 
scenarios, exposure concentration choice, environmental variability, behaviour 
variability. 
 
3.6.3 Nanospecific considerations 
The risk characterisation under REACH may present challenges when it comes to NMs. 
Such nanospecific considerations are illustrated in this sub-section. The currently 
available tools (e.g. guidance documents, models, protocols, decision trees) for 
addressing the nanospecific considerations discussed in this sub-section, including those 
developed under NANoREG, are listed in the NANoREG toolbox (deliverable D1.1262, see 
relevant worksheet in Excel file). 
Risk characterization for NMs is, as for all chemicals, a combination of exposure and 
hazard information and the discussion of the related uncertainties. There are few 
nanospecific aspects directly linked to risk characterisation and those are discussed in 
this sub-section. Nanospecific issues concerning hazard and exposure assessment are 
discussed in sub-sections 3.4 and 3.5, respectively. 
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The current framework for safety assessment under REACH is acknowledged to be 
applicable to NMs but needs to take some nanospecific aspects into account (ECHA 
2014). 
The ECHA GAARN highlighted that there were not enough nanospecific exposure 
information in the submitted REACH registration dossiers that were assessed at that time 
(ECHA 2014). In order to quantitatively or qualitatively characterize the risks, 
identification and estimation of exposure is indeed essential. In addition, NMs may be 
subjected to change in exposure parameters over time since they can assume a different 
nature along their life cycle e.g. going from pristine powder to be dispersed in liquid, 
functionalised, incorporated into polymer, elaborated by intermediate user, and finally 
recycled, all in one value chain. This may dramatically change the release potential and 
likelihood of reaching a given target. The same issue can be envisioned for different 
value chains (i.e. different uses of the same NM), in different environmental media after 
release (e.g. water, air, soil), and over time (i.e. aging, interaction with the 
environment). Hence, it is necessary to consider NM transformation along its life cycle 
and to quantify exposure accordingly. To simplify the assessment, each life cycle stage 
should be considered in a dedicated Exposure Scenario (ES) linked, for example, to a 
specific production process, usage, and environmental release. When a specific target is 
not exposed to the NM under evaluation in any ES, risk characterisation can be waived. 
However, the absence of exposure to the NM has to be demonstrated. At the same time, 
the formation of aggregates and agglomerates is not grounds for waiving the risk 
characterisation of the NM. Aggregates and agglomerates can release constituent 
nanoparticles in various conditions, so it needs to be demonstrated through experimental 
data that aggregates and agglomerates do not release nanoparticles in relevant exposure 
conditions. 
The use of models to estimate the exposure to NMs, both primary particles and 
aggregates/agglomerates, is also often not feasible due to unsuitable assumptions and 
parametrisation as well as lack of model validation for NMs (sub-section 3.5). Therefore, 
field measurements combined with laboratory observations (e.g. TEM-EDX to evaluate 
the size and composition of metallic nanoparticles) are preferred. Conversely, field 
measurements are not easy to perform, and there is the issue of background 
concentrations of natural/accidental nanoparticles generated by processes not related to 
the NM under investigation, which is usually generated by a specific production process 
(sub-section 3.5). In the worst case, the combined fractions of background 
(natural/accidental) nanoparticles and engineered NM need to be considered in the risk 
characterisation. However, this approach may result in overestimated risk. 
Combined and aggregated exposure, even if relevant, is a complex element of risk 
assessment for all chemicals including NMs. Calculating combined and aggregated 
exposure means considering all potential (and relevant) exposure routes and sources. 
Therefore, combined/aggregated exposure is impossible at this time to be considered 
both for an individual NM and a group of 'similar' NMs. On the other hand, aside from a 
few high-volume NMs that are applied in several industrial sectors, most NMs have a low 
penetration into the market and their use is limited to specific technological applications 
and commercial products.  
Another nanospecific issue is metrics, which represents one of the regulatory questions 
directly addressed by NANoREG. The work carried out in NANoREG suggests that the 
most appropriate metric to express the biologically effective dose largely depends on the 
exposure pattern and on the type of NM (NANoREG deliverable D1.0963). The ECHA 
GAARN states that (obviously) the same metric must be used in order to compare 
exposure and hazard and that hazard results should be reported using the metric that 
correlates best with the measured effect, which can be particle size, surface area, 
number of particles, etc. (ECHA 2014). Based on the work conducted within NANoREG, 
mass can also be used, and there is no scientific reason to consider mass not suitable for 
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assessing the dose-response curve in regulatory toxicology. However, relationships for 
converting mass into other metrics need to be developed, expressing hazard information 
in different ways. This is also a recommendation of the ECHA GAARN, which, if properly 
addressed, may allow a proper RCR calculation. The main issue is linked to the possibility 
to carry out a complete NM physicochemical characterization in relevant testing media. 
Technical considerations, such as measurement techniques, available toxicological 
assays, and available exposure measurement methods, thus influence the selection of a 
specific metric. Based on NANoREG deliverable D1.09, some specific considerations for 
groups of NMs have been formulated: 
• Rigid biopersistent fibrous materials (WHO 1997): fibre number concentration is 
the adequate dose metric with additional parameters that are used by models 
such as median particle size, geometric standard deviation, and the density of a 
NM as it occurs in the exposure media (air, fluids). 
• Biopersistent HARN: number concentration is probably the most appropriate 
dose metric, also because all Occupational Exposure Limits (OELs) for all types of 
fibres (not only NMs) are expressed in this way. More work is required to link 
surface area to mass and particle number to provide conversion factors. 
• Granular biopersistent NMs: particle agglomerate volume seems to be the best 
applicable metric to describe long-term toxicity of particles with varying size or 
different chemical identity. 
• Granular NMs (low aspect ratio): different metrics can be calculated following a 
proper physicochemical characterization that should include robust 
measurements, in terms of particles and aggregates, of morphology, particle and 
aggregate size distribution, surface area as well as particle and aggregate 
density. 
• Not-rigid and not biopersistent HARN: the proper metric is not fully understood 
yet. 
The difficulties in deriving reliable long-term DNELs and PNECs for NMs reduce the ability 
to perform a quantitative risk characterisation (sub-section 3.4). For conventional 
chemicals, read-across and modelling approaches (on the basis of experimental data and 
physicochemical properties) can be applied to identify long-term effect concentrations. 
However, long-term studies on NMs are in general scarce for both humans and the 
environment, thus making read-across and modelling more difficult. Moreover, long-term 
studies are often performed with well-known NMs, therefore the possibility of applying 
read-across for NMs used in low volumes or for specific NM applications with modified 
physicochemical properties is limited. Technical difficulties in detecting and measuring 
NM transformation, persistence and environmental fate, the lack of standardized 
methods, and the high costs of carrying out a long-term study are strong limiting factors. 
In environmental risk characterization, it is important to consider indirect effects in the 
PNEC assessment. In case of NMs, their particulate nature can lead to effects other than 
the specific endpoint measured in the single toxicity assay, involving other organisms 
and ecological functions of the investigated compartment (e.g. aquatic or benthic). In 
addition, qualitative risk characterization for the environment is necessary if long-term 
effects are expected. The potential of a NM to cause long-term effect should be assessed 
by using partitioning constants, as indicated in the guidance (ECHA 2016a). However, 
traditional parameters such as Kd or Kow turned out not to be meaningful for those NMs 
that do not dissolve but disperse as particles. Therefore, for those NMs the need for long-
term tests has to be inferred by other means (see sub-sections 3.2 and 3.4 for more 
information). Direct observation of accumulation of a NM in organisms over long periods, 
the calculation of uptake and clearance kinetics, or the evaluation of NM behaviour in 
complex systems such as wastewater treatment plants or mesocosms can support such 
reasoning. However, the implementation of such experimental setups is clearly costly and 
complicated. 
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Risk Management Measures (RMMs), as an integrated part of the qualitative risk 
characterisation, are extremely relevant for both occupational and environmental 
exposure. The ECHA GAARN mentions some documents (i.e. ISO 2008, ISO 2012, Vogel 
et al. 2012), which detail the effectiveness of RMMs for NMs and can be used to discuss 
risk characterisation results, especially in occupational settings. Some nanospecific 
considerations concerning RMMs are reported also in sub-section 3.5. 
Concerning uncertainty assessment, the uncertainty categories, levels and approaches 
discussed in sub-section 3.6.2 are valid also for NMs. Nanospecific issues can arise from 
the type of information that is lacking and the way the lack of information is addressed. 
In other words, where are the main exposure and hazard data-generation bottlenecks 
and how is this related to the qualitative and quantitative risk characterisation? Model 
uncertainty is always relevant and the application of models must always be properly 
validated and justified. However, given the need to fill in data gaps and at the same time 
the lack of validation of available models for NMs, model uncertainty can be considered 
an even more important issue with NMs than with other chemicals. Several available 
models are not applicable to NMs, starting from physicochemical properties estimation 
procedures to more complex hazard, fate and behaviour models. There are some efforts 
to develop models for the estimation of partitioning coefficients for specific NMs (e.g. 
carbon nanotubes) on basis of colloidal theories (Bouchard et al. 2015). There are also 
efforts to develop (Q)SAR (and of the sort) models on basis of experimental 
measurements. More of such models are going to be available in time with more quality 
data available. However, since adequate knowledge of the basics of NM behaviour and 
NM properties affecting such behaviour is missing, great care should be taken in using 
models to perform risk characterisation for NMs and relying on nanospecific experimental 
data is recommended. When a model is used, attention should be paid to clearly 
addressing the applicability domain and the uncertainties related to model 
parametrisation. 
When experimental data are used to characterise the risk those uncertainties that are 
more relevant for NMs and need to be considered are: 
− Suitability of exposure measurement methods (e.g. specific adaptations); 
− Suitability of assays; 
− Relevance of data on other forms (bulk forms or nanoforms) and specific 
endpoints for the hazard assessment of the investigated NM; 
− Extrapolation correctness. 
In the hazard assessment phase, major sources of uncertainty appear to be 
physicochemical and hazard information. Physicochemical information is essential for 
proper interpretation of the results of physicochemical hazard and (eco)toxicological 
testing, both in vitro and in vivo: i.e. what NM is being tested, exactly? However, most of 
the protocols for physicochemical properties are not standardized or are simply not 
available, e.g. protocols for measuring physicochemical properties in complex matrices 
such as environmental matrices, which increases the uncertainty of the obtained 
experimental value and of the models built upon the obtained experimental data. 
Concerning the in vitro and in vivo hazard data, standardized testing methods for 
chemicals are not always considered standardized for NMs, and while the work of OECD 
WPMN is starting to give answers and guidelines there is still a lot of work to do to reach 
the point where validated methods with known uncertainty limits and for all toxicity 
endpoints are available. Therefore, when using the result of a toxicological test, this 
should be done with caution taking into account all possible uncertainties related to the 
type of test used (e.g. NM interference, test not specific for the endpoint, test not 
applicable for NMs, mode of action not relevant for NMs). 
In hazard assessment, there are also uncertainties linked to difficulties in identifying the 
lead health effect. Lacking an accurate measurement of the adverse effects, the lead 
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health effect can be misidentified. This uncertainty needs to be accounted for in the 
discussion of the outcomes of the risk characterisation. 
In exposure assessment, main uncertainties are related to the available models, methods 
and instruments for exposure measurement and data. In general, scenario uncertainties 
are likely to be very similar for NMs as for conventional chemicals. Models that are 
currently available for NMs tend to be qualitative/semi-quantitative and not to have gone 
through a complete model evaluation or validation. In occupational settings, even if 
research work is ongoing and some progress is shown, there is only little personal 
monitoring equipment that is suitable for NMs and can measure the appropriate metrics. 
Unless samples can be analysed off-line for the NM in question, it is often difficult to 
obtain specific estimates of NM exposure (i.e. differentiated from background 
nanoparticles concentrations). Consequently, available measurement data come from 
stationary equipment results, which may not be representative of personal exposure. In 
addition, due to difficulties in and costs of the measurements, available data sets are 
often relatively small (in terms of days covered by the measurement, individuals or tasks 
measured, not in terms of real-time data sets), which limits the possibilities of 
meaningful statistical analysis (ECHA 2012) and raises questions in terms of how 
representative the measurements are. 
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Part II – Forward-looking strategies for the safety 
assessment of nanomaterials 
Part II of the NANoREG framework describes with scientist's lenses three forward-looking 
strategies seeking to facilitate/accelerate the implementation of the REACH Regulation 
1907/2006 for nanomaterials (NMs), while discussing their benefits and potential 
limitations. The three strategies include: i) the use of a Nanospecific approach to 
Prioritisation and Risk Assessment (NanoRA) (section 4); ii) the development and 
implementation of the NANoREG Safe-by-Design (SbD) concept (section 5); and iii) the 
integration of Life Cycle Assessment (LCA) and risk assessment in the case of NMs 
(section 6). 
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4 A new approach towards nanospecific prioritisation and 
risk assessment 
This section introduces a new approach for nanospecific prioritisation and risk 
assessment developed within NANoREG. The tools currently available (e.g. guidance 
documents, models, protocols, decision trees) for addressing the nanospecific 
considerations discussed in this section are listed in the NANoREG toolbox (project 
deliverable D1.1264, see relevant worksheet in Excel file). 
 
4.1 Introduction 
Sections 2 and 3 of this document outline how to address NMs in the current legislative 
context, with focus on the REACH Regulation 1907/2006 (European Parliament and 
Council 2006). For the forward-looking strategies in Part II a different approach was 
chosen, which initially looked beyond the current legislative context to enable a more 
open view on how to tackle the challenges in the safety assessment of NMs. This resulted 
in a proposal for a prioritisation and risk assessment strategy for NMs65 that may not be 
implemented directly in the current legislative context. Nevertheless, the proposed 
approach may still provide valuable insights for risk assessment within REACH, in 
particular when adaptation of the standard testing regime (sub-section 3.3) is 
considered. Where links between the proposed approach and REACH are identified, this is 
indicated in the text and summarised in annex 4 of this document. 
NMs of the same chemical composition can have many different physicochemical 
properties (e.g. size, shape, charge). This triggers a much larger variation of nanoforms 
(sub-section 3.1) compared to non-NMs (Maynard et al. 2006). As it may not be feasible 
for each individual nanoform to obtain the necessary physicochemical, exposure and 
hazard data for all relevant exposure scenarios and endpoints, many initiatives have 
been taken to explore ways that enable the RA of NMs with a smaller data set. Important 
initiatives include amending tools like (Q)SAR, grouping, read-across and high-
throughput screening/testing for NMs. For successful applicability of such new 
approaches it is crucial that sufficient good quality nanospecific information becomes 
available to form a sound scientific basis.  
This section describes a new risk assessment strategy for NMs, which builds upon 
previous project outcomes. It has been developed within task 5.7 of NANoREG and 
published by Dekkers et al. (2016). In the proposed strategy, approaches for (Q)SAR, 
grouping and read-across are integrated and expanded to give direction to where and 
how a more efficient NM risk assessment can be performed (e.g. across multiple 
nanoforms) and what type of information could be used for scientific justification. The 
proposed strategy uses the current scientific insights in the specific properties that are 
crucial in the behaviour and toxicity of NMs. It facilitates further development of a more 
efficient risk assessment for NMs in the future and accelerates the rate at which 
information needed for risk assessment can be generated. The main objectives of the 
proposed approach are: 
a. To prioritise those applications of NMs that have the highest potential to cause 
human health effects (due to high exposure and/or toxicity); 
b. To identify those aspects of exposure, kinetics or hazard that are most important 
to address in the human health risk assessment of NMs; 
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uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_12_DR_Toolbox.org  
65 NANoREG was not meant to cover next generation nanomaterials, therefore they are not explicitly considered 
in the approach illustrated in this section. However, this does not exclude that the approach may be applicable, 
to some extent, to next generation nanomaterials. 
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c. To identify those situations where the use of nanospecific grouping, read-across 
and (Q)SAR is likely to become feasible and regulatory acceptable in the near 
future; and 
d. To identify the type of information needed for the regulatory acceptance. 
 
4.2 Proposed approach 
The proposed approach consists of different phases. The first objective (prioritisation of 
NMs) is addressed in the first phase while the other three objectives (identification of 
information) are mainly addressed in the second and further phases. 
From the first phase, a rough idea on the potential of a specific NM to cause adverse 
health effects should be obtainable by identifying: 
a) Materials that have the highest potential to be hazardous (flagged red); 
b) Materials for which the conventional (non-NM) risk assessment approach can be 
performed (flagged green); and 
c) Materials that need further evaluation (flagged orange). 
It is expected that only a few of the NMs that are currently on the market fall into the 
'red' or 'green' categories, because manufacturers tend to avoid the use of NMs that may 
be hazardous or quickly lose their functionality by falling apart into their ionic or 
molecular form. Therefore, the 'orange' category will probably be the largest group, for 
which further ranking is needed to indicate a relatively 'high', 'medium' or 'low' potential 
to cause harmful effects.  
The proposed approach should be suitable for different uses by policy makers, regulators 
and industry. Policy makers and regulators can predominantly benefit from running the 
first phase of the approach to prioritise those applications that need to be addressed 
most urgently. Industry can use the first phase to get an initial impression on the 
suitability of the NM in a specific product based on the potential of that NM to cause 
adverse health effects across the different life stages of the product. The second and 
further phases can be used by regulators and industry to identify the most important 
information needs to address the nanospecific issues and/or investigate the possibilities 
for grouping or read-across66. 
The proposed approach is developed to be applicable to NMs that are already on the 
market and relates to the existing practice within REACH as described in section 2 and 3 
of this document. Table 4.1 in annex 4 of this document links the different phases and 
aspects of the proposed approach to the content of sections 2 and 3 of the NANoREG 
framework and related toolbox (project deliverable D1.12). 
The current regulatory frameworks on the safe use of chemicals, including REACH, are 
generally considered suitable to address the risks of NMs (EC 2012, OECD 2013). Within 
REACH, NMs fall under the substance identity of the chemical component of which the NM 
is made and are therefore subject to the same obligations as for any substance (see sub-
section 3.1 for a more detailed discussion about substance identification of NMs under 
REACH). ECHA guidance is being modified or developed to provide registrants with 
recommendations on this aspect while there is also a call to adapt the legal text of 
REACH, especially with regard to the information requirements on physicochemical 
properties (DG GROWTH 2016, Roberts 2016) (see sub-section 3.2 for a more detailed 
discussion about the information requirements for NMs under REACH). The proposed 
approach gives direction where and how in REACH a more efficient risk assessment (e.g. 
across multiple nanoforms) can be performed and what type of information could be used 
for scientific justification. Dekkers et al. (2016) provide an overview of the relevant 
                                           
66 Irrespective of the most important information needs identified within the proposed approach, information 
requirements set by regulatory frameworks, e.g. REACH, should be met. 
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information and the tools that can be used to generate this information (reported in table 
SI-1 of the supplementary information). 
The focus of this proposed approach is on human health. The potential risks for 
environment are also important, though were beyond the scope of NANoREG (task 5.7), 
and hence remain to be further investigated. 
 
4.2.1 Elements  
The proposed prioritisation and risk assessment strategy is based on six elements, 
describing the most important nanospecific determinants in the process. Below, the six 
elements are briefly explained and a short argumentation for the selection of the element 
is given. The flow chart in figure 4.1 gives an overview of the different phases of the 
proposed approach with the relevant elements indicated for each phase. Each of the six 
elements has its own colour. Next to the elements, specific aspects (e.g. properties, 
assays) are depicted in the same colour(s) as the elements they relate to.  
Sub-sections 4.3 (on phase I) and 4.4 (on phase II) give more details on how these 
elements are incorporated within the proposed approach and considered in each phase. 
1. Exposure potential 
Exposure potential is included early in the present approach because exposure 
assessment is, in addition to hazard assessment, essential for performing risk 
assessment. Although some of the determinants for exposure (e.g. transformation) are 
also addressed in the other elements, these other elements mainly focus on the 
toxicokinetics and toxicodynamics of the NMs in relation to human health effects. The 
element exposure potential also includes the other determinants (e.g. routes of 
exposure, amount of NM used) that are important in identifying the 'hot spots' for 
exposure throughout the entire life cycle of the NM under investigation. 
2. Dissolution 
Dissolution is the key element to identify whether a NM is stable enough to exert 
nanospecific behaviour. It is very important to know if a NM dissolves into its molecular 
or ionic form and how fast (i.e. dissolution rate), where and under which circumstances 
this takes place. If a NM fully dissolves into its molecular or ionic form before it reaches 
its target, it may not exert any nanospecific behaviour and it is suggested to perform the 
conventional (non-NM) risk assessment approach. If a NM does not fully dissolve before 
reaching the target, the nanospecific behaviour and related effects should be further 
investigated. The NM may distribute to specific sites, where release of ions or molecules 
may cause acute effects. No or very slow dissolution may relate to accumulation in case 
of repeated exposure, and thereby increase the likelihood of nanospecific effects after 
long-term exposure. How fast dissolution occurs can indeed have a huge impact on the 
exposure potential, behaviour and effects of a NM in humans (including absorption, 
translocation to secondary organs and accumulation in tissues)67. 
3. Transformation 
This element is important since NMs may transform during their life cycle. The stability of 
their original appearance during manufacturing and the subsequent transformations 
(including the coating, corona, agglomeration, aggregation and disintegration to smaller 
units, dissolution, precipitation, adsorption and desorption, combustion, abrasion, 
oxidation and reduction) is very important for their behaviour and effects in humans and 
the environment. 
  
                                           
67 This issue is matter for discussion at a regulatory level. 
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Figure 4.1. Flow chart showing the different phases of the proposed approach towards 
nanospecific prioritisation and risk assessment. Black arrows: evaluation of the NM following the 
elements related to kinetics, toxicity and exposure in phase I, II, III and further. Green arrows: the 
material is not a nanomaterial or has such a high dissolution rate in water that it dissolves into its 
molecular or ionic form before it reaches its target  the classical (non-nanomaterial) risk 
assessment can be performed. Red arrows: the material is a "rigid and biopersistent High Aspect 
Ratio Nanomaterial (HARN)"  substitution or information gathering for targeted risk assessment 
to evaluate the potential to cause mesothelioma is needed. Orange arrows: the material does not 
meet the criteria for classical (non-nanomaterial) risk assessment or targeted risk assessment to 
evaluate the potential to cause mesothelioma  use the information from phase I for prioritisation 
and/or further evaluation following the elements related to kinetics, toxicity and exposure in phase 
II, III and further. D = Dermal route of exposure; I = Inhalation route of exposure; NM = 
nanomaterial; O = Oral route of exposure; PROC = Process Category; ROS = Reactive Oxygen 
Species. 
 
Source: Dekkers et al. 2016 
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4. Accumulation 
The ability of NMs to accumulate in the human body may increase the likelihood for 
effects after long-term exposure. Some NMs have been shown to accumulate in the 
human body. Although it is not always known if this accumulation results in toxic effects, 
accumulation is a serious reason for concern in risk assessment and thus needs to be 
included as one of the fundamental elements in the proposed approach. 
5. Genotoxicity 
This element is an important mechanism of toxicity, also for NMs, since genotoxicity is 
one of the possible mechanisms that may lead to cancer and, if germ cells are affected, 
to developmental and reproductive effects. It is known that NMs can induce genotoxicity 
by directly or indirectly damaging or interacting with a DNA molecule (Louro et al. 2015). 
6. Immunotoxicity 
Another important mechanism of toxicity of NMs is the onset or triggering of an immune 
response, causing for example inflammation, immune stimulation or immunosuppression. 
In its chronic form, inflammation may lead to several health effects, such as fibrosis, 
cirrhosis, lung cancer, cardiovascular diseases and neurological diseases. There are 
different pathways along which NMs can trigger an immune response, but not all cellular 
immune responses lead to notable inflammation. 
 
4.3 Description of phase I 
4.3.1 Input (phase I) 
In the following sub-section, the reader is guided through phase I of the proposed 
approach. Going through the flow chart (figure 4.1), suitable information should be 
gathered or generated within each of the boxes. The flow chart starts in phase I on the 
upper left side of figure 4.1, where the dashed black arrow "Start" points to the grey box 
"Nano?". To determine whether the investigated material is a NM, information is needed 
on physicochemical characteristics such as size and/or surface area. Other information 
needed in other boxes of phase I is the aspect ratio (shape and size), rigidity, 
biopersistence, dissolution and reactivity of the NM. For exposure, possible applications 
as well as production volumes and process and operational conditions are important. A 
more detailed description can be found in the paragraphs underneath. The information 
needed in phase I is often available from manufacturers or can be obtained through 
analytical or acellular assays. An overview of the relevant information for going through 
the entire flow chart is given in table SI-1 of the supplementary information to the 
manuscript published by Dekkers et al. (2016). The way to move forward in phase I of 
the flow chart is described below. 
 
4.3.2 Physicochemical characteristics (phase I) 
4.3.2.1 Nano? 
Phase I starts with determining if the material indeed is a NM (figure 4.1: see the dotted 
line from the left). There has been a lot of discussion on the definition of a NM and 
multiple definitions are used in various international organisations, committees and 
jurisdictions all over the world. Within NANoREG, the European Commission's 
Recommendation 2011/696/EU on the definition of 'nanomaterial' (EC Definition) is used 
(see section 2 for more information). The analytical methods to determine whether a 
material meets the criteria of the EC Definition have been evaluated by JRC and within 
NANoREG work package 2 (JRC 2012, De Temmerman et al. 2014). If the material does 
not meet the criteria of the EC Definition, it can be evaluated using the information on 
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the chemical composition of the non-NM (i.e. figure 4.1: follow the green arrow), 
effectively leaving the frame of the proposed approach. If the material does meet the 
criteria of the EC Definition, the black arrow in figure 4.1 should be followed and 
dissolution in water should be evaluated.  
4.3.2.2 Dissolution rate and equilibrium in water 
The water solubility is conventionally measured using the OECD Test Guideline (TG) 105, 
which defines the water solubility of a substance as the saturation mass concentration of 
the substance in water at a given temperature and proposes two methods to measure it 
for conventional substances (the column elution method and the flask method). The 
OECD TG 105 is already used for aggregated and agglomerated NMs but it needs to be 
revised and refined especially for NMs that disperse into small primary nanoparticles 
(OECD 2014). Several approaches for NM risk assessment propose to use the outcomes 
of these types of tests to distinguish soluble from non-soluble NMs (BAuA 2013, Arts et 
al. 2015). However, as no equilibrium is reached in many situations relevant for human 
health risk assessment, the water solubility does not provide sufficient insight in the 
possibility of uptake of NMs as physiologically relevant time frames are not considered 
(Oomen et al. 2015). It might be more informative to use the dissolution rate, because 
the information on whether a NM dissolves into its molecular or ionic form and at what 
rate before (or after) it reaches its potential target is far more relevant. OECD (2001) 
describes how the dissolution rate of metals and metal compounds in aqueous media can 
be measured. However, there are no nanospecific guidelines for such tests and also no 
proposed cut-off values to distinguish soluble from non-soluble NMs are proposed (Tantra 
et al. 2015). Therefore, a comparison of the dissolution rate of the NM with that of its 
constituting chemical components might give an indication on the possibility to use the 
data of the non-NM (read-across). If a NM has a very fast dissolution rate (i.e. close to 
instantly dissolved), the NM can be evaluated using the information on the chemical 
composition of the non-NM (i.e. figure 4.1: follow the green arrow towards the box 
"Classical (non-NM) approach"). If a NM does not have a very fast dissolution rate or a 
slower dissolution rate than its non-NM counterpart, the black arrow down in figure 4.1 
should be followed and the nanospecific behaviour and effects should be further 
evaluated both for kinetics/hazard (figure 4.1: right side) and exposure (figure 4.1: left 
side).  
 
4.3.3 Exposure (phase I) 
4.3.3.1 Exposure: identified uses and exposure scenarios for all life cycle stages 
and applications 
The first indication of exposure for workers and consumers is based on a similar 
(qualitative) approach for identifying priorities in exposure scenarios as described in 
NANoREG deliverable D3.0168. In that report, exposure scenarios (ESs) of the highest 
potential occupational (and environmental) exposure along the life cycle of the currently 
marketed NMs have been prioritised. The approach starts with the identification of the 
main applications in which the NM is used. As next step, the life cycle of the NM and each 
of its main applications are mapped, followed by the identification of identified uses69 and 
ESs70 for each life cycle stage of each application, as required by REACH (see section 3.5 
for more information). 
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uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D3_01_DR_Gap_analysis_report_identifying_the_critical_exposure_scenarios_within_the_key_value_chains
.org  
69 REACH definition of Identified Use (IU): a use of a substance on its own or in a mixture, which is intended by 
an actor in the supply chain, including his own use, or a use that is made known to him in writing by an 
immediate downstream user. 
70 Exposure Scenarios (ES) should address the manufacture and identified uses. According to REACH Annex I, 
registrants who are required to carry out a Chemical Safety Assessment (CSA) with exposure assessment have 
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4.3.3.2 Occupational exposure: PROC and production volume 
In order to get a more specific understanding of the occupational exposure, the 
information gathered on identified uses is coupled to the Contributing Exposure Scenarios 
(CESs) for each life cycle stage of each application. Under REACH, a CES represents a set 
of specific exposure conditions that describe a single worker’s or consumer’s activity. A 
CES can be directly linked to the Process Categories (PROCs) for occupational exposure, 
for which ranking values have been determined within ECETOC Targeted Risk Assessment 
(TRA) (ECETOC 2012). The ranking of the PROCs within ECETOC TRA is mainly based on 
the process and operating conditions, including dustiness, energy in the process, 
enclosure level of the process, concentration in the preparation, duration of the activity, 
ventilation and the use of personal protection (ECETOC 2012). A first ranking of the 
occupational exposure can be obtained by combining the ranking values of the PROCs 
with the estimated production volume of the NM in a certain application (see figure 4.1 
and table 4.1). The relevant route(s) of exposure are also important for determining the 
strategy in phase II of the proposed approach. 
 
Table 4.1. Ranking of the occupational exposure potential in phase I based on production 
volume and PROC of the most important occupational scenarios within the life cycle of each 
nanomaterial application. PROC = Process Category. 
Production Volume → 
PROC ↓  
high medium low 
high high high high 
medium high medium medium 
low medium low low 
 
4.3.3.3 Consumer exposure: NM fixed in matrix/free and production volume 
For consumer exposure, no ranking of the ESs was performed in NANoREG deliverable 
D3.01, because of the absence of information on the main determinant of consumer 
exposure (i.e. the transfer factor71). However, when the main NM applications are known, 
the most important exposure aspects for phase I of the proposed approach can be 
selected based on information from the following sources: Wijnhoven et al. (2009), RIVM 
(2015), and NANoREG deliverable D3.01. For consumer exposure, the first ranking is 
based on the production volume of the NM in the application in combination with the way 
the NM is incorporated in the consumer product (fixed within a matrix or freely available) 
(table 4.2). Products containing freely available nanoparticles suspended in liquids or 
airborne aerosols (e.g. spray applications) are expected to cause a higher consumer 
exposure than products in which the NMs are fixed or incorporated into a solid matrix 
(e.g. a bicycle frame). However, it is not always clear if and how the nanoparticles are 
fixed in the matrix of the product and if they stay fixed or migrate, evaporate, washout, 
wear off, etc. during the use of the product. In addition, the most important route(s) of 
exposure are important for further determination of the strategy in the next phase (i.e. 
phase II). 
 
 
                                                                                                                                    
to address all stages of the life cycle of the substance including those resulting from the manufacture and 
identified uses if they happen in the EU territory (e.g. the use of substances in articles). 
71 Transfer factor is the fraction (0 to 1) of the substance transferred from the product to the skin and 
represents a realistic worst-case dose. 
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Table 4.2. Ranking of the consumer exposure potential in phase I based on production volume 
and way of incorporation in the exposure matrix (fixed/free) for the most important consumer 
exposure scenarios within the life cycle of each nanomaterial application. 
Production Volume → 
Fixed in matrix/free ↓  
high medium low 
fixed in matrix medium low low 
free high high high 
 
4.3.4 Kinetic and hazard aspects (phase I) 
4.3.4.1 Rigid biopersistent HARN 
One of the established mechanisms of toxicity of NMs is the potential of rigid and 
biopersistent High Aspect Ratio (fibre-like) NMs (HARN) to cause "frustrated 
phagocytosis" by macrophages after inhalation. This may lead to mesothelioma, a 
specific form of cancer also known from exposure to asbestos (Donaldson et al. 2010). 
Information needed for determining whether a NM is a potential "rigid biopersistent 
HARN" includes the aspect ratio, rigidity as well as the biopersistence of the NM under 
investigation. Rigid biopersistent HARN materials with a length (L) ≥ 5 μm, a diameter 
(D) < 3 μm and a L/D ratio > 3 should either be substituted by an alternative substance 
or evaluated for their potential to cause this specific type of health effect. This means 
avoiding most elements in phase II and III of the proposed approach and instead target 
information gathering on the potential to cause mesothelioma (i.e. figure 4.1: follow red 
arrow to the box "Information gathering for targeted risk assessment"). 
4.3.4.2 Acellular reactivity  
One of the most important hypotheses of nanospecific toxicity is the increased surface 
reactivity of NMs due to their relatively large surface-to-volume ratio and, sometimes, 
surface modification, too. Due to that ratio and specific functionalization of NMs, the 
reactivity of NMs can be enhanced compared to non-NMs. This reactivity may trigger the 
generation of reactive oxygen species (ROS), leading to oxidative stress and subsequent 
inflammation in biological tissues. 
For metal and metal oxide nanoparticles, the surface reactivity can for example be 
predicted using the conduction band energy levels in combination with the solubility 
(Zhang et al. 2012). Based on this publication, metal and metal oxide particles can be 
ranked for their potential to cause oxidative stress in vitro as well as acute inflammation 
after inhalation in vivo. For other NMs and other exposure routes, a first indication on the 
reactivity of NMs can be obtained by using acellular assays, for example by measuring 
ROS formation or biological oxidant damage in serum (e.g. with the FRAS (Ferric 
Reducing Ability of Serum) assay) (Nel et al. 2014, Arts et al. 2015). It should be noted 
that these assays only provide a first indication of the oxidative properties, since the local 
environment, i.e. cell culture media in vitro or body fluids in vivo, can influence the 
reactivity of the NMs in various ways, for example by containing antioxidants or by 
altering the nanoparticles surface due to biomolecule corona formation. The results in the 
band gap analysis or acellular reactivity assays are used to define further hazard ranking 
or subgroups (table 4.3). In addition, the results can give direction to further 
investigation of the reactivity in cellular environments in phase II. 
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Table 4.3. Further hazard ranking in phase I based on classification and reactivity. 
Classification → 
Reactivity ↓  
high medium low 
high high high medium 
low high medium low 
 
4.3.4.3 Hazard classification of non- or similar NM 
Another important indication on the toxicodynamics of a NM can be obtained by looking 
at the hazard classification of the correspondent non-NM (i.e. bulk form) or a similar NM 
according to the CLP Regulation (European Parliament and Council 2008) (see section 3.4 
for more information on CLP Regulation). It can be expected that NMs having chemical 
components classified, for instance, as genotoxic or sensitizer also have genotoxic and/or 
sensitizing properties. Although there may be differences with respect to the critical dose 
levels and target organs, the possibilities to use read-across and grouping for these 
specific endpoints based on the hazard classification of the non-NM or similar NMs might 
be considered (i.e. figure 4.1: follow the arrow towards the box "Read-across?"). 
Guidance on grouping and read-across for chemicals has been published by ECHA (2013) 
and OECD (2014). The use of read-across and grouping primarily based on the hazard 
classification of non-NMs or similar NMs is probably only feasible and regulatory 
acceptable if this leads to a (worst-case) classification of the NM into the highest 
category, which requires risk reducing measurements that prevent or minimise human 
exposure in all life cycle stages of the NM. If the chemical components of a NM or a 
similar NM are not classified or if no chemical counterpart can be identified, this does not 
mean that the NMs do not cause these specific health effects. Further evaluation of the 
other elements related to kinetics, toxicity and exposure in phase II is then 
recommended by following the orange arrow down in figure 4.1. 
 
4.3.5 Output phase I: prioritisation and ranking  
Within the orange category, prioritisation can be obtained by combining further exposure 
and hazard ranking to indicate a high, medium or low potential to cause harmful effects 
within the life cycle of each NM application. The kinetic behaviour is explicitly included in 
this further ranking, but is already implicitly taken into account by only including NMs 
that do not have a fast dissolution in water in the orange category. 
Further exposure ranking for occupational and consumer exposure is described in 
previous sub-sections 4.3.3.2 and 4.3.3.3 and tables 4.1 and 4.2.  
Further hazard ranking is based on classification according to CLP Regulation and 
reactivity: 
• If one of the chemical components of a NM or a similar NM is classified as 
carcinogenic, mutagenic or reprotoxic (CMR, all categories), then this NM is 
ranked 'high' with respect to its hazard. The 'medium' classification category 
describes NMs that are not classified as CMR, but as (respiratory) sensitizers or 
irritating substances. A material with only acute toxicity or no classification for 
toxicity is ranked 'low'. 
• If a NM has a high reactivity, as predicted by the band gap analysis for metal 
and metal oxide nanoparticles or acellular ROS or FRAS assays for non-metal 
NMs, then it is ranked 'high' with respect to its hazard. At present, the criteria 
for high reactivity are not precisely defined for each of the assays. 
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• If the chemical components or similar NMs are not classified and the NM under 
investigation does not have a high reactivity, then this NM is ranked 'low' with 
respect to its hazard. The total hazard ranking results in the 'medium' category 
when the classification is medium with a low reactivity or when the classification 
is low with a high reactivity (table 4.3). If no information on the hazard 
classification or reactivity is available, the material is ranked 'high' with respect 
to its hazard. 
Combining the exposure ranking with the hazard ranking of the most important 
occupational and consumer ESs within the life cycle of each NM application gives a 
further ranking in three subgroups to indicate a high, medium or low potential to cause 
harmful effects (table 4.4). 
Importantly, 'low' in table 4.4 does not mean that further action for risk assessment is 
not needed. Information in line with regulatory requirements needs to be complete. 
However, this ranking (high, medium, low) can be used for prioritisation as indicated in 
sub-section 4.1. 
 
Table 4.4. Combined ranking of potential exposure and hazard in phase I of the most 
important occupational and consumer exposure scenarios within the life cycle of a NM application. 
Hazard → 
Exposure ↓  
high medium low 
high high high medium 
medium high medium medium 
low medium low low 
 
4.3.6 Output phase I: information used in phase II 
Materials that are flagged 'green' or 'red' do not enter phase II of this flow chart. Those 
flagged 'green' need to be evaluated according to the classical non-nanomaterial risk 
assessment. Materials that are flagged 'red' can skip most elements in phase I, II and 
maybe also III, to enable targeted information gathering on the potential to cause 
mesothelioma. 
Materials flagged 'orange' do enter phase II. The rankings described in the previous sub-
sections are not used as such in phase II. However, the information on which these 
rankings are based is used to give direction to those elements that should be addressed 
in phase II by preference. The information indicating which elements are most important 
is different for each exposure situation and should be evaluated on a case-by-case basis. 
Although it is not possible to describe this for each situation, an attempt for a general 
description of which information in phase I indicates which type of information is most 
wanted in each of the boxes in phase II is given in the following sub-sections. 
 
4.4 Description of phase II 
As depicted with the blue circles in figure 4.1, the most important route(s) of exposure is 
(are) key in determining which type of information is relevant to obtain in each of the 
boxes in phase II. The route(s) of exposure also indicate(s) the relevant media for 
testing the dissolution rate and also the specific in vitro models (cell types and 
endpoints) to be investigated. In addition, information on the hazard classification based 
on CLP Regulation of the chemical components of the NMs may also point towards 
relevant cell types and endpoints to be investigated. 
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Relevant cell types for in vitro assays on the cytotoxicity, immunotoxicity and 
genotoxicity can be selected based on the information on the dissolution rate in relevant 
media and in vitro absorption together with the limited amount of knowledge available on 
the absorption, distribution and translocation of nanomaterials (in general). 
A more detailed description of the type of information and possible methods to generate 
this information is given below, for each of the boxes in figure 4.1. Most information 
needed in phase II can be obtained through analytical and in vitro assays. An overview of 
the relevant information for going through the entire flow chart is given in table SI-1 of 
the supplementary information to the manuscript published by Dekkers et al. (2016). 
Table IV.1 in annex 4 links the different aspects of the flow chart (figure 4.1) to sections 
2 and 3 of the NANoREG framework and related toolbox (project deliverable D1.12). 
 
4.4.1 Exposure (phase II) 
4.4.1.1 Occupational exposure: exposure pattern, physical form and amount or 
concentration 
In phase II, it is proposed to extend the information obtained on the occupational 
exposure in the first phase with information on the exposure pattern (frequency and 
duration), physical form and concentration (in air) or amount (deposited on skin). These 
determinants were selected because they have the largest influence on the final ranking 
score illustrated in NANoREG deliverable D3.01 and information on these determinants is 
generally available for most exposure scenarios. Using this additional information further 
ranking of the most important occupational ESs as described in NANoREG deliverable 
D3.01 can be performed. 
4.4.1.2 Consumer exposure: exposure pattern, direct or indirect, physical form 
and amount 
For consumer exposure, it is proposed to obtain additional information on the exposure 
pattern (including direct or indirect exposure, frequency and duration), physical form, 
amount used and/or amount available for exposure in phase II. This selection was based 
on ECETOC TRA (ECETOC 2012), ConsExpo Nano (RIVM 2015) and Wijnhoven et al. 
(2009). The amount available for exposure is based on the release out of the matrix of a 
product, which is often very difficult to measure. However, based on the product 
description, an indication of the potential release of the NM out of the matrix of the 
product can be obtained. In general, the potential release from solid consumer products 
is expected to be less than the release from liquid or powdered products. In addition, 
incorporation of the NM into the solid matrix of the consumer product itself (e.g. 
incorporation of silver NMs into textile fibres) probably leads to less release of the NM 
than applying a coating to the surface of a solid consumer product (e.g. spraying a 
coating containing silver nanoparticles onto the textile product). If no information is 
available, the assumption that all material is released may be considered as worst-case 
scenario. With this additional information, the most important consumer ESs can be 
further ranked similarly to the ranking described in Wijnhoven et al. (2009). 
 
4.4.2 Kinetic and hazard aspects (phase II) 
4.4.2.1 Dissolution rate (relevant media) 
Recently, the different analytical methods available to measure solubility of NMs have 
been described (Tantra et al. 2015). Although a wide variety of techniques are available 
with the capability to measure total dissolved species or free ions, but not both, only a 
limited number of them are suitable for measurement in biological media. 
Electrochemical and colorimetric based detection schemes are able to measure the latter 
 90 
whilst atomic spectrometry based techniques are able to measure the former if combined 
with separation techniques such as ultrafiltration or ultracentrifugation. 
In general, the exposure route determines what the relevant medium is. For the 
inhalation route of exposure, dissolution in lung airway epithelial lining fluid and 
(macrophage) phagolysosomal simulant fluid is relevant. The oral route can be covered 
by measuring dissolution of NMs in food matrices, gastrointestinal tract simulation fluid 
and macrophage phagolysosomal fluid. For dermal conditions, the dissolution rate in 
artificial sweat could be used. 
In general, the dissolution rate in relevant media can provide information on the forms or 
speciation (coated or uncoated nanoparticle, agglomerate, aggregate, ionic and 
molecular form) of the NM when it comes into contact with the relevant areas in the 
human body, when it is absorbed and when it is distributed and translocated into specific 
organs and/or cellular compartments. This information is very important, because the 
extent and rate at which the NM transforms into these different forms of the material 
(including the extent to which it is dissolved) greatly influence its kinetic behaviour and 
toxicity. For some NMs, the toxicity is mainly determined by the extent and rate at which 
ions are released, while the toxicity of other NMs is mainly determined by the particulate 
properties that induce an inflammatory response (Cho et al. 2012). It should be noted 
that more complex NMs cannot be seen as homogeneous objects when evaluating the 
dissolution rate. 
4.4.2.2 Absorption (barriers) 
In vitro test methods simulating pulmonary (MucilAir™) or gastrointestinal barriers 
(Caco2) have been developed within NANoREG based on existing protocols (ECVAM 
2013), but these still need to be validated. Other physiological barrier models based on 
cell cultures and ex vivo tissues have also been used within NANoREG to simulate the 
blood brain barrier (Dominguez et al. 2014) and the oral mucosa barrier. To investigate 
uptake through the skin, an accepted in vitro test method is available (i.e. the in vitro 
skin absorption method in accordance to OECD TG 428), but it yet needs to be validated 
for NMs. 
For the inhalation route, generally only a very small percentage of insoluble NMs is 
translocated or accumulated in extra-pulmonary organs. Studies with partially soluble 
NMs typically show a larger percentage of particle translocation to extra-pulmonary 
organs as compared to the insoluble particles. However, it should be noted that with the 
current analytical tools it is difficult to determine whether either the particles themselves 
or another form of the material (e.g. molecular or ionic) are translocated (Powell et al. 
2010). Therefore, aggregation and agglomeration state of the NM influence its 
bioavailability. The rate of NM agglomeration in different vehicles is affected by the pH 
level. Different pH conditions in the GT and the presence of digestion enzymes might 
influence the behaviour (i.e. ion release, dissolution) of some NMs. It has been suggested 
that positively charged materials exhibit poor bioavailability due to electrostatic repulsion 
and mucus entrapment (Kermanizadeh et al. 2015). For NMs, dissolution rates in 
physiologically relevant media, like the gastrointestinal simulated fluid, have been 
suggested to be the decisive factor determining oral uptake. 
NM size appears to be highly significant for dermal penetration. Materials larger than 100 
nm in one or more dimensions do not seem to penetrate through the stratum corneum. 
Aggregation and agglomeration state is crucial in the degree of penetration and potential 
translocation (Kermanizadeh et al. 2015). 
Information on absorption into the body provides information on the need to consider 
only local or also systemic effects. However, it is often difficult to distinguish between 
complete absence and little transport in in vitro barrier systems. For NMs even very little 
uptake may result in relevant internal levels due to low elimination and accumulation in 
time. This should be considered when data from in vitro barrier models is used. 
Currently, the scientific knowledge on the behaviour of NMs within the human body is not 
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sufficiently developed to predict the distribution and translocation of NMs throughout the 
human body after inhalation, dermal or oral exposure. Without specific modifications, 
most poorly soluble NMs that reach the systemic circulation are mainly distributed to 
tissues that are rich in reticuloendothelial cells, such as liver and spleen. However, the 
nanospecific Physiologically Based Pharmacokinetic (PBPK) models developed to date 
mostly concern models in rats and mice for a specific type of NM (Bachler et al. 2013, Lin 
et al. 2015, Lin et al. 2016). Development of more general PBPK models and 
extrapolation of these models to humans should, in the near future, make it possible to 
predict the distribution and translocation of several types of NMs in the human body. In 
the meantime, one may use absorption rates in combination with intravenous kinetic 
models developed for specific NMs to estimate internal dose levels, taking into account 
the physicochemical properties of the NM and the NM on which the kinetic model is based 
(e.g. Van Kesteren et al. 2014). Based on these estimated internal dose levels, relevant 
internal barrier models and relevant cell types for in vitro assays can be selected. For 
instance, in vitro blood-brain or placental barrier models might be relevant when a NM is 
likely to reach the systemic circulation. It is worth noting that such in vitro models cannot 
distinguish between low and no translocation. For NMs that are likely to be distributed to 
the liver, hepatic cell lines should be considered for in vitro genotoxicity testing. 
4.4.2.3 Aggregation and agglomeration 
Some of the analytical methods used to determine if a material meets the criteria of the 
EC Definition (JRC 2012, De Temmerman 2015) (see section 2) can also be used to 
characterise the aggregation and agglomeration states. The most suitable methods 
should be selected taking the environment or matrix surrounding the nanomaterial into 
account. If inhalation is one of the most important routes of exposure, information on 
aggregation and agglomeration, as estimated by size distribution of the aerodynamic 
diameter of the aerosol, is very relevant for determining deposition in the respiratory 
tract, and subsequent translocation from the lungs to the blood stream. Those processes 
are largely dependent on the diameter of the aggregated or agglomerated NMs. 
The largest level of deposition is at the smaller sub-micron size range (< 0.1µm), with 
particles able to penetrate the trachea-bronchial and alveolar regions. Deposition of 
particles in the range > 0.5 µm is related to their aerodynamic diameter. For particles < 
0.5 µm, deposition is related to their diffusion equivalent diameter (Schulz et al. 2000). 
The Average Agglomeration Number (AAN) has been proposed to assess the dispersibility 
of NMs (Arts et al. 2015). NMs that remain dispersed as constituent particles (with AAN < 
3) are defined as 'mobile', since they may potentially move between body compartments. 
Information on the aggregation and agglomeration of a NM can be used to predict the 
ability of absorption, translocation and distribution in the body, which can be used in the 
selection of relevant internal barrier models and relevant cell types for in vitro assays. 
4.4.2.4 Cellular uptake, attachment and interaction 
Information on the cellular uptake, attachment and interaction of NMs can be studied 
using flow-cytometry, microscopy and inductively coupled plasma mass spectrometry 
(ICP-MS). Flow-cytometry and ICP-MS can measure quantitatively, but cannot distinguish 
between externally attached and fully internalised NMs. Furthermore, ICP-MS cannot 
distinguish between dissolved ions and nanoparticles and can only be used for electron-
dense material and not for detecting liposomes, polymers, or dendrimers. Confocal 
microscopy gives qualitative insight into the subcellular localisation and three-
dimensional structure of particles. Transmission electron microscopy (TEM) can be used 
to confirm subcellular particle localisation and tree-dimensional structure with high 
resolution. This method allows semi-quantitative assessments but the procedure is time-
consuming. Combining TEM with energy-dispersive X-ray spectroscopy (EDX) makes it 
possible to confirm the elemental composition of the nanoparticles (Kettiger et al. 2013). 
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Several in vitro assays have been tested and further developed within the NanoREG 
project based on standard toxicity protocols developed for pharmaceutical products but 
these still need to be validated for NMs. One may also consider studying the cellular 
uptake, attachment and interaction in the same in vitro assay(s) used to investigate the 
cytotoxicity and cytokine induction. 
Information on cellular uptake, attachment and interaction gives a first indication on the 
possible mechanisms of toxicity, such as damaging different cellular targets through the 
release of ions, the generation of ROS or the binding and interaction with intracellular 
proteins (Nel et al. 2009). For example, direct interaction of a NM with DNA can only 
occur if the NM is taken up by the cell and is able to reach the DNA within the nucleus. 
4.4.2.5 In vitro cytotoxicity, ROS and cytokines 
There are many in vitro assays based on a range of cell types and endpoints to 
investigate cytotoxicity, ROS generation and cytokine induction. Several in vitro assays 
have been tested and further developed within NANoREG. These include standard 
protocols for MTS assay, the neutral red assay (adapted from OECD TG 432), cellular 
impedance (Paget et al. 2014), micronucleus assay (OECD TG 487), mammalian gene 
mutation test (OECD TG 490), colony forming efficacy (OECD TG 476), the comet assay 
(Collins et al. 2004), ROS detection by dichlorofluorescin diacetate (DCFDA), and 
interleukin expression upon exposure of NMs to cells, but these still need to be validated 
for NMs since in several cases the nature of the NMs may interfere with detection 
methodologies (OECD 2013).  
Some of these assays allow studying the cellular uptake, attachment, interaction, 
cytotoxicity, ROS generation and/or cytokine induction in the same in vitro system. The 
appropriate assay should be selected taking into account that NMs often show major 
interference with the in vitro assay or read-out system. Furthermore, it is essential to 
test for endotoxin contamination before studying the immunotoxicity of NMs in vitro 
(Dobrovolskaia et al. 2009). 
As for non-NMs, the results of these in vitro assays cannot be used to predict human limit 
values. However, they give insight in the possible mechanisms of toxicity. Measuring the 
levels of pro-inflammatory cytokines and other inflammatory mediators may give insight 
into the mechanisms of the immunomodulating effects of a NM in vitro, such as 
inflammasome activation or dendritic cell maturation (Elsabahy and Wooley 2013). In 
addition, in vitro assays may give a first indication on the ability of the NMs to cause 
immunotoxic effects in vivo. Cellular ROS assays provide information on the ability of 
NMs to generate ROS within a cellular environment. Measuring the cytotoxicity is 
important for a good interpretation of the results of the in vitro cytokine and genotoxicity 
assays. In addition, in vitro cytotoxicity assays may give insight into the mechanisms of 
cytotoxicity, including damaging the plasma membrane, mitochondria, lysosomes or DNA 
through the release of ions, the generation of ROS or the binding and interaction with 
intracellular proteins (Nel et al. 2009). 
4.4.2.6 In vitro skin and eye irritation tests 
Several in vitro skin and eye irritation tests are available, including the rat skin 
transcutaneous electrical resistance (TER) test (OECD TG 431), the reconstructed human 
epidermis (RHE) skin irritation test (OECD TG 439), the Bovine Cornea Opacity 
Permeability (BCOP) test (OECD TG 437), the Isolated Chicken Eye (ICE) test (OECD TG 
438), and an in vitro cell assay (OECD TG 460). These assays were developed for the 
evaluation of skin and eye irritation of chemical substances but not all of them have been 
validated for chemical substances yet and none of them have been validated for NMs 
(SCENIHR 2015). 
Information on in vitro skin and eye irritation gives an indication on the ability of the NMs 
to cause these effects in vivo. 
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4.4.2.7 Cell transformation assay 
Several in vitro cell transformation assays (CTAs) are available to assess initiation and 
tumour promotion potentials but none of them have been validated for chemical 
substances or NMs (OECD 2016). CTAs measure induction of phenotypic alterations 
characteristic of tumourigenic cells. CTAs mimic some key stages of in vivo multistep 
carcinogenesis and have been shown to have a good concordance with rodent bioassay 
results, detecting both genotoxic and non-genotoxic carcinogens (Creton et al. 2011). 
Information on in vitro cell transformation ability gives an indication on the possible 
mechanisms of carcinogenicity and an indication on the ability of the NMs to cause these 
types of effects in vivo. 
4.4.2.8 In vitro genotoxicity 
The strategy for in vitro genotoxicity testing of NMs needs to include the detection of the 
most relevant events for the multistep process of malignancy (gene mutations, 
clastogenicity and aneugenicity). At each stage of the testing strategy, expert judgment 
is necessary to decide on the relevance of a result considering the existing weight of 
evidence. 
Tests for gene mutation in mammalian cells can be used, e.g. the mouse lymphoma TK 
gene mutation assay (MLA) (OECD TG 490), which uses the autosomal thymidine kinase 
(Tk) gene as a reporter of mutations in the L5178Y/Tk+/− mouse lymphoma cell line or 
the hypoxanthine guanine phosphoribosyltransferase (Hprt) gene forward mutation assay 
in Chinese Hamster Ovary (CHO) cells (OECD TG 476). In addition, the chromosomal 
aberration (OECD TG 473) and the cytokinesis-blocked micronucleus (CBMN) tests (OECD 
TG 487) are sensitive and reliable assays for the analysis of chromosome damage in 
mammalian cells. The former is used for detection of structural chromosome aberrations, 
i.e., chromatid- and chromosome-type breaks and rearrangements in cultured 
mammalian cells (OECD TG 473). The CBMN test allows the detection of micronuclei in 
the cytoplasm of interphase cells (Fenech 2000) containing whole chromosomes 
(aneugenic events) or chromosome fragments (clastogenic events) during cell division 
(OECD TG 487). On the other hand, a genotoxicity assay that has been strongly 
recommended for regulatory purposes is the alkaline single cell electrophoresis or comet 
assay (EFSA 2012). The comet assay is a sensitive and cost-effective method for the 
identification of DNA strand breaks and oxidative DNA lesions having the added 
advantage of requiring a very low quantity of substance or material for analysis 
compared to other in vitro genotoxicity assays. Alternatively, DNA double strand breaks 
could be assessed by analysing the phosphorymation of the H2AX histone using specific 
antibody. Several in vitro genotoxicity assays have been tested and further developed 
within NANoREG (adapted from OECD TG 487, 476 and 490) (Collins et al. 2016). 
Information on in vitro genotoxic mechanisms gives an indication on the possible 
genotoxicity and the ability of the NMs to cause cancer. Positive results indicate that 
these genotoxic endpoints might need to be investigated in vivo (or read-across to in 
vivo studies with similar materials should be considered). Before performing in vivo tests 
kinetic information is needed to assess which target tissues might be reached (including 
germ cells for potential reproductive effects). Negative results might in the future be 
sufficient to rule out these genotoxic effects, provided the most relevant test methods, 
cell types, and dose levels have been tested according to high quality standards to gather 
enough weight of evidence. In the future, when more scientific knowledge becomes 
available, it might also be possible to use in silico methods (e.g. validated (Q)SAR for 
NMs) to build stronger predictions and support the weight of evidence. 
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4.4.3 Output phase II 
In contrast to the output of phase I, the information obtained in phase II does not lead to 
a ranking of NM applications. However, the output gives direction to the information that 
needs to be obtained in phase III. 
 
4.5 Description of phase III and further 
In phase III, additional information on other determinants or exposure measurements 
may be obtained to give further insight into the risks associated to critical ESs. Guided by 
information obtained on the kinetics and hazard in phase II, in vivo studies to confirm the 
potential absorption, irritation, immunotoxicity and genotoxicity indicated by the in vitro 
studies might be needed. What information from phase II may trigger the type of 
information to be gathered in phase III (and further) is different for each NM application 
and exposure situation. Although it is not possible to describe this for each situation, a 
general description of which information of phase II may trigger the need to generate 
which type of information in phase III is given in the paragraphs underneath. Table SI-1 
of the supplementary information to the manuscript published by Dekkers et al. (2016) 
provides an overview of the relevant information and tools, which can be used to 
generate this information. 
Positive results of in vitro absorption assays may trigger further investigation of the 
ability of a NM to become systemically available (and possibly cause systemic effects) in 
an in vivo repeated dose kinetic and toxicity test. Negative results of in vitro absorption 
assays should be interpreted with care because it is often difficult to distinguish between 
complete absence and little transport in in vitro barrier systems. Therefore, negative 
results may indicate the need for more information on the dissolution, transformation 
and systemic toxicity of the NMs under investigation. Together with information on the 
size, aggregation, agglomeration as well as information on the lack of absorption, 
systemic distribution and toxicity of similar NM or non-NMs, the possibility of read-across 
might be considered. 
The results of in vitro assays investigating cellular uptake, attachment, interaction, 
cytotoxicity, ROS generation and/or cytokine induction give insight in the possible 
mechanisms of toxicity, which may trigger the measurement of specific parameters 
(cytokines, oxidative stress markers) in in vivo studies. Eventually, this may also 
highlight the relevance of specific endpoints to be considered. 
Positive results of in vitro genotoxic assays may trigger further investigation of 
genotoxicity by in vivo genotoxicity testing (or read-across to in vivo studies with similar 
materials should be considered). Before in vivo genotoxicity tests are performed, 
information on the kinetics of the NM is needed to enable the selection of the relevant 
tissues. 
Positive results of in vitro cell transformation and in vivo genotoxicity studies together 
with observed systemic availability, expected accumulation and toxicity (e.g. 
inflammatory effects) from in vivo repeated dose toxicity tests may trigger long-term 
repeated dose kinetic and toxicity testing to rule out accumulation and long-term effects, 
including carcinogenic, cardiovascular and adverse reproductive effects. 
 
4.6 Discussion and conclusions 
Performing risk assessment for each individual nanoform on a case-by-case basis may 
require a lot of experimental animals as well as time, effort and money. The proposed 
approach, based on six elements, provides alternative ways to address the risk 
assessment of NMs, by prioritising those applications with the highest potential health 
risks and identifying the most important information to address the nanospecific issues or 
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perform risk assesment across different nanoforms (e.g. using (Q)SAR, grouping or read-
across). 
The prioritisation is just a first indication on the potential health risk of a nano-enabled 
application. Since it should only be used for prioritisation, applications within the 'low' 
risk category should not be disregarded for further evaluation. Potential health risks of all 
categories ('low', 'medium' and 'high') still need to be verified and refined. Possibly, in 
phase I, not all exposure situations have been identified or unexpected toxicokinetic or 
toxicodynamic effects have not been identified. 
The proposal suggests specific steps to gather certain pieces of key information. It is 
worth noting that these selected pieces of information might not always be easy to obtain 
or generate. Within REACH, industry is responsible for providing sufficient information to 
ensure safe use of the application of the NM. The information requirements can be met in 
different ways, including using read-across and grouping. The methods proposed to 
obtain the selected pieces of information should be seen as suggestions. In case similar 
information can be obtained with other methods or tests, which might for example 
appear (scientifically) more suitable for specific cases, these can also be used. Clearly, 
the completeness, quality and uncertainty of the information are of utmost importance, 
but this is not always possible to verify. Without good quality data and the ability to 
assess the quality of the data, the information obtained or generated might be 
inadequate for risk assessment. 
It is also widely accepted that the scientific knowledge on NMs is not yet sufficient for 
defining all benchmarks or cut-off values needed within this approach or for broad 
application of nanospecific (Q)SAR, grouping and read-across tools. With the current 
approach it is possible to identify those situations where defining such benchmarks or 
cut-off values is likely to become feasible in the near future, as well as which type of data 
needs to be generated for scientific justification. Some of the benchmarks and cut-off 
values are rather general and applicable to many different situations while others are 
more specific for the NM application and exposure situation. In general, systematic sets 
of high-quality data are needed to identify, verify and validate which NM characteristics 
influence which aspect of the exposure, kinetics or toxicity. In the near future, only 
interpolation within these tested data sets and not extrapolation outside the tested range 
seems possible.  
The proposed approach, including the type of information linked to the various elements 
and endpoints, is based on the current state of knowledge and is flexible enough to 
accommodate future insights and knowledge of all types of NMs (1st, 2nd, 3rd, and 4th 
generation). Further elaboration and refinement, especially of phase III (and further), are 
needed based on experience with case studies. Although the current approach focuses 
only on human health risk assessment of NMs, it can be expanded to environmental risk 
assessment. 
The proposed risk assessment strategy, based on six elements, can be used to prioritise 
those NM applications that may lead to high risks for human health. The different phases 
of the flow chart guide the user to the most important information needs for addressing 
the nanospecific issues within the risk assessment, depending on the specific NM 
application, life cycle stage and exposure situation. Furthermore, the approach can also 
be used to identify those situations where the use of nanospecific grouping, read-across 
and (Q)SAR tools is likely to become feasible in the future and to point towards the 
generation of the type of data that is needed for scientific justification. This may lead to 
regulatory acceptance of the nanospecific applications of those tools. 
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5 Safe-by-Design 
This section illustrates the NANoREG Safe-by-Design concept. 
The tools currently available (e.g. guidance documents, models, protocols, decision 
trees) for addressing the nanospecific considerations discussed in this section, including 
those developed under NANoREG, are listed in the NANoREG toolbox (project deliverable 
D1.1272, see relevant worksheet in Excel file). 
 
5.1 Scope 
One of the long-term goals of NANoREG was to develop new testing strategies for 
nanomaterials (NMs), which account for innovation requirements and help both 
regulatory authorities and industry with 'keeping pace with innovation'. In this context, 
safety of NMs and related products is turned into a building block of innovation, rather 
than being a hurdle, without compromising the level of safety itself. Innovation 
requirements indicate that something has to change, although industry already takes 
safety into account and although regulators already have defined requirements. Several 
stakeholders have advocated a change of paradigm in the safety assessment of NMs. 
In this context, a forward-looking strategy called the 'NANoREG Safe-by-Design (SbD) 
concept' has been developed (see sections 5.3 and 5.4 for more details). This concept 
has to be regarded as a first outline. Ongoing projects such as ProSafe73 and NanoReg274 
are carrying on with filling in this outline, making it implementable by industry and useful 
for regulators. The concept envisages including safety into innovation from early 
development of a new NM or nano-enabled product onwards. 
 
5.2 Why Safe-by-Design 
Emerging technologies increasingly seem to give rise to questions about the safety of 
their products. Some believe this is due to the convergence of various technologies, 
resulting into products not sufficiently covered by present regulations (Tourney 2012). 
Others (Owen et al. 2009) regard it as an issue of timing; a temporal discrepancy 
between the market readiness of new technologies and the questioning of potential new 
risk issues that come along with this new knowledge and related products. When insights 
in (new) safety aspects are lagging behind development, appropriate legislation cannot 
be developed timely. Present discussions about the potential health risks of NMs are a 
perfect illustration of this time discrepancy.  
Owen et al. (2009) mention that society regards state-led regulations as pivotal, 
providing confidence for both investors and the public that innovations are safe. The 
public counts on a warranted level of safety for human and environmental health each 
time innovative products hit the market. There is, however, a real bottleneck in this 
approach. Various innovations and innovative products require amendment or 
development of existing regulation(s), but the stimulus to come to such adaptions is 
lagging behind considerably. Stimuli come from evidence for undesirable social, health or 
environmental consequences. However, the lack of such evidence in combination with 
products on market results in so-called 'uncertain risks'. The report of the European 
Environment Agency (EEA) "Early warnings, late lessons" (EEA 2013) demonstrates that 
uncertainty about safety has led to early warnings, but too often these warnings were not 
or could not be translated into the required actions.  
                                           
72
uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_12_DR_Toolbox.org 
73 http://www.h2020-prosafe.eu/ 
74 http://www.nanoreg2.eu/ 
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For nanotechnology, and more specifically for NMs, there is awareness that information 
requirements as laid down in regulations and related guidance may not fully cover the 
information needs to characterise the human health and environmental risks of certain 
NMs. This discrepancy between information requirements and information needs may 
lead to uncertain estimations of the risks. 
A possible remedy for this situation lies in the concept of Safe-by-Design (SbD). SbD 
aims at an integrated and iterative process, whereby safety information on a certain 
material, substance or product is integrated from early research and development (R&D) 
phases onwards. Iterations occur in order to search for the best achievable safety 
conditions. This concept seems by nature plausible for many stakeholders. In the end, it 
is thought to reduce the necessity for risk management actions, which can be beneficial 
for both industry and authorities. On the other hand, implementation might require larger 
investments in R&D. SbD can only be an acceptable concept in the innovation chain if it 
does not come at the cost of competitiveness. 
 
5.3 NANoREG Safe-by-Design concept 
Safety by Design or Safe(r)-by-Design is originally a concept that was developed and 
utilized by engineers, particularly those working within the construction industry. The 
basic idea is that it is important to consider and incorporate safety considerations into 
product design and development. Within the SbD concept, the functionality of a material 
and its toxicity are considered in an integrated way. SbD has traditionally been about 
incorporating safety considerations into the design, construction and maintenance of 
engineered products and workplaces.  
SbD in NANoREG has the following features: 
• It forms an exemplary platform for the early stage application of the 
precautionary principle in R&D projects in industrial innovation processes, 
• It includes precautionary measures and tools for the timely identification of 
uncertainties and potential risks, as well as timely actions to reduce or eliminate 
these uncertainties and, if possible, the respective risks at the earliest possible 
and/or feasible stage of development. The basis is a modular approach 
considering the various stages of innovation and allowing for different 
information requirements in line with the stage of innovation, 
• The NANoREG SbD concept is modularly designed based on commonly applied 
innovation models in order to be ready to be implemented in existing industrial 
R&D and innovation processes. 
The NANoREG SbD concept aims at: 
1. Identification and reduction of uncertainty about health risks, products and 
processes, 
2. Management of (potential) health risks of innovative materials, products and 
processes. 
Innovators are encouraged to incorporate considerations on potential health (workers 
and envisaged users) and environmental safety into the R&D phase of an innovation 
process and, where necessary, adapt the process and/or product design so as to enable 
safer outcomes. 
 
5.4 The NANoREG Safe-by-Design approach 
In industry today, structured innovation management processes for R&D projects to 
develop products, processes, technologies are the de facto standard. One of the most 
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common structured innovation processes, the "stage gate innovation model" (Cooper 
2018), is used as the backbone of the NANoREG SbD concept (figure 5.1). 
 
Figure 5.1. An illustration of the "stage gate innovation model" used as backborne of the 
NANoREG Safe-by-Design (SbD) concept. 
 
 
Source: NANoREG deliverable D6.03 
 
The actual work is carried out during the "stages": ideation, development, tests, up-
scaling, etc. Information is gathered about technology readiness, market perspectives, 
and required investments. Information about safety, as required by legislation, is taken 
into account to some extent. At each "gate", so-called "gatekeepers" decide on the fate 
of an innovation project: proceed, alter (proceed through gate though with minor 
alterations in the next phase), recycle (repeat the stage with major alterations), on-hold 
(wait for other projects, technologies, licenses, regulations, etc.) and terminate. 
Decisions are always based on balancing (expected) risks, costs and benefits. 
Whether, how and to which extent a stage gate process is run depends on the scope of 
the R&D or innovation project and the way a specific industry has organized its 
innovation processes. For smaller projects, stages 1 and 2 and/or stages 3 and 4 (figure 
5.1) can be merged; with only one idea for a smaller project, gate 1 may be merged with 
gates 2 and 3 (figure 5.1). The stage gate process can be run in two or more sequences 
and these can also occur in parallel. For instance, a technology is developed during the 
first stage gate of a process/innovation project; during the second one, a product 
platform using this technology is developed (there might be other platforms and products 
developed in yet other stage gate processes); and, in the third one, every geographical 
business unit develops a product for its market requirements (i.e. several daughter 
projects run in parallel). The stage gate process can even contain built-in loops within a 
stage, e.g. if it fails for certain criteria. 
There are different generalised types of stages that can be combined ad libitum: 
- Idea phases (to generate ideas); 
- First conceptual phases (to find technical solutions for one idea, i.e. screening 
phases); 
- Second conceptual phases (development planning for one technical solution); 
- Different development stages (research, technology development, system 
development); 
- Market testing phases; 
- Initial market phases (up until the Post Implementation Review (PIR)). 
The NANoREG SbD concept addresses nanospecific safety issues along the stages of 
innovation. It encourages innovators to think about how to address the following 
questions at each stage of innovation: 
• Is the material/product safe? 
• How to handle waste safely? 
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• How to use the material/product safely? 
Regulations appear to lag behind in addressing these questions for innovations. 
Nevertheless, this does not mean that existing regulations may not form a good basis. 
However, the current situation for NMs and nano-enabled products makes clear that 
insight in potential hazards or risks is needed during the early stages of innovation. To 
make the approach implementable, performing safety testing should be in line with the 
level of technology readiness. When innovations progress towards market application, 
information needs to be lined up in the direction of regulatory requirements. The 
NANoREG SbD approach hence includes for the first stages of innovation the 
identification of the potential for risks, followed by indicators for risk at mid stages of 
innovation, and by demonstrators for risks in the final stages of innovation, as laid down 
in regulatory requirements (figure 5.2). This approach aims at improved insights into 
risks, both environmental and human, before marketing of innovative NMs or nano-
enabled products. Moreover, it supports decisions at the various stages of development, 
for instance for further investments, thereby building up a strong business case. 
 
Figure 5.2. NANoREG Safe-by-Design (SbD) approach: stage-gate innovation process including 
risk terminology (i.e. potential, indicators and demonstrators for risks). 
 
 
 
 
 
Source: NANoREG deliverable D6.04 
 
The NANoREG SbD approach comprises: 
- An innovation-stage dependent approach; 
- A strategy to identify nanospecific risks; 
- Safe use, safe products/materials, safe waste handling. 
Whereas the concept can be applied to many different products, companies and 
industries – albeit with slightly different industrial management processes – data is case-
specific, i.e. for every product a new dataset is needed and needs to be accordingly 
structured. Figure 5.3 gives an overview of the coherent innovation model. 
 
The four elements visualised in figure 5.3 are: 
1. Exemplary illustration of an entire value chain as basis for the arrangement of the 
various innovation and R&D projects along this chain. 
2. Illustration of the arrangement of different types of applied industrial innovation 
and R&D projects along the entire value chains of a material or product. 
3. Exemplary illustration of an industrial innovation model with the different 
phases/stages and the corresponding intermediate milestones/gates. 
INDICATORS FOR RISKS POTENTIAL FOR RISKS DEMONSTRATORS FOR RISKS 
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4. Representation of the various sub-processes within the NANoREG SbD concept such 
as: innovation risk management process, environmental health and safety (EHS) 
management process, pre-regulatory and regulatory management process. 
Within the NANoREG SbD concept, the focus is on risk assessment under data constraints 
in the early stages of product development. For this purpose, control banding tools (such 
as the Swiss Precautionary Matrix75), safety screening strategies, risk potentials, decision 
trees (such as the one discussed in section 4), exposure scenarios, life cycle maps and 
the safety dossiers could be used, amongst others. 
Elaboration towards a full-fledged SbD approach is foreseen to be delivered by the EU-
funded H2020 actions ProSafe76 and NanoReg277. 
 
Figure 5.3. The NANoREG Safe-by-Design (SbD) concept as part of a coherent innovation 
model. The Safety Dossier is under development in ProSafe. GLP = Good Laboratory Practice. EHS 
= Environmental Health and Safety. PPORD = Product and Process Orientated Research and 
Development. R&D = Research and Development. 
 
 
5.5 Managing uncertainties and risks 
5.5.1 Managing uncertainties 
According to ISO standards, risk is the "negative, positive, or deviation from the 
expected effect of uncertainty on objectives". Hence, risks are the consequences of 
uncertainties and uncertainties are a cause of risks. Risk is also often described by an 
event, a change in circumstances or a consequence. 
                                           
75 http://www.bag.admin.ch/nanotechnologie/12171/12174/index.html?lang=en 
76 http://www.h2020-prosafe.eu/ 
77 http://www.nanoreg2.eu/ 
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Alternatively, a risk can be split into the probability of occurrence of an event (e.g. the 
exposure of the human population to a chemical) and the magnitude/impact of the event 
(e.g. the inherent toxicity of that chemical) once it occurs, i.e.: 
• Uncertainty about the occurrence of an event expressed as a probability distribution 
(if a single probability is stated without a safety/error margin and without a caveat 
or assumption, then the uncertainty must be 0%); 
• Uncertainty about the magnitude/impact of the event once it occurs. 
Because ambiguous, missing, or faulty information/data causes uncertainties, they also 
cause increase of risks. Hence, to reduce uncertainties and risks, more or more 
reliable/objective information/data is needed. 
Within the NANoREG SbD concept, an important task is to identify and reduce 
uncertainties. Figure 5.4 exemplifies the process of uncertainty identification and 
evaluation within each stage of innovation. 
 
Figure 5.4. Overall workflow of the NANoREG Safe-by-Design (SbD) concept for dealing with 
identification and evaluation of uncertainties. 
 
 
5.5.2 Managing risks 
In the NANoREG SbD concept, the ISO 31000:2009 standard for risk management78 can 
be used. Risk management is split into risk assessment (including risk identification and 
formulation, analysis, evaluation) and risk treatment. ISO also designed the standard 
ISO 21500 "Guidance on Project Management"79 to align with ISO 31000:2009. This is 
                                           
78 http://www.iso.org/iso/home/standards/iso31000.htm 
79 http://www.iso.org/iso/catalogue_detail?csnumber=50003 
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important, because proper project management is a prerequisite and necessity for a 
successful innovation project. 
Innovators are, however, also encouraged to actively seek for products or NMs with the 
best achievable inherent safety. This might mean redesigning instead of going over to 
the next stage of innovation. 
 
5.5.3 Risks and their general risk treatment options 
Once risks have been identified, analysed and evaluated in risk assessment according to 
ISO 31000:2009 standard, all techniques for risk treatment fall into one or more 
categories ranked from the one aimed to address the highest risk (i.e. "Risk Avoidance") 
to the one aimed to address the lowest risk (i.e. "Risk Retention") (see table 5.1). 
 
Table 5.1. Risk types and their treatment options according to ISO 31000:2009 standard. 
Risk type 
High impact and 
High probability 
Low impact and 
High probability 
High impact and 
Low probability 
Low impact and 
Low probability 
Risk treatment option Risk Avoidance Risk Reduction Risk Sharing Risk Retention 
What to do with the 
risk? 
Eliminate 
Withdraw from 
Avoid involvement 
Optimise 
Mitigate (impact) 
Reduce probability 
Transfer 
Outsource 
Insure and budget 
Accept and budget 
 
The NANoREG SbD approach proposes a selection of the best risk treatment options per 
stage of innovation. The followings aspects need to be looked at in any case in the course 
of this SbD approach. 
Risks with low occurrence/probability, but high impact, are often overestimated (e.g. the 
public discussion tends to focus on these risks with nuclear energy being the prime 
example for this). These risks tend to be perceived as catastrophes. With respect to 
hazard of chemicals and NMs, these types of risks should be thoroughly examined for 
both acute and chronic toxicity.  
By contrast, risks with low impact, but high occurrence/probability, are underestimated 
because of inurement, i.e. in case of chemicals and NMs, people tend to neglect the 
significant contribution of exposure and tend to focus on the low impact, be it consciously 
or unconsciously. With respect to hazard of chemicals and NMs, these types of risks 
should be thoroughly examined for chronic toxicity, with acute toxicity usually being low. 
A high exposure or a high hazard in itself does not exclude a NM a priori; instead, it 
should be thoroughly examined and proper risk treatment options should be developed, 
e.g. constrict applications of high hazard NMs to those with controlled and/or very low 
exposure; prescribe the usage of personal protective equipment to reduce exposure, so 
that the NM application is only slightly risky, despite the NM inherent hazard. 
It is worth noting that some functionalities, like high reactivity, may inherently lead to 
high hazardousness in the context of chemicals. This may be a challenge in the search 
for the most optimal balance between functionality and safety. 
 
5.5.4 Risk analysis and costs 
Costs of measures to reduce a risk have a direct impact on the remaining risk: the higher 
the costs, the lower the remaining risk. However, to find the most efficient solutions, the 
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costs of risk reduction have to be balanced with the costs of the remaining risk (e.g. a 
reduction of a risk to zero is usually inefficient, due to exponentially increasing costs). 
As it can be seen from table 5.2, the earlier a potential risk is addressed, the smaller the 
necessary costs for a given risk-reduction or for a given remaining risk are. 
 
Table 5.2. Costs of risk reduction based on timing. 
Timing 
Risk reduction 
investment 
Benefit of 
investment 
Remaining 
risk 
Remark 
Early small large small Small investments have large benefits 
In time medium medium medium - 
Late large small large Large investments have small benefits 
 
5.5.5 Uncertainty identification and risk assessment in the stages 
Uncertainty is also reduced in an innovation-stage dependent way: 
 Potentials for risks: during early stages uncertainties are identified and 
information is gathered to reduce them. Potential risk situations and scenarios 
are formulated as well as risks identified and listed for the next stage(s). 
 
 Indicators for risks: uncertainties are further reduced and new ones identified. A 
theoretical, i.e. using only subjective and existing objective data, risk 
assessment is carried out and risk treatment options are prepared. This may be 
an iterative process until the results of market testing and scaling up can be 
included. 
 
 Demonstrators for risks: addressing uncertainties is guided by regulatory 
requirements and, at a later phase, also by placement on the market, i.e. the 
post-launch review. 
 
5.6 Identification of nanospecific risks along stages of innovation 
An innovative screening strategy is proposed to identify potential nanospecific risks along 
the innovation process (figure 5.5). Subsequently, appropriate methods need to be 
described to measure the required parameters. At this moment, the development of a 
kind of manual rather than defining benchmark values is preferred. The latter is still a 
source of debate and may distract attention from working towards safe designs. Within 
NANoREG, only the first part of this strategy is elaborated. The next steps are worked out 
in NanoReg2. 
Identifying potential nanospecific risks during the first stages of innovation requires a 
screening strategy. It was developed in NANoREG based on six topics: 
solubility/dissolution rate, stability of coating, accumulation, genotoxicity, inflammation 
and environmental toxicity (figure 5.5). These topics resemble the ones discussed in 
section 4, but are addressed from another perspective, since during the first steps of 
innovation little is known about the NM and/or the nano-enabled product. 
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Parameters to be measured and applicable tests to measure them are described in 
NANoREG deliverables D6.0380 and D6.0481. Those tests can be found in the NANoREG 
toolbox under the relevant Excel worksheet (project deliverable D1.12). 
 
Figure 5.5. Schematic view of the screening strategy for risk assessment of nanomaterials in 
relation to the stages of innovation, the testing strategy and the test methods. 
 
Source: NANoREG deliverable D6.04 
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6 Life Cycle Assessment 
In this section, the Life Cycle Assessment (LCA) approach and its application to 
nanomaterials (NMs) in the REACH context are illustrated. Supporting information on this 
subject is reported in annex 5 of this document. 
Tools currently available (e.g. guidance documents, models, protocols, decision trees) for 
addressing the nanospecific considerations discussed in this section, including those 
developed under NANoREG, are listed in the NANoREG toolbox (project deliverable 
D1.1282, see relevant worksheet in Excel file). 
 
6.1 Introduction 
Life Cycle Assessment (LCA) is a standardized method for the compilation and evaluation 
of the inputs, outputs and related potential environmental impacts of a product system 
throughout its life cycle, from raw material acquisition through production, use, end-of-
life treatment, recycling and final disposal (i.e. cradle-to-grave) (ISO 2006a, 2006b). LCA 
considers the overall impacts of a product system on both human health and the 
environment, i.e. depletion of resources and emissions in air, water and soil. It is an 
important tool in evaluating the negative and positive environmental implications of a 
product, process, and technology, which can also be employed for the sustainability 
assessment of nanomaterials (NMs) (OECD 2013). Such a method permits the 
identification of the environmental issues, the definition of the hotspots of a product, 
process and technological system, the analysis of alternative solutions to improve the 
their environmental performance and the comparison of different scenarios. It therefore 
represents a powerful tool for supporting decision-making and policy development 
processes on nanotechnology, NMs and nano-enabled products. 
According to ISO (2006a, 2006b), there are four phases in an LCA study (see also 
supporting information in annex 5 of this document). In "Goal and scope definition" the 
objective of the study is defined, a description of the product system is provided in terms 
of the functionality and functional unit, the system boundaries, allocation and the target 
audience of the study are defined. The functional unit is a quantitative measure of the 
functions that the products (or service) provide. In accordance with the functional unit, 
the reference flow shall be defined, i.e. the flow to which all other input and output flows 
are quantitatively related. Comparisons between systems are made on the basis of the 
same function(s), quantified by the same functional unit(s). In "Inventory analysis" 
procedures for data collection and calculation in order to quantify from cradle-to-grave 
the relevant inputs (e.g. material inputs) and outputs (e.g. emissions to air) of the 
product/technological system are defined. The result of this phase is the Life Cycle 
Inventory (LCI), which is a compilation of the inputs (resources) and the outputs 
(emissions) from the product over its life-cycle in relation to the functional unit and to 
the system boundary defined. In "Life Cycle Impact Assessment (LCIA)" the inputs and 
outputs that have been collected and reported in the inventory are evaluated to 
understand the magnitude and significance of the potential environmental impacts for a 
product/technological system throughout its life cycle. The data are translated into a set 
of indicators for each environmental impact category (e.g. global warming potential as an 
indicator for climate change). In "Interpretation" the findings from both LCI and LCIA are 
used to draw conclusions and recommendations. 
LCA can be a comprehensive and powerful tool for environmental sustainability 
assessment of emerging technologies, such as nanotechnologies and related nano-
enabled products, and their comparison with conventional technologies/products. The 
"Report on the European Commission's Public Online Consultation towards a Strategic 
                                           
82
uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_12_DR_Toolbox.org 
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Nanotechnology Action Plan (SNAP) 2010-2015"83 recommends that NMs safety 
throughout their life cycle is ensured and suggests that sustainability of nanotechnologies 
and related nano-enabled products may be evaluated using tools such as LCA and Social 
Impact Assessment. However, the new functions and properties of nano-enabled 
products along with the lack of available information on their life cycle and releases into 
the environment are crucial limitations to the use of LCA in this field; this is discussed in 
section 6.2. 
The application of LCA to NMs was also proposed and encouraged by the OECD Working 
Party on Manufactured Nanomaterials (WPMN). During a workshop on the 
"Environmentally Sustainable Use of Manufactured Nanomaterials" held in Rome (Italy) 
on the 14th of September 2011 (OECD 2013), experts agreed on two main conclusions: 
1) LCA is an important tool to evaluate the negative and positive environmental 
implications of a product, process, or technology and it is a suitable for NMs; and 2) 
establishing linkages between LCA and risk assessment is a key aspect since LCA 
practitioners need risk-related information in the LCIA. As a follow-up on the conclusions 
of this workshop, the Guidance Manual "Towards the integration of risk assessment into 
Life Cycle Assessment of nano-enabled applications" was prepared, which proposes a 
complementary use of risk assessment and LCA for a more complete evaluation of nano-
enabled products (OECD 2015). The Guidance Manual also takes on board the experience 
accumulated by several authors in the recent years, who compared the environmental 
performances of emerging nanotechnologies and nano-enabled products with 
conventional ones.  
Furthermore, integration of LCA and risk assessment for NMs was discussed in the 
context of the EU NanoSafety Cluster84 (Savolainen et al. 2013). Finally, as highlighted 
by Askham (2012), the implementation of REACH Regulation 1907/2006 (European 
Parliament and Council 2006) and associated guidance published by ECHA can provide 
sources of data to fill gaps in LCIA and also strengthen the use of LCA methodology. Both 
these arguments are discussed in section 6.3. 
For more information on international initiatives concerning LCA consult annex 5 of this 
document. 
 
6.2 LCA and nanomaterials 
ISO 14040 and 14044 on LCA (ISO 2006a, 2006b) are in principle considered to be 
applicable to NMs (OECD 2015). 
In literature, the number of scientific papers with LCA studies on NMs and 
nanotechnologies/nano-enabled products has been increasing in the last three years. To 
date, about 40 studies have been published. These studies, carried out in agreement with 
ISO (2006a), have different goals and focused on different applications, such as: 
• To support the eco-design of a new nanotechnology, define the hotspots in the 
life cycle of a product from the early phase (Joshi 2008; Pizza et al. 2014), and 
suggest improvement options in the production phase, for example the use of 
different technologies (Li et al. 2014, Pini et al. 2014) or new materials (Dahlben 
et al. 2009, Scalbi et al. 2014); 
• To compare the environmental performance of new technologies with traditional 
ones, with the goal to evaluate if the new nano-enabled 
products/nanotechnologies reach better environmental performance (Sengu ̈l et 
al. 2011; Meyer et al. 2011; Walser et al. 2011); 
• To compare different nanotechnologies in order to choose the most 
environmentally-friendly one (Barberio et al. 2014); and 
                                           
83 https://ec.europa.eu/research/consultations/snap/report_en.pdf 
84 http://www.nanosafetycluster.eu 
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• To examine the implications of life cycle thinking on nanotechnologies and 
related market products (Bauer et al. 2008). 
From these studies it emerges that several scientific aspects need to be addressed before 
the ISO standards can be fully applied to nano-enabled products. To this end, CEN/TC 
352 (Nanotechnologies) is currently adapting the ISO standards to NMs. 
When carrying out comparative assessments, different products with the same function 
need to be considered. However, due to the fact that nano-enabled products offer quite 
novel functions, it may be difficult to identify alternative products and define the 
functional unit (Klöpffer et al. 2006; OECD 2015). It is therefore often necessary to 
expand the system boundary to include additional functions. 
A critical issue in LCA is considering the entire life cycle of the investigated applications. 
Indeed, the amount of available information is scarce for new applications such as 
nanotechnologies: 1) there are not commercial or public LCA databases that include 
specific processes on NMs (Hischier 2014); 2) the literature data on LCA of NMs often do 
not cover the use and end-of-life stages of the life cycle; 3) data on the production stage 
are generally obtained at laboratory or pilot scale, and therefore may lack reliability and 
robustness when transferred at macro scale (Hischer and Walser 2012, Gavankar et al. 
2012, Li 2014); 4) there is no consolidated method to calculate the release into the 
environment of NMs along life cycle stages and predict the physicochemical modifications 
that these NMs undergo in the environment (Subramanian et al. 2015; Hischier 2014); 
and 5) it is necessary to identify a specific elementary flow for NMs, which considers 
chemical composition, size, crystalline structure and any other parameter that influence 
the toxicity of these materials (Hischier 2014). 
All these aspects affect the reliability of the results of LCA when applied to NMs. Solutions 
have been proposed in the scientific literature to overcome these problems. For example, 
the use and end-of-life stages as well as the scale-up of production can be assumed from 
literature data and background data of proxy materials (Roses et al. 2007, Bauer et al. 
2007, Walser et al. 2012, Pizza et al. 2014, Hischier et al. 2015). Hischier (2014) 
proposed a framework for modelling the release scenarios of NMs along their life cycle 
and the characteristics of the elementary flow of NMs. 
To assess the environmental profile of NMs there are no particular difficulties in the 
application of 'traditional' LCA-impact categories (e.g. global warming, acidification, 
eutrophication, abiotic resource depletion). The application of toxic impacts category 
(human and ecological toxicity), instead, deserves special attention as the 
Characterisation Factors (CFs) of NMs for the toxicity-related impact categories are not 
available. Some attempts have been made to incorporate toxicity effect of NMs in LCIA. 
Some authors such as Eckelman et al. (2012), Rodriguez-Garcia et al. (2014) and Salieri 
et al. (2014) proposed ecotoxicity CFs for carbon nanotubes, MWCNTs and SWCNTs, and 
for nanotitania emitted into freshwater, respectively. Moreover Rodriguez-Garcia et al. 
(2014) developed human toxicity CFs for MWCNTs and SWCNTs. Another approach was 
proposed by Pini et al. (2014) for NanoTiO2 with the use of two new impact categories 
called "NanoTiO2 ecotoxicity in freshwater" and "NanoTiO2 carcinogens in fresh water" in 
the frame of the IMPACT 2002+ method. Hishier et al. (2015) in the LCA study on 
coatings containing nano-TiO2 used the CF of nanotitania and showed that the release of 
nano-TiO2 in the freshwater ecotoxicity is not negligible and depends on the magnitude of 
the impact factor. A detailed discussion on CFs for NMs is reported in annex 5 of this 
document. 
In this context, it is particularly effective to carry out an uncertainty analysis related both 
to the process and assessment data in terms of elementary flows and CFs (i.e. stochastic 
uncertainty) and to the methodological choices, such as system boundary setting, cut-off 
criteria, selection of impact assessment, assumption, etc. (i.e. sensitivity analysis). Some 
examples are available in the scientific literature: Walser et al. (2011), Pizza et al. 
(2014), Kanna et al. (2008), and Barberio et al. (2014). However, further studies should 
be developed to define harmonized approaches, to produce robust and reliable data and 
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therefore calculate scientifically sound CFs for toxicity-related impact categories (Scalbi 
et al. 2015). 
More details on LCA applied to NMs, nano-enabled products and nanotechnologies are 
reported in annex 5 of this document. 
 
6.3 LCA and risk assessment 
Sustainability assessment of NMs, nano-enabled products and nanotechnologies should 
take into consideration the impacts on the environment, health and safety (EHS). This 
integration requires the combined use of different methods such as risk assessment and 
LCA. 
Risk assessment evaluates the possible risk to workers, the public health and the 
environment due to exposure to chemical substances, whilst LCA quantifies the potential 
environmental impacts of the whole life cycle of a product. Indeed, the risk assessment 
focuses on the toxic impacts, while LCA provides a more comprehensive overview of the 
potential environmental impacts of a chemical product, including all other substances 
used during the entire life cycle of that product. Furthermore, there is a difference in how 
the 'life cycle' is perceived in risk assessment and LCA. Finally, LCA allows the 
environmental assessment at a global/regional scale, but the assessment of local impacts 
relevant for human health and ecological receptors is critical. For these evaluations, risk 
assessment is a better tool, as it allows the identification at a local scale of situations that 
are critical (i.e. above a defined threshold) at an early stage for a specific substance 
release. 
According to the scientific literature, risk assessment and LCA can be applied in different 
ways in the sustainability assessment of NMs: 
1. Combined use of risk assessment and LCA (section 6.3.1): the two methods are 
applied separately and the results of both are discussed to improve the 
performance of NMs/nano-enabled products/nanotechnologies; 
2. Risk assessment is applied from a life cycle perspective (section 6.3.2); 
3. Risk assessment under REACH and LCA (section 6.3.3). 
 
6.3.1 Combined use of risk assessment and LCA 
OEDC (2015) proposes the complementary use of risk assessment and LCA for a more 
comprehensive evaluation of nano-enabled products. The main aim of the OECD Manual 
is to provide guidance on how to combine risk assessment and LCA for NMs/nano-
enabled products and how to improve the applicability and quality of LCA studies for 
decision making. The OECD Manual presents a case study on carbon nanotubes (CNTs) in 
semiconductors packaging. 
Another interesting case study was performed by OECD (2014), which gives an overview 
on applications of nanotechnology in tyres, selects the key drivers for innovation, 
evaluates socio-economic impacts and environmental impacts in the context of LCA, and 
promotes EHS of NMs throughout a risk management framework as well as the transfer 
of knowledge and best practices. 
Furthermore, Grieger et al. (2012) provide recommendations for combined or separate 
use of LCA and risk assessment for NMs, addressing the specific needs of risk assessors 
and decision-makers throughout a literature review of LCA and risk assessment for 
chemicals and NMs. 
Starting from the consideration that a more tailored risk assessment can be performed 
by addressing the hot spots highlighted by LCA through the entire life-cycle, Barberio et 
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al. (2014) proposed to assess the EHS of two types of production of nanofluid alumina by 
the application of both LCA and a qualitative risk assessment of workplace85 . The 
authors highlighted conflicting results between LCA, which identified the production 
having the best environmental performance, and risk assessment, which identified the 
production having the highest risk for workers. The need emerged for the optimisation of 
the future industrialization phase, by using strategies of risk management or by 
improving the efficiency in the use of resources. The authors concluded that the 
combined use of both tools allowed a more detailed analysis of the systems to better 
support a Safe-by-Design (SbD) approach and the decision-making process. 
Walser et al. (2015) developed a framework for indoor emissions of synthetic 
nanoparticles. The goal of the framework is to implement occupational exposure as 
impacts category in LCA studies on synthetic NMs. Indeed, the authors highlight the 
importance of the health of workers during the production of NMs and propose to include 
this aspect in the LCA studies, thus developing a new impact category that considers the 
human toxicity of indoor emissions, using data from workplace exposure obtained from 
risk assessment. 
 
6.3.2 Risk assessment applied from a life cycle perspective 
For NM risk assessment purposes, it is very important that the material´s life cycle is 
comprehensively mapped, and put in the context of the value chain. The life cycle 
contains several stages and it is illustrated in figure 6.1.  
 
Figure 6.1. The generic life cycle of an engineered nanomaterial (ENM) that is integrated into a 
product. Thick arrows indicate the general progression of the life cycle. Thin red arrows symbolize 
additional fates for the ENM. Thin black arrows show where ENM release can occur. 
  
                                           
85 Risk assessment was assessed by using Stoffenmanager Nano tool, which allows the qualitative assessment 
of occupational health risks from inhalation exposure to manufactured nano-objects 
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Measurements of the released amounts, as well as description of the NM forms, are 
necessary for each of these stages. The release of a NM, irrespective of its form, possibly 
occurs during production of the NM-containing product. Such a release is likely of primary 
concern for a worker, although environmental exposure cannot be excluded per se. 
Consumers can possibly experience exposure to one or more of the NM forms during use 
and maintenance of the product. A major part of the release to the environment is 
expected to occur at the end-of-life, where recycling, reuse of material, and various 
disposal activities are taking place. Occupational exposure can possibly also take place in 
connection with these processes.A large knowledge gap exists regarding almost all NM-
containing products and their respective life cycles. What form the specific NM takes at 
different stages is often unknown, and there are question marks regarding the possible 
NM release. This lack of knowledge precludes a relevant exposure assessment and, thus, 
one of the cornerstones for risk assessment. 
Most studies so far related to specific safety aspects of a given NM have used the pristine 
form of the NM for at least hazard identification studies. Such pure materials are useful 
for studies of mechanisms and mode of actions, but are not necessarily the best choices 
for understanding the toxicological potential of the NM in a specific, 'real world' setting. 
For that purpose, LCA provides information about which form(s) a NM is taking at 
different stages of its life cycle, which can be used for further analysis in risk assessment. 
The big challenge regarding consequences for risk assessment deals with the exposure 
assessment aspects related to the different stages of a life cycle. Thus, it is necessary to 
establish: 
 If there is any release of NM at specific stages of the life cycle; 
 The specific physical form that the NM is taking if there is any release; 
 The actual quantity (taking the most appropriate metric(s) into consideration) of 
the NM; 
 The interaction between the NM and its surrounding environmental matrix 
(water, soil, sediment); and 
 Any background level of similar but naturally occurring materials. 
These data then guide the work related to other aspects of risk assessment. 
There are only a few published studies where a life cycle perspective has been applied to 
NM risk assessment. In a recent review, Mitrano et al. (2015) concluded that few studies 
have been able to establish what changes a given NM undergoes when it is incorporated 
into and released from products. 
Specific case studies covering substantial parts of the life cycle are nevertheless available 
(see e.g. Sotiriou et al. 2015, Bekker et al. 2015, Pirela et al. 2015). A conclusion from 
these studies is that very variable exposure situations develop depending on the species 
of NM, and also on the life cycle stage and handling method. 
 
6.3.3 Linking risk assessment under REACH and LCA 
Differences between how risk assessment is applied under REACH and LCA have been 
analysed in Askham et al. (2012), but also possibilities of linking can be explored. 
Askham et al. (2012) suggest that the good availability of toxicity data in REACH can 
improve LCA toxicity assessments and methods for elaborating new nanospecific CFs. On 
the other hand, the authors highlight that LCA has an iterative approach that gives a 
holistic vision on the life cycle of products and can be useful to design optimisation and to 
compare different options. This approach can be usefully taken into account when the 
REACH principles are implemented in companies not just for complying with REACH 
information requirements, but to assess other scenarios/options with improved 
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environmental performance and exploit the potential for innovative solutions (i.e. 
substitution of harmful chemicals with safer alternatives). 
Following a 'substance-based' approach, REACH aims to evaluate the risk assessment at 
different stages of its life cycle. Indeed, the knowledge of exposure is of regulatory 
relevance throughout the different life cycle stages: production process of the substance 
itself, releases during the production process of products in which substances are used, 
waste treatment, consumer articles. Following a 'product-based' approach, LCA aims to 
evaluate and quantify the environmental impacts of products and services considering 
their whole life cycle from cradle to grave: in this context, it may deal with the substance 
described in REACH or its application or a product containing it. The linking of these 
approaches could lead to define common system boundaries of the scenarios investigated 
in REACH and LCA: in this case the object under investigation is the same, though there 
is a difference concerning the environmental indicators as REACH considers the 
(eco)toxicity at local scale and LCA allows the environmental assessment at a 
global/regional scale. To date, REACH requires that risks associated with chemicals are 
expressed as risk-phrases (R-phrases) in line with the international hazard labelling 
standards86. Data collected for REACH implementation could be included in LCA, but 
presently these data are not suitable for a direct insertion in a LCA study, as they are, 
and need further elaboration; indeed, LCA data include processes and amount of input 
and output while data from REACH concern substance properties. Some authors (Askham 
et al. 2012, 2013) suggest a holistic evaluation for linking R-phrases and LCA and 
including chemical hazard information in LCA with the aim of obtaining product 
development options and reducing potential risk of chemical hazard. The authors 
developed the REACH/LCA Screening Tree Tool in close collaboration with an enterprise, 
in order to ensure relevance to and usefulness in their product development process. The 
Screening Tree Tool represents an integration among the "only above threshold" (risk 
assessment-based) and "less is better" approaches (LCA-based). The tool was developed 
in a current software LCA tool (Pre consultant 2011) and is based on an impact 
assessment method already existing, with further improvement for considering the R-
Phrases, threshold limit values and the calculation of hazard indicators and exposure 
pathway indicators. The Screening Tree Tool provides information in a visual overview 
and facilitates the link to a life cycle perspective, useful to communicate the importance 
of such issues to suppliers, suggesting the level of impurity that is acceptable (also 
calculable using this tool) or identifying which chemicals are important in specific raw 
materials from known suppliers. Often, the stimulation of a broader awareness of 
stakeholder across the supply chain could lead to better business decisions. The 
Screening Tree Tool is a good starting point for combining LCA and REACH in the product 
development process. Useful information in the priorities of product development is given 
but further work is needed to achieve full function-based life cycle hazard assessment. 
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7 Take-home messages and final considerations 
Considering the diversity of issues that are addressed by the NANoREG framework, the 
reader is provided with a list of take-home messages for both Part I (section 7.1) and 
Part II (section 7.2) of the document. Section 7.3 offers final considerations. 
 
7.1 Take-home messages on Part I 
Part I of the NANoREG framework aims to: i) illustrate the European Commission's 
definition of 'nanomaterial' (EC Definition), ii) illustrate step-by-step how REACH applies 
to nanomaterials (NMs), ii) identify where the issues still reside, and iii) 'show the path' 
to solutions based on available guidance and work presented in peer-reviewed scientific 
literature. The main outcomes from this work on gathering and consolidating existing 
information are summarised below, section by section, as take-home messages. 
Take-home messages on EC Definition of 'nanomaterial' (from section 2) 
• Currently, the EC Definition is not included in the REACH legal text (and REACH 
does not define 'nanomaterial'), but the EC Definition is referred to in the ECHA 
guidance for implementation of REACH, in the appendices which contain 
recommendations for NMs. 
• The European Commission's policy services are in the process of deciding if and 
how the EC Definition should be revised. The decision takes into account options 
provided by the JRC in 2015. The options included, for instance, suggestions to 
improve the clarity and implementability of the definition, analysis of the 
consequences of varying thresholds for the particle number fraction and a 
discussion on the role of VSSA. 
• No single technique, but rather a range of measurement methods is needed to 
test whether a material meets the EC Definition. 
• There thus appears to be a need to develop a detailed guidance on the 
implementation of the EC Definition to indicate: i) which measurement methods 
are more appropriate and for which NMs, ii) the sequence of the measurements, 
and iii) how to address or harmonise as many factors as possible that can 
influence each technique (e.g. SOPs for sample preparation). This guidance has 
to be in line with the future revised EC Definition. 
Take-home messages on REACH Substance Identification (from section 3.1) 
• REACH addresses substances regardless of their size, shape and physical state. 
NMs are therefore covered by the definition of 'substance' under REACH and are 
subject to the same obligations as any other substance. 
• REACH currently does not explicitly address NMs in its legal text. A process of 
revision of the REACH Annexes VII-X is ongoing, and explicit obligations for NMs 
are planned in the near future. 
• A new appendix to the "Guidance on Registration" including recommendations 
for NMs has been developed by ECHA (under consultation in February 2017) in 
order to provide advice to registrants who prepare their NM registration dossiers. 
This Guidance may need to be updated when explicit obligations for NMs are 
introduced (see previous bullet). 
• The term 'nanoform' refers to a particular form of a substance that meets the 
criteria of the EC Definition of nanomaterial, as opposed to the 'bulk form(s)' of 
the same substance, i.e. (the) form(s) of the substance not meeting the criteria 
of the EC Definition. Several nanoforms of the same chemical composition may 
exist. 
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• Registrants can address all the nanoforms of a substance under the same 
registration and together with the corresponding non-nanoform. The hazard 
information submitted to demonstrate the safe use of the registered substance 
must cover all forms of the substance proposed in the registration and explicitly 
cover the nanoforms. 
• The information included in registration dossiers shall contain sufficient 
characterization of surface-treated NMs. Potential hazard difference(s) between 
surface-treated and untreated nanoforms should not be underestimated.  
• IUCLID 6 includes new "conditionally active" fields to describe composition-
related information on NMs (particle number size distribution, shape and aspect 
ratio, specific surface area and surface treatment), hence providing the 
opportunity for registrants to improve clarity when presenting information on 
nanoforms within their registration dossiers. 
Take-home messages on REACH Information Requirements (from section 3.2) 
• REACH Standard Information Requirements (Annexes VII-X) in principle apply to 
all forms of the substance addressed in the registration dossier, e.g. bulk (non-
nanoforms) and nanoform(s) of a substance. While preparing a registration 
dossier, the registrant must ensure that the data provided are representative of 
all the specified form(s). 
• In 2012, ECHA published a series of appendices to the guidance for 
implementation of REACH, containing recommendations for NMs in relation to 
the Standard Information Requirements. These appendices are currently under 
revision and may need to be updated when explicit obligations for NMs are 
introduced in REACH. 
• Concerning several physicochemical properties, no nanospecific 
recommendations are provided in ECHA guidance for several of them: state of 
the substance at 20 °C and 101.3 kPa, melting / freezing point, boiling point, 
relative density, vapour pressure, surface tension, flash point, flammability, 
explosive properties, self-ignition temperature, oxidizing properties, stability in 
organic solvents and identity of relevant degradation products, dissociation 
constant and viscosity. For the endpoints having an associated OECD TG87, those 
available TGs are either considered to be applicable to NMs without adjustments 
or in need of further evaluation before decisions about modifications are made. 
• Literature suggests that current methods for water solubility assessment 
developed for bulk materials could in principle be used for NMs. However, OECD 
TG 105 is not applicable to NMs and is currently under review. Furthermore, 
specific nano-tailored protocols and guidelines are under development in the 
scientific literature. Both ECHA and OECD highlight that it is important to 
distinguish between 'solubility' and 'dispersibility' in the case of a NM. 
• Measurement of the water-octanol partition coefficient for NMs has turned out 
not to be meaningful for those NMs that do not dissolve, but rather disperse as 
particles. When a NM dissolves sufficiently so that the water-octanol partition 
coefficient is meaningful, the NM safety assessment can then follow the bulk 
material one. 
• Under REACH, in ECHA guidance, granulometry is defined as the determination 
of particle size distribution. When a group of particles covers a size range, it may 
be described by a particle size distribution. In the case of NMs, additional 
information on shape, specific surface area and dustiness should also be 
provided, as they are key parameters that describe granulometry. 
                                           
87 http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section-1-physical-
chemical-properties_20745753 
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• Concerning toxicological properties, for skin irritation or skin corrosion, eye 
irritation, skin sensitization and reproductive toxicity, OECD TGs are deemed 
valid for NMs.  
• For mutagenicity, the majority of the OECD TGs are applicable to NMs. However, 
the bacterial reverse mutation test (Ames test) is not considered reliable for the 
assessment of NMs and should not be used for mutagenicity testing on NMs. 
• When testing acute toxicity and repeated dose toxicity, inhalation may be the 
most likely route of exposure for NMs. It is important to include aspects on lung 
overload in the interpretation of the study results. 
• Regarding toxicokinetics, it is suggested to pay attention to potential 
modifications of the NM occurring in the test system. The evaluation of 
toxicokinetic data is encouraged for grouping and read-across, as well as for 
extrapolation of information from in vitro to in vivo. 
• Concerning ecotoxicological properties, when testing NMs for acute toxicity to 
fish, it is recommended to collect data on: fish ventilation rate, gill pathologies, 
mucus secretion, brain pathology, animal behaviour and activity levels of 
enzymes. 
 Regarding algal tests, OECD recommends that the assay selected to be used is 
tested in advance for interference arising from particle presence, as this has 
been reported to confound the measurement of algal cell counts. 
• For degradation, ECHA has clarified that a majority of OECD TGs on 
biodegradability are applicable to NMs of organic nature. 
• For adsorption/desorption screening, Kd has to be based on actual testing, since 
estimations from Koc and Kow have questionable or no merit for NMs. OECD TG 
106 is not appropriate for testing the adsorption/desorption of NMs and a new 
test should be developed. 
• It is not possible to estimate bioaccumulation from Kow, since NMs are usually 
dispersed rather than in solution. Hence, OECD TG 305 on bioaccumulation in 
fish needs to be adjusted for NMs. 
• For Effects on terrestrial and sediment organisms, guidance on detection 
techniques for NMs in soil and sediment is needed. Understanding the state of 
the NM in soils and sediments is considered critical for interpreting results. 
• For all properties, non-testing approaches (e.g. (Q)SAR, grouping and read-
across) are applicable on a case-by-case basis only and require detailed scientific 
justification. 
Take-home messages on Adaptations of REACH Information Requirements (from section 
3.3) 
• An appendix to ECHA guidance on "QSAR and grouping of chemicals" with 
recommendations on how to apply grouping and read-across for NMs is currently 
(February 2017) under development. The general approach is in principle 
applicable to NMs. However, similarity cannot be exclusively based on structural 
or chemical composition. Indeed, grouping and read-across for NMs largely 
involve different nanoforms of the same chemical composition. 
• Several (Q)SAR methods for NMs are under development, but their usefulness as 
alternative methods in a regulatory context still needs to be demonstrated. 
Take-home messages on REACH Hazard Assessment (from section 3.4) 
• The CLP Regulation provides the framework for the classification of NMs as it 
applies to substances and mixtures in all physical states and forms. It is likely 
that there may be a need to classify a NM in a different way than the same 
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substance in a bulk form or in a slightly different nanoform. In IUCLID, it is 
already possible to specify the classification and labelling of the nanoform. 
• When deriving DNELs for NMs, the choice of metrics is of critical importance, 
since it is not possible to establish a single metric that is applicable to all cases.  
• When using OEL in place of DNEL for NMs, it is critical to consider whether the 
route and duration of exposure, as well as the physicochemical attributes that 
may affect the toxicity, are the same as for the substance for which the OEL has 
been set. 
• For NMs, it is unwise to extrapolate from one exposure route to another. 
• The thermodynamic equilibrium generally does not apply to NMs in the 
environment and, thus, care must be taken when applying the equilibrium 
partitioning method to NMs and interpreting the results. Indeed, as NMs may 
spread in the environment as particles, the equilibrium partitioning method may 
underestimate the exposure of soil and sediment environments and overestimate 
the exposure in water. 
• AFs and SSDs do not take nanospecific processes, such as aggregation, into 
account during the testing of NMs. The tests may thus not always be 
representative of natural conditions. Three other methods are suggested in 
literature: the probabilistic species sensitivity distribution (PSSD), the dissolved 
metal ion and the indicative no effect concentration (INEC). 
Take-home messages on REACH Exposure Assessment (from section 3.5) 
• There are currently no agreed standardised and validated methods for measuring 
personal exposure to NMs.  
• There are currently no validated models providing quantitative estimates of 
human (worker and consumer) or environmental exposure to NMs. 
• A number of control banding tools and semi-quantitative exposure assessment 
tools are being developed that can be used to determine if exposure to NMs 
needs to be controlled. 
• A number of instruments that are able to generate measurement data on particle 
size, number and/or surface area are available. However, these instruments are 
unable to distinguish between engineered nanoparticles and any 
background/ambient nano-sized particles.  
• NMs are released from consumer products in forms that are different from the 
primary particles handled at the manufacturing stage. Further transformations in 
the environment affect what exactly humans or the environment are exposed to. 
This is currently difficult to address in exposure or risk assessment. 
Take-home messages on REACH Risk Characterisation (from section 3.6) 
• The same metric must be used in order to compare exposure and hazard. The 
work carried out in NANoREG suggests that the most appropriate metric to 
express the biologically effective dose largely depends on the exposure pattern 
and on the type of NM. 
• Relationships for converting mass into other metrics need to be developed. 
• Given the need to fill in data gaps and, at the same time, the lack of validation 
of available models for NMs, model uncertainty can be considered an even more 
important issue with NMs than with other chemicals. 
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7.2 Take-home messages on Part II 
Part II of the NANoREG framework examines from the scientist's point of view three 
forward-looking strategies that are expected to facilitate and accelerate an efficient 
implementation of REACH, discussing their benefits and potential limitations. The main 
outcomes from these analyses are summarised below, section by section as take-home 
messages. 
 
Take-home messages on Nanospecific Risk Assessment (from section 4) 
• The approach aims to i) prioritise the assessment of the NM applications that 
have the highest potential to cause adverse human health effects, and ii) to 
identify the information that should be collected or generated in order to address 
the nanospecific issues in risk assessment, for instance under REACH. 
• The approach can also be used to identify situations where the use of grouping, 
read-across and (Q)SAR for NMs is likely to become feasible in the future, and to 
point towards the generation of the data types needed to scientifically justify the 
use of those tools. 
• The most important nanospecific elements to be considered in human health risk 
assessment of NMs are: exposure potential, dissolution, transformation, 
accumulation, genotoxicity and immunotoxicity. 
Take-home messages on Safe-by-Design (from section 5) 
• SbD aims at providing an integrated and iterative process where safety 
information on a certain material, substance or product is integrated within the 
innovation process from early R&D phases onwards. Iterations occur in order to 
search for the best achievable safety conditions. Safety hence becomes a 
component of the innovation process, not a hurdle. 
• The NANoREG SbD concept includes the identification of the "potential for risk" in 
the first stages of innovation, followed by "indicators for risk" at the middle 
stages of innovation and, eventually, by "demonstrators for risk" in the final 
stages of innovation, as laid down in regulatory requirements such as in REACH. 
• The identification of "potential for nanospecific risk" during the first stages of 
innovation requires a screening strategy. The NANoREG screening strategy is 
based on six questions: solubility/dissolution rate, stability of coating, 
accumulation, genotoxicity, inflammation and environmental toxicity.  
• The NANoREG SbD concept also supports the selection of the best "risk 
treatment options" per stage of innovation. 
• Elaboration towards a fully-fledged SbD approach is foreseen by the EU-funded 
H2020 actions ProSafe (CSA, for industry) and NanoReg2 (RI, for regulators). 
Take-home messages on Life Cycle Assessment (from section 6) 
• The ISO 14040 and 14044 standards on LCA are considered to be in principle 
applicable to NMs and nano-enabled products. However, there are scientific 
aspects that remain to be solved and CEN/TC 352 - Nanotechnologies is 
currently working on an adaptation of the ISO standards. 
• Due to the fact that nano-enabled products have novel types of functions, it may 
be difficult to identify alternative products and to define the functional unit in an 
LCA study. 
• The amount of available information to define the entire life cycle of a nano-
enabled product is scarce, especially for the end-of-life stages. 
• The application of "human toxicity" and "ecological toxicity" impact categories 
deserves special attention, as the respective characterisation factors (CFs) are 
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not yet available for NMs (although some attempts are illustrated in scientific 
literature). 
• Combined use of risk assessment and LCA for NMs is encouraged.  
• The availability of toxicity data in REACH may help with the derivation of 
nanospecific CFs. However, these data are presently not suitable for a direct 
insertion into an LCA study, but need further elaboration. Indeed, LCA data 
include 'processes' and amounts of 'input and output', while data from REACH 
concern substance properties. 
• On the other hand, LCA gives a holistic vision on the life cycle of products, which 
can be taken into account when REACH principles are implemented by 
companies, for instance to assess other scenarios/options with improved 
environmental performance, i.e. with substitution of harmful chemicals by safer 
alternatives. 
 
7.3 Final considerations 
The NANoREG framework is the result of a collective effort of experts from more than 20 
project partners from well-recognised organisations. They generated, gathered and 
linked together in a single document a large amount of information from several diverse 
fields on EHS of NMs.  
The document was conceived as a manual that both regulators and industry could consult 
to understand the state-of-the-art in performing safety assessment of NMs under REACH, 
including closed and open issues. It also provides them with forward-looking strategies to 
be further developed from a scientific perspective, which could pave the way for a more 
efficient and practical implementation of REACH principles for NMs.  
The three forward-looking strategies identified by NANoREG partners are: the use 
NanoRA as a screening tool, the application of the SbD process to NMs, and the combined 
use of LCA and risk assessment for NMs. The strategies are at present at conceptual 
stage of development. NanoRA has the form of a comprehensive flow chart aimed to 
enhance the efficiency of the risk assessment process for NMs. The next step towards 
practical implementation is to verify and, if necessary, refine its assumptions through 
dedicated case studies. SbD is a well-known concept in industry. Its application to NMs 
has been first proposed by NANoREG. This NM SbD concept is maturing in the EU-funded 
actions ProSafe and NanoReg2, with the development of operational tools to support both 
industry and regulators expected in the short-term. LCA is also a well-established 
procedure, but its application to NMs is presently hampered by methodological 
uncertainties and lack of data, which still need scientific work to be solved. 
In spite of the hurdles in the development and practical application of the forward-
looking strategies, NANoREG partners consider NanoRA, SbD and LCA as valuable paths 
worth exploring by scientists, industry and regulators to achieve a more efficient 
implementation of REACH principles for NMs in the near future. However, as shown in 
figure 1.1 (section 1), the three strategies need to be further developed, tested and 
debated before a decision can be made on how far they are actually relevant for 
assessment methodology under REACH and, if so, how they can be properly implemented 
at both industrial and regulatory level. 
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List of abbreviations and definitions 
 
AAN average agglomeration number 
ADP average particle diameter 
AE assessment entity (reporting tool) 
AF assessment factor 
ALI air-liquid interface 
BAL bronchoalveolar lavage 
BALF bronchoalveolar lavage fluid 
BCF bioconcentration factor 
BMF biomagnification factor 
BCOP bovine cornea opacity and permeability 
CBMN cytokinesis-blocked micronucleus (test) 
CES contributing exposure scenario 
CF characterisation factor 
CHO Chinese hamster ovary (cells) 
CMR carcinogenic, mutagenic or reprotoxic 
CPC condensation particle counter 
CSA chemical safety assessment, or coordination and support action 
CSR chemical safety report 
CTA cell transformation assay 
D diameter 
DCFDA dichlorofluorescin diacetate 
DLS dynamic light scattering 
DMEL derived minimal effect level 
DNEL derived no effect level 
E effect 
EC engineering control 
EDX energy-dispersive X-ray spectroscopy 
EEPS engine exhaust particle sizer 
EHS environmental health and safety 
EINECS European inventory of existing commercial chemical substances 
ELPI electrical low pressure impactor 
ENM engineered nanomaterial 
ES exposure scenario 
FFF-ICPMS field-flow fractionation - inductively coupled plasma mass spectrometry 
FMPS fast mobility particle sizer 
FRAS ferric reducing ability of serum 
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FU functional unit 
GES generic exposure scenario 
GHS globally harmonized system (of classification and labelling of chemicals) 
GLP good laboratory practice 
GT gastrointestinal tract 
HARN high aspect ratio nanomaterials 
HEPA high efficiency particulate air (filter) 
HPRT hypoxanthine guanine phosphoribosyltransferase 
ICE isolated chicken eye 
ICP-MS inductively coupled plasma mass spectrometry 
INEC indicative no effect concentration 
IU identified use 
IUCLID international uniform chemical information database 
Kd distribution coefficient 
Koc organic carbon-water partitioning coefficient 
Kow octanol-water partitioning coefficient 
L length 
LAS laser aerosol spectrometer 
LCA life cycle assessment 
LCI life cycle inventory 
LCIA life cycle impact assessment 
L/D length/diameter (ratio) 
LD50 lethal dose, 50 % 
LDH lactate dehydrogenase 
LEV local exhaust ventilation 
LIBS light-induced breakdown spectroscopy 
LOAEC lowest observed adverse effect concentration 
LOAEL lowest observed adverse effect level 
MLA mouse lymphoma (thymidine kinase (TK) gene mutation) assay 
MNO manufactured nano-object 
MoA mode of action 
MPS mini particle sampler 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium 
MWCNT multi-wall(ed) carbon nanotube 
NM nanomaterial 
NO nitrogen oxide 
NOAA nano objects, aggregates and agglomerates 
NOAEC no observed adverse effect concentration 
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NOAEL no observed adverse effect level 
NOM natural organic material 
NSAM nanoparticle surface area monitor 
OC operational condition 
OEL occupational exposure limit 
OPS optical particle sizer 
OSOR one substance, one registration (principle) 
P probability 
PBPK physiologically based pharmacokinetic (model) 
PBT persistent, bioaccumulative and toxic 
PC particle concentration/counter 
PE polyethylene 
PEC predicted environmental concentration 
PIR post implementation review 
PNC particle number concentration 
PNEC predicted no effect concentration 
PPE personal protective equipment 
PPORD product and process orientated research and development 
PROC process category 
PSLT poorly soluble low-toxicity 
PSSD probabilistic species sensitivity distribution 
PVC polyvinyl chloride 
(Q)SAR (quantitative) structure-activity relationship 
(Q)NAR (quantitative) nanostructure-activity relationship 
R risk 
R&D research and development 
RC risk characterization 
RCR risk characterization ratio 
RI research and innovation 
RHE reconstructed human epidermis 
RMM risk management measure 
ROS reactive oxygen species 
SAXS small-angle x-ray scattering 
SbD safe-by-design 
SEM scanning electron microscopy 
SMEs small and medium-sized enterprises   
SMPS scanning mobility particle sizer 
SNAP strategic nanotechnology action plan 
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SOP standard operating procedure 
SpERC specific environmental release category 
SRD scientific research and development 
SSD species sensitivity distribution 
STIS short-term inhalation study 
STP sewage treatment plant 
SWCNT single-wall(eg) carbon nanotube 
TC technical committee 
TEM transmission electron microscopy 
TER transcutaneous electrical resistance 
TG test guideline 
Tk thymidine kinase 
TNF-alpha tumour necrosis factor alpha 
TRA targeted risk assessment 
U uncertainty 
UA uncertainty analysis 
UVCB (substance of) unknown or variable composition, complex reaction 
products or biological materials 
vPvB very persistent and very bioaccumulative 
VSSA volume specific surface area 
WoE weight of evidence 
XRD X-ray diffraction 
 
European Union legislation 
BPR Biocidal Products Regulation (EU) 528/2012 concerning the making 
available on the market and use of biocidal products 
CLP Regulation (EC) 1272/2008 on the classification, labelling and packaging 
of substances and mixtures 
FIC Regulation (EU) 1169/2011 on provision of food information to 
consumers 
REACH Regulation (EC) 1907/2006 concerning the registration, evaluation, 
authorisation and restriction of chemicals 
 
Organisations, committees and groups 
CEN European Committee for Standardization 
DTI Danish Technological Institute 
EC European Commission 
ECETOC European Centre for Ecotoxicology and Toxicology of Chemicals 
ECHA European Chemicals Agency 
ECVAM European Centre for the Validation of Alternative Methods 
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EEA European Environment Agency 
GAARN Group Assessing Already Registered Nanomaterials 
ICG Informal Correspondence Group 
ISO International Standardisation Organisation 
JRC Joint Research Centre 
NMWG Nanomaterial Working Group 
OECD Organisation for Economic Co-operation and Development 
SCENIHR Scientific Committee on Emerging and Newly Identified Health Risks 
UNSCEGHS United Nations Economic and Social Council's Sub-Committee on Experts 
on Globally Harmonized System of Classification and Labelling of 
Chemicals 
WPMN Working Party on Manufactured Nanomaterials 
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Annexes 
Annex 1. Terminology 
JRC has published the harmonised terminology for environmental health and safety of 
nanomaterials as NANoREG output here: 
http://publications.jrc.ec.europa.eu/repository/bitstream/JRC100906/jrc%20technical%2
0report-nanoreg%20terminology%20ehs%20assessement%20nms.pdf 
The document is also reported on the NANoREG website: 
http://www.nanoreg.eu/media-and-downloads/publications/267-nanoreg-harmonised-
terminology-for-environmental-health-and-safety-assessment-of-nanomaterials 
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Annex 2. Supporting information on nanomaterials for section 3.2 REACH 
information requirements 
Additional information on physicochemical, toxicological and ecotoxicological properties of 
nanomaterials (NMs) to be considered in order to address REACH Standard Information 
Requirements specified in Annex VII-X are discussed below. Information comes from 
different sources including ECHA guidance, IUCLID 6 database, OECD documents and 
peer-reviewed scientific literature. 
 
Physicochemical properties 
Shape 
In ECHA guidance (ECHA 2012), it is recommended to provide information on the shape 
of NMs as a part of the standard information requirement on "Granulometry", except in 
cases where the substance is marketed or used in a non-solid or non-granular form. 
ECHA defines 'shape' as: "qualitative or, at best, semi qualitative geometrical description 
or dimension-less term(s) of the extremities of the particle or collections of particles, 
their agglomerates or aggregates, that make up the material under investigation 
(adopted from OECD 2009)". ECHA provides information on mesodescriptors and 
descriptors for shape, criteria for shape classification as well as available qualitative and 
semi-quantitative techniques for particle shape and morphology characterization. The 
reported data should contain information on: sample preparation method and analysis 
method used, a microscopy image, suspending medium, pH and temperature as well as a 
qualitative or semi-quantitative geometrical description of the particle and/or its 
aggregates or agglomerates. For details and methods, please consult ECHA (2012). 
Surface area 
It is recommended to present data on specific surface area of NMs (ECHA 2012). The 
requirement does not apply to substances marketed or used in a non-solid or non-
granular form. The data should include information on the specific surface area (m2/kg) 
and where appropriate also the calculated volume specific surface area (m2/cm3). In 
addition, information on the sample preparation, test method and test conditions, 
temperature, purity of the sample tested, mass of degassed sample, adsorption 
isotherm, evaluation parameters, physical state and reference substance used (if any) 
should be included. For details and methods, see ECHA (2012). ECHA also highlights that 
surface area is an important parameter in the characterisation of NMs, with emerging 
evidence of quantitative value as a dose metric or descriptor for hazard assessment. The 
total surface area should not be confused with the specific surface area, which is the ratio 
between total surface area and mass (mass specific surface area) or volume (volume 
specific surface area, VSSA) of the analysed material. 
Adsorption/desorption 
In the case of NMs, the distribution coefficient Kd cannot be derived from the organic 
carbon-water coefficient (Koc) or from the octanol-water coefficient (Kow). Instead, Kd 
must be based on actual testing (ECHA 2012). Methods for the measurement of 
adsorption are summarized in ECHA guidance (ECHA 2015) (e.g. OECD TG 106 and 121).  
The assessment of existing TGs performed by OECD concluded that OECD TG 106 
"Adsorption-desorption" and OECD TG 121 "Adsorption to soil or sediment" might be 
applicable under some circumstances or to some classes of manufactured NMs only. 
However, it is not known how the test results might be impacted by the presence of a 
colloidal suspension, which might be present if the sample manufactured NM does not 
completely dissolve. Hence, further work is required to determine this and to modify the 
TGs, if necessary (OECD 2009). In the latest document, OECD further confirms that 
OECD TG 106 is not applicable to NMs (OECD 2014). 
Furthermore, ECHA (2015) states that the methods may not be suitable for: i) 
substances that react with the column; ii) solvent or other test system components; iii) 
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surface active substances; iv) substances that interact in a specific way with inorganic 
soil components such as clay minerals; v) inorganic compounds; and vi) moderate to 
strong acids and bases. NMs may be close in their properties to clay minerals, surface 
active substances and inorganic compounds. All methods require a quantitative analytical 
method for the substance, reliable over the range of test concentrations. This presents 
an issue for many NMs, if identification both by chemical nature and physical structure is 
to be performed. A practical solution for most cases is elemental analysis, e.g. by ICP-MS 
of fractions, since most NMs contain inorganic elements (Hankin et al. 2011). 
IUCLID 5.6 fields for physicochemical endpoints 
When preparing the registration dossier, information on the physicochemical 
characterisation of the substance is foreseen to be reported under sections 4.1-4.36 of 
IUCLID 5.6. The registrant should note the following endpoints, which are of particular 
relevance for NMs: Agglomeration/aggregation, Crystalline phase, Crystallite and grain 
size, Aspect ratio/shape, Specific surface area, Zeta potential, Surface chemistry, 
Dustiness, Porosity, Pour density, Photocatalytic properties, Radical formation potential, 
and Catalytic activity (IUCLID 5.6 sections 4.24-4.36). Although these endpoints are not 
explicitly mentioned in REACH Annexes VII-X on Standard Information Requirements, 
they are considered as parameters that provide relevant information on REACH Standard 
Information Requirements. For example: Granulometry is characterised by size 
distribution, crystallite grain and size, shape/aspect ratio, dustiness, specific surface area 
and porosity; Water solubility is characterised by dispersibility and 
agglomeration/aggregation.  
Future developments in IUCLID may include additional nanospecific fields to enable 
better reporting on NMs. 
OECD identity and physicochemical characterisation endpoints 
In 2006, OECD launched the Working Party on Manufactured Nanomaterials (WPMN) to 
provide a global forum for discussion on environmental, health and safety issues 
concerning manufactured NMs. The WPMN set up an exploratory test programme (the 
"OECD WPMN Sponsorship Programme") to examine information needs and testing 
methods for manufactured NMs and a "Guidance Manual for Sponsors" (OECD 2010) was 
drafted to help the sponsors. A list of NMs to test was published in 2008 as well as a list 
of endpoints thought to be relevant for the safety assessment of NMs (OECD 2010), 
including endpoints describing the identity and physicochemical characterisation (table 
II.1). Later on, the WPMN published an evaluation of the methods used for 
physicochemical characterisation (OECD 2016a, 2006b). The Programme was finalised in 
2013 and the dossiers containing the raw data obtained from testing activities were 
published in 201588. An overview of the WPMN work and outcomes of the testing 
programme is given by Rasmussen et al. (2016). The assessment of the methods (OECD 
2009) and the initial considerations of the test results (SCENIHR 2009) concluded that 
not all proposed endpoints were relevant for all NMs. 
 
Toxicological properties 
Respiratory tract corrosion and irritation 
These endpoints are not required as standard information in REACH and at the moment 
there are no EU or OECD test methods for these effects; however, as reported in the 
ECHA guidance (ECHA 2015), the inhalation toxicity of some fibre-like NMs may cause 
persistent pulmonary inflammation leading to the destruction of the respiratory tract 
mucosa and the development of a granulomatous disease (Harkema et al. 2013). 
  
                                           
88 http://www.oecd.org/chemicalsafety/nanosafety/dossiers-and-endpoints-testing-programme-manufactured-
nanomaterials.htm 
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Table II.1. OECD list of endpoints regarding chemical identity and physicochemical properties 
for nanomaterials to be tested during the Working Party on Manufactured Nanomaterials 
Sponsorship Programme (modified after OECD 2010). CAS = Chemical Abstracts Service; TEM = 
Transmission electron microscopy. 
N° Nanomaterial Information/Identification 
1 Nanomaterial name 
2 CAS number 
3 Structural formula/molecular structure 
4 Composition of the nanomaterial being tested (incl. degree of purity, known 
impurities or additives)  
5 Basic morphology  
6 Description of surface chemistry (e.g. coating or modification) 
7 Major commercial uses 
8 Known catalytic activity  
9 Method of production (e.g. precipitation, gas phase) 
Quantity 
10 Agglomeration/aggregation 
11 Water solubility  
12 Crystalline phase  
13 Dustiness 
14 Crystallite size  
15 Representative TEM picture(s) 
16 Particle size distribution  
17 Specific surface area  
18 Zeta potential (surface charge)  
19 Surface chemistry (where appropriate) 
20 Photo-catalytic activity 
21 Pour density 
22 Porosity 
23 Octanol-water partition coefficient, where relevant 
24 Redox potential 
25 Radical formation  
26 Other relevant information (where available) 
 Fat solubility/oleophilicity  
 Melting point 
 Boiling point 
 Relative density 
 Vapour pressure 
 Dissociation constants 
 
In order to assess inflammatory and pro-fibrogenic effects, some authors suggested a 
series of non-standardized assays in vivo, such as cytokine production profile, specific 
cell count and protein analysis in the bronchoalveolar lavage fluid (BALF), and in vitro 
with pulmonary, endothelial and immune cell lines (Hankin et al. 2011, Morimoto et al. 
2012). 
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In vitro testing 
The RIP-oN 2 report found a number of studies considering the inclusion of other non-
standardised in vitro tests relevant for human toxicity assessment of NMs: cell viability 
(e.g. cell morphology, lung cell damage, or cell metabolic activity), oxidative stress (e.g. 
ROS production, glutathione status, NO generation), and pro-inflammatory effects (e.g. 
cytokine production). These endpoints have been linked with genotoxicity, potentially 
followed by carcinogenicity or cell death (Hankin et al. 2011, Kermanizadeh et al. 2013). 
Certain in vitro studies, while not required under REACH or validated, may provide 
supporting information in a Weight of Evidence approach or other adaptations to the 
Standard Information Requirements (see section 3.3).  
Assay inhibition/enhancement 
NMs may interfere with a number of assays utilised to determine their cellular or toxic 
effects. For details, see ECHA (2012). Several authors advise as a general precaution to 
use more than one assay to assess the endpoint or effect in question (Hankin et al. 2011, 
Kroll et al. 2012, Guadagnini et al. 2015). 
Inhalation toxicity testing 
OECD (2012) suggested specific changes to adapt the actual Test Guidelines (TGs) for 
assessing inhalation toxicity of NMs. Aerosol preparation and characterisation, dosimetry, 
application of biokinetics and detailed pathology of the brain and nervous systems are 
some of the requirements discussed by OECD (2012). Most experts also agreed on the 
inclusion of the analysis of the bronchoalveolar fluid as a mandatory test to assess the 
inhalation toxicity of NMs. OECD published a study on dosimetry in 2015: "Concerning 
toxicological test special attention needs to be given to measuring, dosing, delivery, 
tracking of nanomaterials in the test system. Concerning toxicological endpoints it is also 
important to consider the physicochemical characteristics of the nanomaterial including in 
the dosing vehicle. There is need for guidance on sample preparation and in situ 
characterization for the toxicological assessment of nanomaterials. For toxicological tests, 
adequate characterization of tested nanomaterial should have consideration of actual 
exposure of the test system (possible agglomeration and disagglomeration) appropriate 
dose metric should be given". Dosimetry and sample preparation of NMs has also been a 
top priority for OECD, and the organization has developed a specific guidance on this 
topic (OECD 2012). 
Cell viability 
The most non-standard tests used are: cell morphology, in vivo BALF (bronchoalveolar 
lavage fluid cell counts) and protein analysis, cell metabolic analysis; cellular membrane 
integrity (LDH release); lung cell damage (gamma glutamyl transferase assay); Trans 
Epithelial Electricals Resistance; apoptosis and necrosis. 
Oxidative stress 
It refers to: ROS production, gluthatione status, nitric oxide (NO) generation. 
Inflammatory and pro-fibrogenic effects 
It refers to: TNF-alpha, Trypan Blue assay, cytokine production and analysis of signalling 
pathway. In particular, pulmonary inflammation and genotoxicity studies within 
pulmonary, endothelial and immune cell lines should be performed. 
Short-Term Inhalation Study (STIS) 
OECD has prepared a document (draft) reporting the discussion on the "feasibility to 
include lung burden and BALF analysis measurements as part of study supporting 
amendments to OECD subacute and subchronic inhalation test guidelines for testing of 
nanomaterials". The document also discusses the purpose of the Short-Term Inhalation 
Study (STIS) as pre-screening tool for grouping and read-across or to establish the 
testing dose of NMs for a later subsequent sub-chronic inhalation study. The study is 
based on the determination of three key elements that indicate inhalation toxicity: 
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inflammation potency of the respiratory tract tested through the cytokine profile analysis 
in the BALF; potential reversibility; or progression. For details, see OECD (2015). 
 
Ecotoxicological properties 
OECD (2014) identified dissolution, dispersibility, agglomeration, degradation and 
transformation as important pieces of information to be known before further fate tests in 
water compartments are conducted, and stated that a decision tree or tiered approach, 
to be added to the specific TG, should be established for NMs as prior testing before 
further ecotoxicity or environmental fate tests are conducted. Such a decision tree or 
tiered approach should also be developed as prior testing before soil or sediment toxicity 
testing. OECD (2014) also called for the development of guidance for pre-treatment 
scenarios which include the most probable transformation processes, in order to 
harmonize the handling of aging and transformation processes. The following issues were 
discussed in the "Conclusions and Recommendations" chapter (OECD 2014): 
• For a better comparability of results from ecotoxicity and fate tests, the same 
test conditions should be used. 
• Environmental tests should also be conducted with aged NMs. The aged NM 
should reflect the most likely transformation processes after its introduction into 
the environment compartments. Pre-treatment scenarios must therefore be 
identified and harmonized. 
• During the environmental tests, a loss of the applied NM is expected. An 
adjustment should be made for the acceptance of loss of NM during the test. 
• The importance of natural organic material (NOM) for the fate and transport of 
NMs in the environment is recognized. The type of NOM used for testing or which 
is already available in the system must be specified. 
• Depending on the environmental behaviour of a NM, zebrafish may not be the 
right target organism and other organisms should be tested. The applicability of 
the OECD TG 305 bioaccumulation test for other organisms, e.g. mussels or 
daphnids, should be tested in further studies. 
Recommendations for the future needs in regulatory environmental testing include 
method development for detection, identification and quantification of NMs in both 
environmental and test media, the characterization and understanding of particle 
behaviour in these media, data gaps in toxicity testing and category approached to group 
NMs (OECD 2014). 
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Annex 3. Supporting information on nanomaterials for section 3.4 REACH 
hazard assessment 
In addition to the nanospecific considerations concerning how to carry out the hazard 
assessment required by REACH in the case of nanomaterials (NMs) (see section 3.4.1), 
there are additional nanospecific issues that merit mentioning since they can influence 
the interpretation or the execution of the hazard assessment. 
 
Nanospecific intracellular pathways and effects 
A large number of in vitro studies using either primary cultures from different origins or 
established cell lines have been performed and many types of NMs and endpoints have 
been studied. It has been shown that the NM size can determine the pathway of cell 
entry (Rejman et al. 2004, Jana 2011). The studies show that after NMs enter the cell 
they interact with the cytoplasm and subcellular organelles. Depending on the cell type 
and also on the material type, they can accumulate for longer periods of time and induce 
specific cellular effects (e.g. Oberdorster et al. 2005, Simko et al. 2015). The intracellular 
localization of the NM defines its further fate. Thus, if there is a release of ions, such as 
in the case of soluble NMs in lysosomes, oxidative stress, apoptosis and also cell cycle 
disturbances can be induced. The observed effects are dose dependent. Furthermore, 
these effects are not unique to nano-sized particles since they can appear as 
consequences of exposure to the bulk material as well. Thus, there are no nanospecific 
biological effects known so far, but known cellular and toxic reactions that are caused by 
NMs. 
 
Nanospecific developed protocols 
Limitations of traditional approaches to toxicity testing range from ethical issues linked to 
the high number of animals required in in vivo studies to practical aspects regarding high 
throughput methodologies and accuracy of the predicted toxicities. The multitude of 
possible formulations of NMs to be assessed for relevant toxic properties makes in vitro 
approaches highly attractive. Within NANoREG and other European projects, e.g. 
NanoValid89, Nanogenotox90, standard toxicological protocols have been adapted to NMs 
toxicity assessment. Assays cover viability (MTS, Alamar blue, neutral red, colony 
forming efficacy), genotoxicity (Comet assay, micronucleus, in vitro mammalian cell gene 
mutation test), immunotoxicity (interleukin expression), and Cell Transformation Assay 
(CTA). Some of the aforementioned protocols have been subject to inter-laboratory 
comparisons to assess the reproducibility of the assay e.g. the round robin exercises 
performed within NANoREG. 
Exposure methodologies are also highly relevant for risk assessment. In this context, 
conventional submerged cultures exposed to NM in a liquid form do not represent the 
ideal exposure scenarios. Different efforts to solve these issues have been made in 
different initiatives (e.g. NanoDevice91, NANoREG). Generally, it is currently accepted 
that cellular systems grown in air-liquid interphase (ALI) and exposure to NM in aerosol 
(or similar) better represent the occupational and consumer settings when dealing with 
the inhalation route. In this context, 3D reconstructed cellular models representing the 
epithelial airway systems (even as disease states) become a potential option for hazard 
studies focusing on the inhalation route. As the complexity of cellular models and 
exposure systems increases, it becomes more challenging to harmonize and validate 
procedures. The costs of such systems become relevant when considering the large 
number of NMs that may require toxicological assessment. In this context, NANoREG has 
considered both simple, monolayer cultures and complex systems; results can pave the 
                                           
89 http://www.nanovalid.eu/ 
90 http://www.nanogenotox.eu/ 
91 http://www.nano-device.eu/ 
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way for a future compromise between low- throughput expensive but accurate systems 
and high-throughput screening methodologies. 
 
Carcinogenicity in vitro 
There are promising in vitro approaches to recognise genotoxic as well as non-genotoxic 
carcinogens such as the CTA. These assays measure cell transformation that is one step 
in the multistep cancer process and can detect both genotoxic and non-genotoxic 
carcinogens. Several of them such as Bhas42 CTA have been used to detect in vitro 
transformation of NMs (Sasaki et al. 2014). Two guidance documents on cell 
transformation assays have been drafted under the OECD umbrella to allow the scientific 
and regulatory communities to use them as part of a weight of evidence approach in the 
testing of substances for carcinogenic potential. These are the "In vitro Syrian hamster 
embryo cell transformation assay", adopted in 2015 (OECD 2015), and the "In vitro Bhas 
42 cell transformation assay", adopted in 2016 (OECD 2016). There are also new in vitro 
toxicogenomics tools that may be potentially used to detect both genotoxic and non-
genotoxic carcinogens by using global gene expression profiling via microarray 
technology (Doktorova et al. 2012). 
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Annex 4. Supporting information on nanomaterials for section 4 A new approach 
towards nanospecific prioritisation and risk assessment 
Table IV.1. Links between phase I/II of the flow chart illustrated in figure 4.1 and sections 2 
(focused on European Commission's definition of nanomaterial) and 3 (focused on REACH) of the 
NANoREG framework and toolbox (project deliverable D1.1292). EC = European Commission; FRAS 
= Ferric Reducing Ability of Serum; ID = Identification; HARN = High Aspect Ratio Nanoparticles; 
(Q)SAR = (Quantitative) Structural Activity Relationship; ROS = Reactive Oxygen Species; TEM = 
Transmission electron microscopy. 
 
Phase I 
Phase I   
[flow chart in 
figure 4.1] 
Link with sections 2 and 3 of the 
NANoREG framework  
Link with sections 2 and 3 of the 
NANoREG toolbox 
Nano? 2.1: EC Definition of nanomaterial 
 
 
 
 
 
3.1: REACH Substance identification  
2: EC Nano Definition 
 Measuring Particle Number Size 
Distribution 
 Measuring Volume Specific Surface 
Area (VSSA) 
 
3.1: REACH Substance ID 
Dissolution in 
water 
3.2: REACH Information requirements 
[3.2.1.2: Physicochemical properties 
(water solubility) 
3.2: REACH Information requirements 
 Water solubility 
Exposure 3.3: REACH Adaptation rules 
[3.3.1: Substance-tailored exposure-
driven testing] 
 
3.5: REACH Exposure assessment  
3.3: REACH Adaptation rules 
 
 
 
3.5: REACH Exposure assessment 
 Exposure ranking methods in Control 
Banding Tools 
HARN  
 
 
 
 
 
 
3.2: REACH Information requirements 
[3.2.1.2: Physicochemical properties 
(size, shape, rigidity and 
biopersistence)] 
2: EC Nano Definition 
 Measuring Particle Number Size 
Distribution 
 
3.1: REACH Substance identification 
 Shape (e.g. by TEM) 
 
3.2: REACH Information requirements 
 Rigidity 
 Biopersistence 
Hazard 
classification 
3.3: REACH Adaptation rules 
[3.3.1: Grouping of substances and 
read-across approaches] 
 
3.4: REACH Hazard assessment 
[Step 2 Classification and Labelling]  
3.3: REACH Adaptation rules 
 Grouping of substances and read-
across approaches 
 
3.4: REACH Hazard assessment 
 Hazard classification 
Reactivity  3.2: REACH Information requirements 
[3.2.1.2: Physicochemical properties 
(reactivity)] 
 
3.3: REACH Adaptation rules 
[3.3.1: (Q)SAR and Grouping of 
substances and read-across 
approaches]  
3.2: REACH Information requirements 
 Acellular reactivity assay (e.g. ROS or 
FRAS assay) 
 
3.3: REACH Adaptation rules 
 (Q)SAR (e.g. conductivity band gap 
Zhang et al.) 
 Grouping of substances and read-
across approaches 
  
                                           
92
uhttp://rivm.nl/en/About_RIVM/International/International_Projects/Completed/NANoREG/deliverables/NANoR
EG_D1_12_DR_Toolbox.org 
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Phase II 
Phase II 
[flow chart in 
figure 4.1] 
Link with sections 2 and 3 of the 
NANoREG Framework  
Link with sections 2 and 3 of the 
NANoREG Toolbox 
Dissolution in 
relevant media 
3.2: REACH Information requirements 
[3.2.1.2: Physicochemical properties 
(water solubility)] 
3.2: REACH Information requirements 
 Solubility or dissolution rate and 
transformation in relevant media 
Absorption 3.2: REACH Information requirements 
[3.2.1.3 Toxicological properties 
(toxicokinetics, in vitro testing)] 
 
3.3: REACH Adaptation rules 
[3.3.1 In vitro methods] 
 
3.4: REACH Hazard assessment 
[in vitro assays] 
3.2: REACH Information requirements 
 
 
 
3.3: REACH Adaptation rules  
 
 
3.4: REACH Hazard assessment 
 In vitro absorption and barrier models 
Aggregation and 
agglomeration 
3.2: REACH Information requirements  
[3.2.1.2: Physicochemical properties 
(aggregation and agglomeration)] 
3.2: REACH Information requirements 
 Aggregation and agglomeration  
Cellular uptake 
and interaction 
3.3: REACH Adaptation rules 
[3.3.1 In vitro methods] 
 
3.4: REACH Hazard assessment 
[in vitro assays]  
3.3: REACH Adaptation rules 
 
 
3.4: REACH Hazard assessment 
 Cellular uptake, attachment and 
interaction 
Cytotoxicity, ROS 
and cytokines 
3.3: REACH Adaptation rules 
[3.3.1 In vitro methods] 
 
3.4: REACH Hazard assessment 
[in vitro assays]  
3.3: REACH Adaptation rules  
 
 
3.4: REACH Hazard assessment 
 In vitro cytotoxicity, ROS and cytokine 
induction assays 
In vitro skin and 
eye irritation  
3.2: REACH Information requirements 
[3.2.1.3 Toxicological properties 
(skin irritation, skin corrosion and 
eye irritation)] 
3.2: REACH Information requirements 
 In vitro skin and eye irritation tests 
 
3.3: REACH Adaptation rules 
 Grouping of substances and read-
across approaches 
Cell transformation  3.3: REACH Adaptation rules 
[3.3.1 In vitro methods] 
 
3.4: REACH Hazard assessment 
[in vitro assays]  
3.3: REACH Adaptation rules 
 
 
3.4: REACH Hazard assessment 
 Cell transformation assays 
Genotoxicity 3.2: REACH Information requirements 
[3.2.1.3 Toxicological properties 
(mutagenicity)] 
 
3.3: REACH Adaptation rules 
[3.3.1 (Q)SAR, Grouping of 
substances and read-across 
approaches] 
 
3.4: REACH Hazard assessment 
[Step 2 Classification and Labelling, 
Mode of action] 
3.2: REACH Information requirements 
 
 
 
3.3: REACH Adaptation rules 
 
 
 
 
3.4: REACH Hazard assessment 
 In vitro genotoxicity tests 
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Annex 5. Supporting information on nanomaterials for section 6 Life Cycle 
Assessment 
 
Introduction 
Life Cycle Assessment (LCA) is a tool for the analysis of potential environmental impacts 
associated with products (goods and services) over their whole life cycle (i.e. product 
systems): supply, use and end-of-life stages are taken into account. 
According to ISO (2006a), there are four phases in an LCA study as shown in figure V.1. 
 
Figure V.1. Life Cycle Assessment (LCA) phases. 
 
Source: ISO 2006a 
 
In "Goal and scope definition", the objective of the study is defined, a description of the 
product system is provided in terms of functionality and functional unit, system 
boundaries, allocation and target audience. The functional unit is a quantitative measure 
of the functions that the products (or services) provide. In accordance with the functional 
unit, the reference flow shall be defined, i.e. the flow to which all other input and output 
flows are quantitatively related.  
Comparison between systems is made on the basis of the same function(s), quantified by 
the same functional unit(s) in the form of their reference flows. 
The system boundary defines the processes of production system, included in the study. 
Therefore, the system boundary must be clearly defined for the product system to be 
evaluated and shall be consistent with the goal of the study. LCA suggests considering 
the entire life cycle of the investigated applications from the extraction of raw materials 
to waste treatment ("from cradle to grave"). However, simplifications can be made in 
order to reduce the complexity of the product system to a manageable size. Moreover, 
the allocation criteria used in establishing the system boundary shall be identified and 
explained (ISO 2006b). 
The "Life Cycle Inventory analysis" phase (LCI) defines data collection and calculation 
procedures in order to quantify from cradle-to-grave the relevant inputs (e.g. material 
inputs) and outputs (e.g. emissions to air) of the product system. The result of the LCI is 
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a compilation of the inputs (resources) and the outputs (emissions) from the product 
over its life cycle in relation to the functional unit and to the system boundary defined. A 
large number of data must be collected for each unit process included within the system 
boundary. Some data, "primary data", are collected directly on site, while "secondary 
data" is derived from literature and databases. Several databases were developed and 
are still under development. These include public national or regional databases, industry 
databases, and consultants' databases that are often offered in combination with LCA 
software tools (Finnveden 2009). Moreover, the collected data need to be referenced 
along with details about the relevant data collection process, the time when data have 
been collected, administrative information, the method used to measure, calculate or 
estimate (ISO 2006b). 
The "Life Cycle Impact Assessment" phase (LCIA) aggregates the results from the LCI 
analysis to evaluate the significance of the product’s potential environmental impacts. 
Moreover, the inventory data are connected with specific environmental impact 
categories and the respective category indicators, such as global warming potential as an 
indicator for climate change. 
The ISO 14044 standard defines the LCIA as the phase of LCA aimed at understanding 
and evaluating the magnitude and significance of the potential environmental impacts for 
a product system throughout the life cycle of the product (ISO 2006b). 
In LCIA, the inputs and outputs of elementary flows that have been collected and 
reported in the inventory are translated into impact indicator results, related to human 
health, natural environment, and resource depletion (JRC 2010). According to the ISO 
standard on LCA (ISO 2006a, 2006b), LCIA consists of mandatory elements as selection 
of impact categories and classification. The phase includes: selection of impact category 
in accordance with goal and scope; definition of indicators for each impact category; 
assignment of the inventory data to the chosen impact categories (classification); and 
calculation of impact category indicators using Characterisation Factors (CFs). Several 
methods have been developed including different impact categories (JRC 2010). 
The LCIA includes two optional phases: "Normalization" and "Grouping or Weighting". 
The first one relates the results of characterisation to reference values (e.g. a whole 
country or an average citizen). The latter requires the use of weighting factors, which 
indicate the different relevance that the impact categories may have (Finnveden 2009, 
JRC 2010).  
LCIA methods can be grouped into two families: classical methods determining impact 
category indicators at an intermediate position (midpoint level) of the impact pathways 
(e.g. climate change, human toxicity, eco-toxicity and acidification) and damage-oriented 
methods aiming at more easily interpretable results in the form of damage indicators at 
the level of the ultimate societal concern (e.g. human health, ecosystem health and 
resource depletion). In figure V.2 an example of LCIA model is reported. 
The "Interpretation" phase considers the findings from both LCI and LCIA and provides 
conclusions and recommendations.  
The LCA is an iterative process, in each phase more information becomes available; this 
aspect permits to improve the system and promotes an iterative loops of goal and scope 
definition, inventory data collection and modelling (LCI), impact assessment (LCIA), and 
with completeness, sensitivity and consistency checks (evaluation). In this phase the aim 
is to implement robust conclusions and recommendations from the analysis, for example 
suggesting environmental improvements. Robustness can be achieved by developing: 
completeness checks of process coverage in the inventory analysis; sensitivity checks to 
assess if the results are affected by specific methodological choices; consistency checks 
of assumptions, methods, and data quality. The recommendations are referred to as "hot 
spot" or "weak point" analysis and identify environmental improvement potentials 
associated with specific management interventions. 
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International initiative of LCA framework harmonization 
LCA is becoming more and more a policy support method, thanks to its characteristics, 
and, in particular, its standardisation has been one key aspect of its diffusion and 
acceptance. However, for a full exploitation of its potentiality in policy, additional efforts 
are needed, in particular in the field of harmonization to make the LCA results more 
reproducible and comparable.  
 
Figure V.2. Overall scheme of the IMPACT 2002+ framework, linking Life Cycle Inventory (LCI) 
results via the "Midpoint categories" to "Damage categories". 
 
Source: Jolliet et al. 2003 (modified). 
 
In Europe, in its conclusion on the "Sustainable materials management and sustainable 
production and consumption: key contribution to a resource-efficient Europe – Draft 
Council conclusions" (December 2010), the European Council invited the Commission to 
"develop a common methodology on the quantitative assessment of environmental 
impacts of products, throughout their life-cycle, in order to support the assessment and 
labelling of products"93. This has led to the publication of the Communication from the 
European Commission on "Building the Single Market for Green Products"94 and of the 
"Commission Recommendation on the use of common methods to measure and 
communicate the life cycle environmental performance of products and organisations"95 
(April 2013). A three-year test of the two methods to measure environmental 
performance throughout the lifecycle named Product Environmental Footprint (PEF) and 
Organisation Environmental Footprint (OEF) is now in progress. Both methodologies are 
ISO 14040 and ISO 14044 compliant (ISO 2006a, 2006b), with further specifications and 
recommendations. Moreover, the two methodologies adopt the concept of Product 
Category Rules (named PEFCR and OEFSR, respectively), in order to minimize the degree 
of freedom of the practitioner and simplify his work. The work in progress96 is developing 
several guidelines for addressing "horizontal issues", which are aspects common to many 
or all the PEF/OEF studies. In addition, the European Commission is also developing a 
database for its use in the background processes of PEF and OEF studies, reducing the 
                                           
93 http://register.consilium.europa.eu/doc/srv?l=EN&f=ST%2017495%202010%20INIT 
94 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52013DC0196&from=EN 
95 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32013H0179&from=EN 
96 https://webgate.ec.europa.eu/fpfis/wikis/display/EUENVFP/EU+Environmental+Footprint+Pilot+Phase 
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variability of the results due not to real differences in the life cycle of product with the 
same function but to differences in the background data. 
Furthermore, the work of the UNEP – SETAC Life Cycle Initiative, started in the 2002 with 
the aim of fostering the Life Cycle Thinking globally, is now in its third phase, with the 
objectives to:  
• Enhance the global consensus and relevance of existing and emerging life cycle 
methodologies and data management; 
• Expand capability worldwide to apply and to improve life cycle approaches; 
making them operational for organisations; 
• Communicate current life cycle knowledge and be the global voice of the Life 
Cycle community to influence and partner with stakeholders97. 
Besides a strong effort in "Capacity Building" and in "Communication & Stakeholder 
Outreach", the technical work is focussed on: improving environmental life cycle impact 
assessment indicators, promoting the LCA of organisations, and developing global 
principles and practices for hot spot analysis and data management.  
On this last issue, the International Forum on LCA Cooperation, a global governmental 
initiative that aims to provide a space for discussion among governmental programs 
supporting LCA, launched the Global Network of Interoperable LCA Databases, with "an 
aspirational objective that by 2017, an electronic system and protocol should be available 
- based as much as possible on existing structures - to enable access by users to the 
majority of the LCA databases and other relevant sustainability data, meaning that the 
LCA datasets and other data therein can be easily accessed in an exchange format that 
allows using them seamlessly in LCA software, with sufficient documentation of metadata 
that allows for defining "fitness for purpose" by any end user"98. Indeed, access to data 
of well described quality is key for the wide spread of LCA, but the use of different 
formats, nomenclature and metadata among the existing databases is a major barrier, 
making difficult the combined use of data from different databases. 
 
LCA and nanomaterials  
Several LCA studies on nanotechnologies and nanomaterials (NMs) have been published 
in the recent years, with different goals and focused on different products and 
applications. The main issues with regard to the application of LCA to NMs are discussed 
in section 6. Suggestions on how to address those issues including examples from recent 
scientific publications are also reported in section 6. In this annex, more attention is 
given to the nanospecific issues in the impact assessment phase, as human and 
ecological toxicity categories have not been completely defined for NMs. In fact, scientific 
consensus on these topics is currently under development and CFs of emissions of NMs 
into the environment (fresh and marine water, soil and air) for human and ecological 
toxicity categories are not available under conventional impact categories methods. 
Some efforts to incorporate toxicity effects of NMs in LCIA have been made and tentative 
approaches have been proposed. Some relevant ones are listed here below: 
• Eckelman et al. (2012) proposed ecotoxicity CFs for carbon nanotubes emissions 
into freshwater; 
• Rodriguez-Garcia et al. (2014) developed human toxicity CFs and freshwater 
ecotoxicity CFs for carbon nanotubes; 
• Salieri et al. (2014) developed an ecotoxicity CF for nanotitania emitted into 
freshwater; 
                                           
97 http://www.lifecycleinitiative.org/activities/phase-iii/ 
98 Report of the 4th Meeting of the International Forum on Life Cycle Assessment (LCA) Cooperation Including 
the Launch of the Global Network of Interoperable LCA Databases. Shangrila Hotel, Putrajaya and SIRIM, Shah 
Alam, Malaysia. 10-12 March 2015 
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• Pini et al. (2014) proposed the use of two new impact categories ("NanoTiO2 
ecotoxicity in freshwater" and "NanoTiO2 carcinogens in fresh water") in the 
frame of the IMPACT 2002+ framework; 
• Walaser et al. (2014) developed a framework for indoor emissions of synthetic 
nanoparticles; 
• Barberio et al. (2014) proposed a combined approach between LCA and RA 
where the LCA identifies the processes having the best environmental 
performance and RA identifies the scenarios having the highest risk for workers. 
Ecotoxicity CFs calculated with USEtox model 
In USEtoxTM (Rosenbaum et al. 2008), the ecotoxicological CF of chemicals is calculated 
in agreement with equation (1): 
XFFFEFCF    (1) 
Where: EF (m3 kg−1) is the Effect Factor and represents the ecotoxicity of the substance 
expressed in terms of Potentially Affected Fraction (PAF) of species; FF (day) is the Fate 
Factor expressing the residence time of the substance in a particular environmental 
compartment (such as freshwater); and XF (dimensionless) is the eXposure Factor. 
CFs are reported for freshwater aquatic ecotoxicological effects. 
By applying the USEtoxTM model, Eckelman et al. (2012) and Rodriguez-Garcia et al. 
(2014) calculated ecotoxicity CFs for carbon nanotubes and Salieri et al. (2014) for 
nanotitania.  
In agreement with USEtoxTM, EF is defined by equation (2): 
50
5.0
50 HCHC
PAF
EF           (2) 
EF reflects the relationship between the PAF of aquatic organisms and the hazardous 
concentration of a pollutant that causes effects on the 50% of aquatic organisms (HC50). 
The numerator is defined as the slope of the concentration-response relationship up to 
the point when the PAF reaches 50% (0.5) and the denominator is the geometric mean 
of species-specific EC50 data. EC50 is the effective concentration of a pollutant at which 
50% of a single species population experiences a response, and values for EC50 found in 
the literature were used by the authors.  
As regards the FF factors, starting from USEtox formulation, which provides a nested-
multimedia mass balance model, the papers make some distinctions in their calculations. 
Eckelman et al. (2012) modelled two scenarios of calculation of the FF by using 
physicochemical properties of the substance: a worst (unrealistic) case that maximizes 
the exposure of aquatic microorganisms to carbon nanotubes and a "realistic scenario" 
estimated by using literature data. Also Rodriguez-Garcia et al. (2014) used 
physicochemical properties retrieved from ECHA public database on registered 
substances and made some assumptions in case of lack of data. 
Salieri et al. (2014) used colloidal science to develop the fate model, because, in 
agreement with some other authors, they assumed that substance-specific input 
parameters required for the fate calculation in USEtoxTM are suitable for organics but not 
applicable to NMs, due to their different chemical and physical properties.  
In USEtoxTM, the environmental exposure factor for freshwater ecotoxicity is the fraction 
of a chemical dissolved in freshwater and can be estimated via equation (3): 
  6101
1


massDOCp BIOBAFDOCKSSK
XF      (3) 
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Where Kp is the partition coefficient between water and suspended solids (l/kg), SS is the 
suspended matter concentration in freshwater (= 15 mg/l in USEtoxTM), KDOC is the 
partitioning coefficient between dissolved organic carbon and water, DOC is the dissolved 
organic carbon concentration in freshwater (= 5 mg/l in USEtoxTM), BAF is the 
bioconcentration factor in fish (l/kg) and BIOmass is the concentration of biota in water (= 
1 mg/l in USEtoxTM). 
Eckelman et al. (2012) and Rodriguez-Garcia et al. (2014) applied equation (3) while 
Salieri et al. (2014) decided to not use it but to consider the different nature of the 
chemical investigated, which is insoluble. As bioavailability and bioaccumulation factors, 
which could replace the XF factor, were not available in literature Salieri et al. (2014) 
assumed a precautionary approach by setting XF equal to 1 without weighing the final 
results of the model on the basis of the exposure factor.  
Table V.1 shows the CF for carbon nanotubes (CNTs), single walled carbon nanotubes 
(SWCNTs), multi walled carbon nanotubes (MWCNTs) and nanotitania proposed by 
Eckelman et al. (2012), Rodriguez-Garcia et al. (2014) and Salieri et al. (2014). 
 
Table V.1. Characterisation factors (CFs) for carbon nanotubes (CNTs), single walled carbon 
nanotubes (SWCNTs), multi walled carbon nanotubes (MWCNTs) and nanotitania (nanoTiO2) 
proposed by Eckelman et al. (2012), Rodriguez-Garcia et al. (2014) and Salieri et al. (2014). EF = 
Effect Factor. FF = Fate Factor. XF = Exposure Factor. PAF = Potentially Affected Fraction. 
Substance 
EF  
[(PAF ˣ m3) 
/kg)] 
FF 
[day] 
XF 
CF 
[(PAF ˣ m3 ˣ 
day)/kgemitted)] 
Reference 
CNTs "worst case" 200 143 1 29000 Eckelman et al. 
(2012) CNTs "realistic case"  200 18.5 1 3700 
SWCNTs 650 92 6.5E-06 0.125 Rodriguez-Garcia 
et al. (2014) MWCNTs 8 29 1 740 
NanoTiO2 (species level) 31.1 10
-2 1 0.31 Salieri et al. 
(2014) NanoTiO2 (trophic level)
  28.1 10-2 1 0.28 
 
Eckelman et al. (2012) highlighted that significant uncertainty exists in the estimates of 
CNTs release-based ecotoxicity, so Montecarlo analysis was performed within the USEtox 
model. Also, Rodriguez-Garcia et al. (2014) agreed that the calculated CFs should be 
considered only as interim due to the assumptions that were needed for parameters 
calculations. Salieri et al. (2014) highlighted high variability of toxic data on nanoTiO2 
and difficulties of calculating FF, because it is site-specific and time related, while in LCA 
emissions are global, considering both time and place. However, the authors do not 
present uncertainty analysis. 
Moreover, some other critical issues stood out from these papers, in particular 
concerning the following aspects: 
 The fate model, which should consider the semi colloidal behaviour of materials 
like CNTs affected by both molecular and physical forces (kinetics of aggregation, 
filtration, and deposition); 
 The huge gap existing between the current body of research and the number of 
toxicity studies necessary to make a robust, specific assessment of 
ecotoxicological risks; 
 The need for continuous updating of the CFs calculated to follow progress in the 
ecotoxicity research; 
 The importance of a robust statistical analysis to improve the reliability of the 
toxicity impacts results. 
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Human toxicity characterization factors calculated with USEtoxTM model 
In USEtoxTM (Rosenbaum et al. 2008), the human toxicity CF of chemicals is calculated 
in agreement with equation (1). The FF and EF are combined to reflect the intake 
Fraction (iF), which is the fraction of the emitted mass that enters the human population, 
mainly considering intake through inhalation and ingestion. The EF reflects the change in 
disease probability due to change in life time intake of a chemical (cases/kgintake). 
Rodriguez-Garcia et al. (2014) proposed the calculation of human toxicity (non-cancer) 
CF for SWCNTs and MWCNTs emitted in different environmental compartments. The 
potential carcinogenicity of CNTs was unknown at the date of publication, so no 
carcinogenic effects were assessed. 
The need for further investigations was highlighted by the authors, in particular data to 
assess chronic effects of the ingestion and empirical data for the estimation of iF. 
Toxicity of TiO2 nanoparticle released into water 
Pini et al. (2014) proposed two new impact categories in the IMPACT 2002+ method: 
• NanoTiO2 ecotoxicity in freshwater, where "Particulates, <100 nm, in freshwater" 
has been introduced as a representative substance of the damage on freshwater 
ecosystem, with a CF calculated by Salieri et al. (2014). 
• NanoTiO2 carcinogens in freshwater, where "NanoTiO2 human toxicity, in 
freshwater" has been introduced as a representative substance of a local 
damage on human health (considering an area of Emilia Romagna region in the 
north of Italy), with a calculated damage assessment factor determined by the 
Eco-indicator 99 (2001) calculation method for carcinogenic substances. 
The aim was to quantify the contribution to the total damage of TiO2 nanoparticles 
released into water with an approach of local damage on human health. This approach 
allows a preliminary screening of the relevance of this NM emission in freshwater, which 
is particularly interesting for the application of ecodesign principles to chemical 
processes. However, the published documentation is not detailed enough to evaluate 
reliability, consistency and uncertainty of the assessment. 
Life Cycle Interpretation 
Life cycle interpretation of NMs and nano-enabled products does not seem to be different 
from that of standard products. Uncertainty and sensitivity analyses are indispensable in 
the case of products with incomplete and uncertain production characteristics and 
impacts. Indeed, LCA studies on NMs often are based on data at laboratory and pilot line 
scale or even completely lack data for the use and end-of-life stages as well as lack 
information on emissions of NMs in the environment and on the toxicity impact 
categories that characterise these emissions. 
To calculate the uncertainty on the accumulated LCI data, Walser et al. (2011) and Pizza 
et al. (2014) include information on stochastic variable as variance, mean, and 
probability distribution of background data, Walser et al. (2011) on primary data too, and 
perform a Monte Carlo analysis. Furthermore, to improve the robustness of data other 
authors perform a sensitivity analysis about methodological choices (e.g. system 
boundaries setting, cut-off criteria, selection of impact assessment methods, 
assumptions). Indeed, nanotechnology applications are quite new and many assumptions 
are often done in the LCA study. Kanna et al. (2008) developed a LCA on environmental 
impact of carbon nanofibers synthesis and applied a sensitivity analysis to study the 
effect on the life cycle energy consumption of varying 1) cycle times of production and 2) 
feedstock and carrier gas recycle rates. Walser et al. (2011), in comparative analysis 
among nanosilver T-shirts and conventional T-shirts with and without biocidal treatment, 
analyse several scenarios changing single parameter values, such as biocidal 
concentrations, different precursor production technologies, and altering assumptions of 
consumer behaviour, within realistic value ranges. Li et al. (2014) in LCA of a high-
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capacity LIB pack using SiNW consider the effects of multiple factors, including the 
cathode material, the service life of battery pack, the electricity mix for battery charging, 
and the operating geographic region of the EVs. Pizza et al. (2014), in LCA on epoxy-
based composites filled with graphite nanoplatelets (GnP), verify the robustness of 
results considering scenarios with different electricity mix in the GnP production process 
and composite production. Barberio et al. (2014), in LCA of production of alumina 
nanofluid with two processes, check the assumption made in the precursor material used 
to produce the nanofluid comparing several scenarios with different precursor materials 
(OECD 2015). 
 
Conclusions 
LCA is an effective tool to evaluate the environmental sustainability of NMs, nano-
enabled products and nanotechnologies throughout the life cycle and to highlight their 
environmental hot spots, which can help to identify more environmentally friendly design 
solutions. LCA quantifies the potential environmental impacts of the whole life cycle of 
the product and provides a comprehensive overview of the potential environmental 
impacts of nano-enabled products in several impacts categories, including all other 
substances used over the life cycle of that products. However, further studies should be 
developed to define harmonized approaches and robust and reliable data and 
scientifically approved CFs for the human and ecotoxicity impact categories. 
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